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ABSTRACT 
Triacylglycerol is the major source of stored energy in humans, yet, excessive accumulation 
of triacylglycerols in tissues leads to obesity, diabetes and heart disease. Triacylglycerol synthesis is 
catalyzed by diacylglycerol acyltransferase (DGAT) enzymes, DGAT1 and DGAT2. Although 
recent studies have shed light on the metabolic functions of these enzymes, little is known about 
their regulation.  
We have found that DGAT2 is a short-lived protein and is degraded via the ubiquitin-
proteasome pathway. Our objective was to identify the lysine residues that are ubiquitinated and 
determine the role of ubiquitination in regulating DGAT2 stability and triacylglycerol synthesis. 
Initial experiments found that a lysine-less DGAT2 mutant (Lys-less-DGAT2) was not degraded.  
Moreover, Lys-less-DGAT2 exhibited altered subcellular localization and disrupted lipid droplet 
biogenesis.  Screening of a DGAT2 lysine-to-arginine mutant library demonstrated that several 
lysine residues are involved in regulating DGAT2 stability.  Substitution of two lysine clusters was 
sufficient to mislocalize DGAT2 and perturb typical lipid droplet formation, suggesting that these 
lysines may have a role in targeting DGAT2 to lipid droplets. Interestingly, DGAT2 on lipid 
droplets was ubiquitinated and stimulating lipogenesis did not reduce DGAT2 degradation. 
 Monoacylglycerol acyltransferase (MGAT) enzymes, MGAT2 and MGAT3, are closely 
related to DGAT2 and produce the DGAT2 substrate, diacylglycerol.  MGAT2 and MGAT3 
interact with DGAT2 and appear to stabilize it.  We determined that DGAT2, MGAT2 and MGAT3 
are targeted for endoplasmic-reticulum-associated degradation (ERAD), as ERAD inhibition caused 
poly-ubiquitinated species of all three proteins to accumulate.  Moreover, overexpression of 
DGAT2 and MGAT2 resulted in redistribution of the ERAD ATPase, valosin-containing protein 
(VCP/p97), where it becomes concentrated in the ER, co-localizing with both DGAT2 and 
MGAT2.  Interaction of DGAT2 and MGAT2 with VCP/p97 was also demonstrated in situ. 
 We took a non-targeted mass spectrometry approach to identify proteins interacting with 
DGAT2.  The carbohydrate binding protein, calnexin, was one of the candidates identified.  This 
interaction was confirmed in vitro and in situ.  The possible impacts of calnexin on triacylglycerol 
metabolism were examined in calnexin knockout mouse embryonic fibroblasts, which exhibited 
stunted lipid droplet size compared to wild-type cells.    
Collectively, these investigations provide insight into the post-translational regulatory 
mechanisms of DGAT2 and DGAT2 family members. 
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CHAPTER 1: Literature review 
1.1 Obesity and complications 
Obesity is a condition of energy imbalance.  Excessive intake of food coupled with 
insufficient energy expenditure results in an over-abundance of adipose mass.  Obesity is 
clinically estimated by body mass index (BMI) (Fig. 1.1) (Keys et al., 1972).  Guidelines 
endorsed by the World Health Organization (WHO) categorize a healthy weight as a BMI of 
18.5-24.9 kg/m2, overweight or pre-obesity as 25-29.9 kg/m2 and obesity as BMI ≥ 30 kg/m2.  
Obesity is further subdivided to represent the elevated health risk associated with increasing 
BMI: class I - moderately obese (30.0-34.9 kg/m2), class II - severely obese (35.0-39.9 kg/m2), 
class III - very severely obese (≥ 40.0 kg/m2) (World Health Organization, 2000; Lau et al., 
2007; Health Canada, 2003).   
The 1970-1972 Nutrition Canada Survey identified that ~10% of Canadian adults were 
obese (Katzmarzyk, 2002).  The 2009-2011 Canadian Health Measures Survey found that 34% 
of Canadian adults were overweight and an additional 26% considered obese.  Moreover, 4% of 
the population was categorized as class III (Statistics Canada, 2012).  Based on 2009-2011 data, 
24% of Canadian obese adults were class II and 14% class III, representing an increase over 
1978-1979 data which reported 17% were class II and 6% class III (Tjepkema, 2006; Statistics 
Canada, 2012).  Childhood obesity has also increased in prevalence.  In 1981, less than 2% of 
those under 18 years were obese, as of 2012 that had jumped to 9% (Tremblay, 2002; Statistics 
Canada, 2012).  Obesity among most ethnic groups is similar, ranging from 14-16% for White, 
Black and Latin American Canadian adults. However, obesity in East/Southeast and South 
Asian Canadians is significantly lower at 3% and 8% respectively (Tremblay et al., 2002).  
Conversely, obesity in Aboriginal populations is elevated.  The 2000-2003 Canadian 
Community Health Survey identified obesity in 27% of off-reserve Aboriginals, while the 
2008-2010 First Nations Regional Health Survey reported that obesity had reached 40% in 
reservation populations (Tremblay et al., 2002; First Nations Information Governance Center, 
2012).  In the United States, based on 2011-2012 data, approximately 34% of adults were 
overweight and additional 35% were obese (Ogden et al., 2014). As of 2014, roughly 39% of 
the global adult population was classified as overweight and 13% as obese (World Health 
Organization, 2000).  
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BMI =
Weight kg
(Height m )2
 
Figure 1.1.  Equation for the calculation of body mass index (BMI) - A Healthy weight is a 
BMI of 18.5-24.9 kg/m2, overweight or pre-obesity ranges from 25-29.9 kg/m2 and obesity is 
represented by a BMI ≥ 30 kg/m2. 
  
The clinical consequences of excess fat manifest in the predisposition towards a host of 
diseases.  A causal link has been established between obesity and diseases such as metabolic 
syndrome, dyslipidemia, chronic obstructive pulmonary disease, hypertension, congestive heart 
failure, non-alcoholic fatty liver disease, deep vein thrombosis, gout, reproductive disorders and 
numerous cancers.  It is clear that dangers associated with obesity extend far beyond classically 
associated type II diabetes.  Researchers commonly express the increased likelihood of 
developing a disease secondary to elevated BMI, versus those with a normal BMI, as “relative 
risk”.  A weak effect is denoted by values of 1.01 – 1.49 and represents increased risk of 1% to 
49%.  Moderate risk is considered 1.5 (50%) – 2.99 (199%) and a strong risk is present above 
3.0 (200%) (Oleckno, 2002).  A 2009 report conducted meta-analysis on 89 studies to identify 
relative risk for overweight and obese individuals in relation to several diseases (Table 1.1) 
(Guh et al., 2009; Janssen, 2013).  Both obese men and women are at strong risk for type II 
diabetes and pulmonary embolism.  Men are also at strong risk for osteoarthritis while women 
are at strong risk for endometrial cancer and coronary artery disease.  A recent study found that 
all-cause mortality was 18% higher in obese adults and reached as high as 29% in class II and 
III adults (Flegal et al., 2013). 
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Co-morbidity Overweight Obese 
Male Female Male Female 
Endocrine and 
Metabolic Type II Diabetes 2.40 3.92 6.74 12.41 
  Gallbladder Disease 1.09 1.44 1.43 2.32 
Cancer Breast (postmenopausal) - 1.08 - 1.13 
  Colorectal 1.51 1.45 1.95 1.66 
  Endometrial - 1.53 - 3.22 
  Esophageal 1.13 1.15 1.21 1.20 
  Kidney 1.40 1.82 1.82 2.64 
  Ovarian - 1.18 - 1.28 
  Pancreatic 1.28 1.24 2.29 1.60 
  Prostate 1.14 - 1.05 - 
Cardiovascular Hypertension 1.28 1.65 1.84 2.42 
  Coronary Artery Disease 1.29 1.80 1.72 3.10 
  Congestive Heart Failure 1.31 1.27 1.79 1.78 
  Stroke 1.23 1.15 1.51 1.49 
Musculoskeletal Osteoarthritis 2.76 1.80 4.20 1.96 
  Chronic Back Pain 1.59 1.59 2.81 2.81 
Respiratory Asthma 1.20 1.25 1.43 1.78 
  Pulmonary Embolism 1.91 1.91 3.51 3.51 
 
Table 1.1.  Summary relative risk of co-morbidities associated with elevated BMI - The 
summary relative risk of disease in overweight or obese individuals as determined by meta-
analysis.  Weak effect: 1.01 – 1.49 represents increased risk of 1% to 49%.  Moderate risk: 1.5 
– 2.99 represents increased risk of 50% - 199%.  Strong risk:  ≥ 3.0 represents increased risk of 
200% (Guh et al., 2009). 
 
In addition to the medical complications attributable to excess weight, obesity has a 
profound economic impact.  In terms of health care costs, Canadian studies have identified that 
average yearly medical expenses are increased by 25% for obese adults and 21% for obese 
children.  Based on 2006 data, the direct and indirect costs associated with obesity were 
calculated (Janssen, 2013).  Direct costs account for expenses of medical care while indirect 
costs cover aspects such as short-term and long-term disability, lost productivity and premature 
death.  It is estimated that overweight adults in Canada added $2.1 billion in direct medical 
expenses while obesity accounted for an additional $3.9 billion.  In-direct costs added $1.9 
billion for overweight adults and a further $3.2 billion for obese adults.  In total, the economic 
impact of excess weight in Canada can be estimated at $11 billion annually, as of 2006. 
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1.2 Storage lipids 
Lipids are a biologically diverse group of compounds that play a variety of roles, 
including: energy storage molecules, membrane components, enzyme cofactors, chaperones, 
hormones, and intracellular signaling molecules.  Fatty acids are the main reservoir of stored 
energy in eukaryotic cells. They are carboxylic acids with highly reduced hydrocarbon chains 
4-36 carbons in length.  Hydrocarbon chains can be saturated - containing no double-bonds, or 
unsaturated - containing at least one double-bond.  The most prevalent fatty acids are composed 
of even numbers of carbon atoms between 12 and 24 units in unbranched chains (Fig. 1.2A).  
They are formed through sequential condensation reactions, resulting in the addition of two 
carbon units in the form of acetate. The polar carboxylic acid group is ionized at neutral pH and 
hydrophilic.  However, the nonpolar hydrocarbon chains are very hydrophobic and therefore 
only short fatty acids exhibit any solubility in water.  Fatty acids of increased length and fewer 
double-bonds exhibit increased hydrophobicity.   
Three fatty acids esterified to a glycerol backbone form a triacylglycerol (Fig. 1.2B).  
Triacylglycerols are prevalent in eukaryotes such as fungi, plants and animals. They are non-
polar and highly hydrophobic, which contributes to their efficiency in energy storage.  Other 
energy storage molecules, such as glycogen and starch, while more readily accessible, must be 
hydrated, requiring the organism to carry extra water.  In addition, the hydrocarbon chains of 
fatty acids are more reduced; oxidation of triacylglycerols produces over double the energy 
obtained from an equal mass of carbohydrate.  A healthy (70 kg) person stores ~141,000 kcal as 
fat as compared with 24,000 kcal in the form of protein and 1000 kcal as carbohydrate (Wang 
et al., 2013).  In mammals, triacylglycerols also protect cells from the toxicity associated with 
free fatty acids (lipotoxicity), enabling fatty acid storage.  Moreover, they provide ligands for 
nuclear hormone receptors and signal transduction pathways, in addition to substrates for the 
production of lipids important in maintaining the permeability barrier  (Coleman and Lee, 2004; 
Listenberger et al., 2003; Smith et al., 2000; Farese et al., 2000; Liu et al., 2012) 
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Figure 1.2.  Lipid structure – (A) Fatty acid structure of palmitic acid (16:0) and oleic acid 
(18:1).  (B) Representative structure of triacylglycerol noting the position of the ester linkage 
between the glycerol backbone and fatty acids. 
 
1.3 Triacylglycerol biosynthesis 
1.3.1 Mitochondria-associated membranes 
 Lipid biosynthetic enzyme activity is particularly enriched in a subdomain of the 
endoplasmic reticulum (ER) known as mitochondria-associated membranes (MAM).  The ER 
has several morphologically and functionally distinct regions - the rough ER, smooth ER, 
transitional ER and MAM.  MAM are characterized by their close proximity to mitochondria 
and delineated by the enrichment in lipid biosynthetic enzyme activities, such as: acyl-CoA: 
cholesterol O-acyltransferase (ACAT), acyl-CoA: 1,2-diacyl-sn-glycerol O-acyltransferase 
(DGAT)-2 and phosphatidylserine synthase (Franke and Kartenbeck, 1971; Morré et al., 1971; 
Rusiñol et al., 1994; Stone et al., 2009, 2000).  The only known marker protein to dependably 
distinguish MAM is phosphatidylethanolamine-N-methyltransferase-2, which is abundant in 
MAM but undetectable by Western blotting in other regions of the ER or mitochondria (Cui et 
al., 1993).  It is postulated that physical contact between MAM and the outer membrane of the 
mitochondria facilitates intracellular lipid transport between the ER and mitochondia (Shiao et 
al., 1995, 1998; Stone and Vance, 2000; Vance and Shiao, 1996, Vance, 2014).  MAM are also 
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closely apposed to intracellular sites of triacylglycerol storage, known as lipid droplets (Farese 
and Walther, 2009).  
 
1.3.2 The Kennedy pathway 
The Kennedy pathway, also known as the glycerol-3-phophate pathway, is the primary 
triacylglycerol synthesis mechanism in most mammalian cells (Fig 1.3) (Kennedy, 1957; 
Kindel et al., 2010; Storch et al., 2008).  This four-step step pathway describes the sequential 
esterification of fatty-acyl groups to a glycerol backbone and occurs primarily on the ER 
membrane. Prior to incorporation in the Kennedy pathway, a fatty acid must be activated to 
form an acyl-coenzyme A (CoA) by acyl-CoA synthetase (Groot et al., 1976; Cleland, 1963ab). 
 
Figure 1.3.  The Kennedy pathway - Alternatively known as the glycerol-3-phosphate 
pathway, it describes the sequential esterification of fatty acids to a glycerol backbone.  The 
rate-limiting step in triacylglycerol synthesis is catalyzed by glycerol-3-phosphate 
acyltransferase isozymes, while the only committed step is performed by diacylglycerol 
acyltransferase isozymes.  Triacylglycerol serves as a prominent energy storage molecule. 
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1.3.3 Glycerol-3-phosphate acyltransferase 
Triacylglycerol synthesis begins through ester bond formation between glycerol-3-
phosphate and an activated fatty acid (fatty acyl-CoA), forming lysophosphatidate.  This 
reaction is catalyzed by acyl-CoA: sn-1-glycerol-3-phosphate O-acyltransferase (GPAT), the 
rate-limiting enzyme in triacylglycerol synthesis (Wendel et al., 2009).  Four GPAT isoforms 
(GPAT1-4), each an independent gene product, have been identified.  GPAT isoforms differ 
mainly in localization, tissue expression, and substrate specificity  (Lewin et al., 2008).  All 
isoforms are integral membrane proteins predicted to contain two transmembrane domains 
(TMD) and a cytosolic facing active site (Gonzalez-Baro et al., 2001).  Mammalian GPATs 
have yet to be crystallized.  While the structure of a related GPAT isoform from squash has 
been determined, there are several key differences with mammalian GPATs (Turnbull et al., 
2001).   
GPAT1 is localized to the outer membrane of the mitochondria and is enriched in MAM 
(Pellon-Maison et al., 2007).  Protein levels are greatest in the heart, however activity is low.  
Conversely, hepatocytes and adipocytes contain low GPAT protein levels but exhibit the 
highest GPAT activity (Lewin et al., 2001).  This discrepancy could be explained by regulation 
of GPAT activity by post-translational modification.  Mitochondrial localization allows GPAT1 
to compete with carnitine palmitoyl transferase-1 for acyl-CoA substrate.  This shunts fatty 
acids into triacylglycerol synthesis and away from β-oxidation (Hammond et al., 2005).  
Moreover, GPAT1 plays an important role in modulating triacylglycerol production in 
hepatocytes, as it accounts for 30-50% of totally liver GPAT activity (Wendel and Coleman 
unpublished; Hammond et al., 2005).  The GPAT1 promoter is activated by sterol regulatory 
element-binding protein 1c, increasing GPAT1 expression and activity under lipogenic 
conditions (Ericsson et al., 1997).  GPAT1 activity is also stimulated by AMP-activated kinase, 
casein II kinase (through direct phosphorylation) and insulin (Collison and Jolly, 2006; Onorato 
et al., 2005; Bronnikov, 2008).  Little is known about GPAT2.  Like GPAT1, it is localized to 
the mitochondria.  It is expressed highly in the testes yet its significance is unknown (Lewin et 
al., 2004; Wang et al., 2007).  GPAT3 is localized to the ER and protein levels are elevated in 
mouse tissues with increased triacylglycerol synthesis rates (adipose tissue, heart, small 
intestine).  In humans, expression is highest in kidney, heart, thyroid, and skeletal muscle (Cao 
et al., 2006).  Triacylglycerol synthesis is increased in HEK-293 cells overexpressing GPAT3, 
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while knockdown in 3T3-L1 adipocytes reduced synthesis by 60% (Cao et al., 2006; Shan et 
al., 2010).  Like GPAT3, GPAT4 is localized to the ER.  GPAT4 has also been found to traffic 
to lipid droplet, facilitating droplet expansion (Wilfling et al., 2013).  Expression is highest in 
adipose tissue (brown and white), testes, liver and heart (Nagle et al., 2008; Beigneux et al., 
2006; Vergnes et al., 2006).  Interestingly, Gpat4-/- mice presented with reduced subcutaneous 
fat deposits, yet knockdown of Gpat4 in adipocytes had minimal effect on total GPAT activity 
or triacylglycerol production (Vergnes et al., 2006).  Activity of both GPAT3 and GPAT4 is 
induced by insulin-stimulated phosphorylation on serine and threonine residues in 3T3-L1 
adipocytes (Shan et al., 2010). 
 
1.3.4 1-Acyl-glycerol-3-phosphate acyltransferase 
Following GPAT acylation of glycerol-3-phosphate to lysophosphatidate, 1-Acyl-sn-
glycerol-3-phosphate O-acyltransferase (AGPAT) carries out an analogous reaction, esterifying 
a second fatty acid (donated from a fatty acyl-CoA) to the second carbon position of 
lysophosphatidate to form phosphatidate.  AGPATs, like GPATs, are integral transmembrane 
proteins and lysophosphatidate conversion to phosphatidate has been found to occur at the ER 
and mitochondrial membranes (Chakraborty et al., 1999).  While numerous AGPAT isoforms 
have been identified, only AGPAT1-3 isoforms have been confirmed to acylate 
lysophosphatidate to form phosphatidate (Leung, 2001; Lu et al., 2005).  Human Agpat1 is 
expressed most highly in the liver, lungs, heart and pancreas - but is present in most tissues 
(Eberhardt et al., 1997; West et al., 1997).  AGPAT1 overexpression in 3T3-L1 adipocytes or 
C2C12 myoblasts caused increased fatty acid uptake and lipogenesis (Ruan and Pownal, 2001).  
Regulation of AGPAT1 has gone largely uninvestigated, yet, neuron-derived orphan receptor 1 
and peroxisome proliferator-activated receptor (PPAR) α binding sites in the gene promoter 
region suggest it may play a role in muscle development (Subauste et al., 2010).  AGPAT2 
demonstrates high similarity with AGPAT1 in sequence and predicted topology.  Transcript 
levels are most abundant in liver, heart and adipocytes (Agarwal et al., 2002; West et al., 1997).  
The Agpat2 promoter region fosters consensus-binding regions for CCAAT/enhancer-binding 
protein (C/EBP) β and PPARγ, key transcriptional activators required for adipogenesis 
(Coleman and Mashek, 2011; Tanaka et al., 1997; Gurnell et al., 2000).  This is supported by 
findings in 3T3-L1 differentiated adipocytes as Agpat2 mRNA is increased 30-fold.  Moreover, 
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Agpat2 specific siRNA suppressed C/EBPβ and significantly delayed PPARγ expression, 
thereby slowing adipogenesis.  Intriguingly, cells produced 3-fold greater phosphatidate, yet 
triacylglycerol levels were low while phospholipids remained normal (Gale et al., 2006).  
Agpat3 transcripts are detectable in adipose tissue (brown and white), liver and testis - the 
protein localizes to membranes of the ER, Golgi and lipid droplets (Schmidt et al., 2010; 
Wilfling et al., 2013).  Protease protection assays suggest AGPAT3 contains two TMDs and is 
oriented with the N-terminus in the cytosol and the C-terminus in the lumen of the ER or Golgi 
(Schmidt et al., 2010).   Studies have elucidated a role for AGPAT3 in the formation of Golgi 
membrane tubules and intracellular protein trafficking.  Knockdown of Agpat3 caused Golgi 
fragmentation in HeLa cells, possibly due to changes in membrane curvature triggered by 
aberrant ratios of lysophosphatidate and phosphatidate (Schmidt and Brown, 2009; Schmidt et 
al., 2010; Bankaitis, 2009).    
 
1.3.5 Lipin 
The next step in the Kennedy pathway requires displacement of the phosphate group at 
the 3-carbon of phosphatidate.  Lipins, alternatively known as phosphatidate phosphatases, 
traffic from the cytosol to the ER and hydrolyze phosphatidate to form 1,2-diacylglycerol.  
Depending on cellular needs, diacylglycerol can be utilized as a precursor for phospholipid or 
triacylglycerol synthesis (Carman and Han, 2006).  Three mammalian isoforms of Lipin have 
been identified (Lipin1-3).  It appears that structurally, these isoforms possess some common 
elements.  These include a nuclear localization sequence, a DIDGT motif (containing the active 
site) and an LXXIL motif thought to confer activity as a transcriptional coactivator (Han et al., 
2006; Finck et al., 2006).   
Lipin1 mRNA is most abundant in adipose tissue, skeletal muscle and testes (Peterfy et 
al., 2001).  The human LPIN1 gene has 3 splicing products designated α, β and γ (Han and 
Carman, 2010).  Overexpression of Lipin1α or Lipin 1β in McA-RH7777 rat hepatoma cells 
increased glycerolipid abundance and triacylglycerol secretion while reducing degradation of 
apolipoprotein B-100, the primary apolipoprotein in liver derived lipoproteins.  Moreover, 
knockdown of Lipin1 in this cell line markedly reduced triacylglycerol secretion (Bou Khalil et 
al., 2009; Khalil et al., 2010).  Lipin1 transcription has been shown to be increased by 
glucocorticoids, sterol regulatory element binding protein 1 and nuclear factor Y (Manmontri et 
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al., 2008; Zhang et al., 2008; Ishimoto et al., 2009).  Nuclear localization of Lipin1 is promoted 
by sumoylation and inhibited by interaction with cytosolic scaffold protein 14-3-3 (Peterfy et 
al., 2010; Liu and Gerace, 2009).  In the nucleus, Lipin1 interacts with, and enhances the 
activity of, transcription factors peroxisome proliferator-activated receptor-gamma coactivator 
(PGC)-1α and PPARα.  These transcription factors also increase LPIN1 expression.  Lipin1 
transcriptional coactivation of PPARγ, PPARδ and hepatocyte nuclear factor-4α has also been 
noted (Finck et al., 2006).  Accordantly, Lipin1 has been hypothesized to play a role in 
regulating the expression of numerous genes associated with glucose and fatty acid metabolism.  
Accordingly, mutation of the nuclear localization signal caused a reduction in triacylglycerol 
synthesis and secretion in McA-RH7777 cells (Bou Khalil et al., 2009; Khalil et al., 2010).  
Stimulation of the mammalian target of rapamycin pathway through insulin signaling has been 
shown to cause phosphorylation of serine and threonine residues on Lipin1, increasing 
interaction with 14-3-3 proteins and thereby promoting cytosolic localization (Peterfy et al., 
2010; Huffman et al., 2002; Harris et al., 2007).  Similarly, stimulation of triacylglycerol 
synthesis by oleate loading in hepatocytes reduced Lipin1 phosphorylation and increased its 
phosphatidate phosphatase activity and membrane localization - enhancing triacylglycerol 
synthesis (Harris et al., 2007; Cascales et al., 1984; Hopewell et al., 1985).  Further, Lipin1 
phosphorylation during mitosis reduces phosphatidate phosphatase activity (Grimsey et al., 
2008).  Mice deficient in Lipin1 present with fatty liver dystrophy.  As pups, they exhibit fatty 
liver and hypertriglyceridemia.  After weaning, they experience lipoatrophy, a reduction in 
brown and white adipocytes.  This appears to be caused by a lack of Lipin1-facillitated 
activation of adipogenic transcription factors PPARγ and C/EBPα rather than insufficient 
phosphatidate phosphatase activity (Phan et al., 2004).  Fatty liver dystrophy mice eventually 
experience neurodegeneration (Langner et al., 1989; Langner et al., 1991; Nadra et al., 2008).  
In humans, mutations that compromise Lipin1 activity appear to cause myoglobinurea, a 
symptom of muscle destruction (Yen et al., 2008). 
Lipin2 and Lipin3 are not as well characterized as Lipin1.  Expression of Lipin2 appears 
to be highest in the liver, brain and kidney, and while it exhibits comparable transcriptional 
coactivation function, its phosphatidate phosphatase activity is reduced relative to Lipin1 
(Csaki and Reue, 2010).  A role distinct from that of Lipin1 is indicated, as Lipin2 is not 
upregulated by glucocorticoids or PGC-1α and it is down-regulated during adipogenesis (Finck 
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et al., 2006; Grimsey et al., 2008).  Also of interest, Lipin2 is elevated in obesity while 
transcript levels remain unaltered (Gropler et al., 2009). All that is currently known of Lipin3 is 
that transcripts are expressed most highly in the liver and intestine (Donkor et al., 2007). 
 
1.3.6 1, 2-Diacylglycerol acyltransferase 
The terminal step in the Kennedy pathway is the conversion of 1,2-diacylglycerol to 
triacylglycerol.  This occurs via the formation of an ester bond between a long chain fatty acid 
and the free hydroxyl group of diacylglycerol (Fig. 1.3).  This reaction is catalyzed by the 
microsomal DGAT enzymes.  Two DGAT genes have been identified, DGAT1 and DGAT2, 
which produce distinct protein products of no sequence similarity.  While both DGAT1 and 
DGAT2 catalyze the same reaction, in vitro evidence suggests structural dissimilarity (Cases et 
al., 1998; Stone et al., 2006). DGAT1 is a member of a large family of membrane-bound O-
acyltransferases.  This family includes ACATs, which catalyze acyl-group transfer to 
cholesterol, forming cholesterol esters (Klein and Rudel, 1983).  DGAT2 belongs to the 
DGAT2/acyl CoA: monoacylglycerol acyltransferase family that includes several 
monoacylglycerol acyltransferases (MGAT) and a wax synthase (Cases et al., 1998, 2001 
Farese et al., 2000; Hofmann, 2000; Buhman et al., 2001; Yen et al., 2002; Cao et al., 2003a; 
Cheng et al., 2003; Yen and Farese, 2003; Turkish and Sturley, 2007).  Neither DGAT1 nor 
DGAT2 has an apparent preference in regard to acyl-CoA chain length or saturation; bias 
towards certain diacylglycerol species has yet to be determined (Cases et al., 2001).  In vitro, it 
has been noted that DGAT2 is more sensitive to alterations in Mg2+ concentration and may 
demonstrate increased activity at lower substrate concentration, however, the relevance in vivo 
is unknown (Cases et al., 2001).  DGAT1 has retinol acyltransferase, MGAT and mono- and di-
ester wax synthase activities.   DGAT1 retinol acyltransferase activity, esterifying retinol esters 
to form retinyl esters, may be important in the absorption of dietary vitamin A (Yen et al., 
2005).   
Upregulation of Dgat1 and Dgat2 mRNA has been identified during differentiation of 
3T3-L1 adipocytes but neither gene is essential for differentiation (Harris et al., 2011).  C/EBPβ 
and C/EBPα have been implicated in the induction of the DGAT2 gene during 3T3-L1 
differentiation (Payne et al., 2007).   A PPAR binding site is present in the promoter of 
DGAT1; activators of PPARγ have been found to increase Dgat1 mRNA in both adipocyte cell 
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lines and in mouse and human adipose tissue (Ludwig et al., 2002; Ranganathan et al., 2006).  
Both transcripts become more abundant following glucose treatment in mature adipocytes.  
Interestingly, Dgat2, but not Dgat1, transcripts accumulate in response to insulin (Meegala et 
al., 2002).  X-box binding protein 1, a transcription factor involved in the regulation of the 
unfolded protein response, augments expression of DGAT2 and other lipogenic genes in the 
liver (Lee et al., 2008).  DGAT2 expression was increased when X-box binding protein 1 was 
overexpressed in primary hepatocytes of wild-type and X-box binding protein 1-deficient mice 
(Lee et al., 2008).  mRNA levels of Dgat2 appear to be elevated in genetic and chronic diet-
induced obesity while Dgat1 transcripts are reduced (Meegala et al., 2002;Suzuki et al., 2005).   
Further reciprocal regulation is observed as Dgat2 transcripts are reduced in white adipose 
tissue (WAT) and liver during fasting but increase upon refeeding.  Dgat1 mRNA exhibits 
converse cycling (Meegala et al., 2002; Yen et al., 2008).  There is evidence that leptin 
suppresses DGAT2.  mRNA levels are induced 3-fold in WAT of leptin deficient ob/ob mice as 
well as in the WAT, skeletal muscle and small intestine of db/db (leptin receptor deficient) and 
Agouti KK-Ay (leptin resistant) mice (Chen et al., 2002; Wakimito et al., 2003).   
DGAT1 and DGAT2 are highly expressed in WAT and to a lesser extent in liver, small 
intestine, mammary glands and skeletal muscle; tissues with a prominent role in triacylglycerol 
metabolism (Cases et al., 1998; Cases et al., 2001; Kennedy, 1957; Kuerschner et al., 2008; 
Shockey et al., 2006; Stone et al., 2009; Weiss and Kennedy, 1956).  Despite the fact that 
DGAT1 and DGAT2 catalyze the same reaction and show similar general localization to the 
ER, these enzymes have distinct roles in triacylglycerol metabolism.  Results obtained from 
gene knockout studies in mice implicate DGAT2’s involvement in bulk triacylglycerol 
synthesis while DGAT1 appears to play a modulatory role in whole body energy homeostasis 
(Smith et al., 2000; Chen et al., 2002; Chen et al., 2003a; Stone et al., 2004; Yen et al., 2008).  
Mice lacking Dgat1 (Dgat1-/-) exhibit a 50% reduction in adipose mass relative to wild-type.  
They are also resistant to diet-induced obesity through a mechanism involving increased 
activity and thermogenesis, and reduced rate of intestinal triacylglycerol absorption (Smith et 
al., 2000; Chen et al., 2002, 2003b; Buhman et al., 2002). Additionally, Dgat1-/- mice have 
decreased triacylglycerol levels in liver and skeletal muscle, as well as increased insulin 
sensitivity, resulting in improved glucose metabolism (Chen et al., 2002; Chen et al., 2003b; 
Wang et al., 2007).  Dgat1+/- mice exhibit an intermediate phenotype   (Yen et al., 2008).  In 
	 13	
contrast, DGAT2 (Dgat2-/-) deficient mice exhibit severe skin abnormalities, leading to rapid 
dehydration and death within hours of birth (Stone et al., 2004).  This phenotype is attributed to 
reduction in in the synthesis of acylceramide, a key lipid component of the skin barrier, as well 
as a ~90% decrease in triacylglycerol content - yielding insufficient quantities of substrate to 
sustain energy metabolism.  Dgat2+/- mice are healthy and all physical and metabolic features 
are similar to wild-type mice (Yen et al., 2008).  Overexpression of DGAT2 in cells and mice 
resulted in significantly higher levels of intracellular triacylglycerol accumulation relative to 
DGAT1 overexpression, suggesting a larger role for DGAT2 in bulk triacylglycerol synthesis - 
consistent with mouse knockout studies (Monetti et al., 2007; Stone et al., 2004). 
At present, information regarding the molecular structure and function of DGAT1 and 
DGAT2 is limited.  DGAT1 contains three TMDs and is oriented with the N-terminus in the 
cytosol and the C-terminus in the ER lumen (Fig. 1.4A) (McFie et al., 2010). A highly 
conserved histidine residue (H426 murine DGAT1) facing the ER lumen is essential for 
enzymatic activity and has been proposed to represent part of the active site (McFie et al., 
2010).  Luminal residence of the active site implies DGAT1 involvement in the synthesis of 
triacylglycerol for incorporation into nascent lipoproteins and secretion into the circulation.  
The cytosolic N-terminus is not required for activity but may promote tetramer formation 
(Cheng et al., 2001).  This proposed topology of DGAT1 is supported by findings 
demonstrating latent DGAT activity in the ER lumen of liver microsomes (Waterman et al., 
2002). 
 Like DGAT1, DGAT2 is an integral membrane protein of the ER.  DGAT2 is well 
conserved in fungi, plants, and animals – with most of the variation occuring in residues of the 
N-terminal region (Fig. 9.1).  Studies have shown that murine DGAT2 has two TMDs and is 
oriented with both the N- and C-termini exposed to the cytosol (Fig. 1.4B) (Stone et al., 2006; 
McFie et al., 2014).  Due to the presence of a short loop connecting the TMDs, it has been 
proposed that DGAT2 may not span the membrane.  Rather, a hairpin like structure, consisting 
of the TMDs with a short loop between them, is inserted into the lipid bilayer.  Yet, a recent 
study suggests that the short loop (≤ 8 amino acids) does extend into the ER lumen (McFie et 
al., 2014).  Interestingly, the topology of yeast DGAT2 ortholog, Dga1, differs significantly 
from that of murine DGAT2.  Dga1 also has N- and C-termini facing the cytosol, but contains 
four transmembrane domains and two extended luminal regions (Liu et al., 2011) 
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Catalytic activity of DGAT2 has been linked to a highly conserved (H/E)PH(G/S) 
(HPHG in most species) sequence present in all members of the DGAT2 family.  Mutational 
analysis has demonstrated that this sequence, particularily the second histidine residue, is 
required for full enzymatic activity, suggesting that it may represent part of the active site 
(Cases et al., 2001; Stone et al., 2011).  Additional regions of high conservation are present but 
their significance remains largely unknown (Fig. 9.1). 
Interestingly, it appears that DGAT2 molecules form a large heterologous multimeric 
complex, likely facilitated by disulfide bond formation between adjacent members of the 
multimer (Man et al., 2006; McFie et al., 2011).  A chemical-crosslinking study revealed that 
DGAT2 dimerizes and is also part of a large protein complex  of ~650 kDa that is present in 
membranes and on lipid droplets (Jin et al., 2014)  The cytosolic orientation of the active site 
allows for deposition and storage of synthesized triacylglycerol into cytosolic lipid droplets, 
distinct cellular organelles key to lipid metabolism.  
 
 
 
Figure 1.4.  DGAT topology –  Domain topology of (A) DGAT1 and (B) DGAT2.  Included 
are locations of membrane spanning sections as well as positions of putative active sites.  
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DGAT2 is enriched in MAM of the ER (Cuie et al., 1993; Rusinol et al., 1994; Stone et 
al., 2009; Stone and Vance, 2000).  Studies focusing on the mechanism of DGAT2 localization 
have concluded that typical ER targeting signals are absent (Stone et al., 2006; Stone et al., 
2009; Teasdale and Jackson, 1996).  However, localization studies utilizing DGAT2 deletion 
mutants assert ER localization via the TMDs (amino acids 66-115) (McFie et al., 2011).  
DGAT2 mutants lacking both TMDs continue to associate with membranes, however they do 
not localize to the ER.  Rather, they localize to the mitochondria, most likely promoted by an 
N-terminal mitochondrial targeting sequence (McFie et al., 2011; Stone et al., 2009).  Deletion 
of the TMDs in combination with a region predicted to contain two α-helices (amino acids 156-
199), one amphipathic and the other hydrophobic and containing the putative acitve site, caused 
a significant portion of DGAT2 to localize to the cytosol (McFie et al., 2014).  Generation of 
chimeric proteins consisting of either TMD1 or TMD2 fused to a fluorescent reporter molecule 
(mCherry) revealed that TMD1, unlike TMD2, was sufficient to target the fluorescent construct 
to the ER (McFie et al., 2011).  While it is not entirely clear, it is possible that MAM situated 
DGAT2 interacts with mitochondria in order to promote channelling of substrates to DGAT2, 
increasing the production of triacylglycerols (Stone et al., 2009; Coleman and Lee, 2004; 
Coleman et al., 2000).  MAM localization could increase access to activated fatty acyl-CoAs 
produced by acyl-CoA synthetases in the outer mitochondrial membrane (Ikeda et al., 2001). 
DGAT2, but not DGAT1, associates with lipid droplets. Oleate loading of COS-7 cells 
expressing DGAT2 was observed to stimulate DGAT2 accumulation on the surface of cytosolic 
lipid droplets (Kuerschner et al., 2008; Stone et al., 2009).  Moreover, this localization pattern 
is found in adipocytes expressing endogenous DGAT2 (Kuerschner et al., 2008).  The current 
topology model, in conjunction with the unlikely ability for the phospholipid monolayer of lipid 
droplets to incorporate a bilayer spanning protein, suggests that DGAT2 remains imbedded in 
the ER membrane but is positioned in close proximity to droplets.  This model is bolstered by 
electron micrographic data demonstrating lipid droplets in close proximity to the ER (Cinti, 
2001; Kuerschner et al., 2008; Stemberger et al., 1984). However, if DGAT2 is imbedded in, 
but does not span the ER lipid bilayer, it is possible that the phospholipid monolayer of the lipid 
droplet could accommodate DGAT2 (Kuerschner et al., 2008; Yen et al., 2008).  Findings by 
Xu et al. support the idea that DGAT2 does localize directly to droplets.  A fusion protein 
expressed in DGAT2 mutant (lipid droplet defficient) round worms, consisting of an ER-
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anchoring domain fused to the C-terminus of GFP-DGAT2, failed to initiate droplet growth. 
Disruption of ER tethering was sufficient to partially re-establish lipid droplet expansion and 
DGAT2 localization to lipid droplets. The group also generated convincing 
immunofluorescence data documenting co-localization with lipid droplet specific marker, 
perilipin-2, on the droplet surface (Xu et al., 2012).   
A study by Jacquier et al. provided insight into DGAT2 homolog, Dga1, ER to lipid 
droplet trafficking in S. cerevisiae.  Using a fluorescence recovery after photobleaching 
approach, they found that the relocation of Dga1 occured independent of energy and 
temperature.  Thus, Dga1 does not reach the lipid droplet surface through traditional vesicular 
transport.  Noting that the observed rate of Dga1 fluorescence recovery was characteristic of 
two-dimensional diffusion, the group concluded that localization to lipid droplets may be 
attributed to lateral diffusion within a continuous membrane.  This study advocates that lipid 
droplets are functionally connected to the ER membrane and that transport of membrane 
proteins between the lipid droplet and ER is mediated by this connection.  Jacquier et al. also 
observed that droplet-localized Dga1 was able to shuttle back to the ER following stimulation 
of lipolysis (Jacquier et al., 2011).  Finally, a recent study suggested that the short 
transmembrane loop is important in allowing DGAT2 to function on lipid droplets; extension of 
the loop inhibited DGAT2 localization to droplets (McFie et al., 2014) 
DGAT2 interaction with other proteins involved in triacylglycerol synthesis has been 
noted.  Stearoyl-coenzyme A desaturase (SCD) 1, responsible for catalyzing the desaturation of 
Δ9-cis fatty acids, was found to co-localize with DGAT2 in the ER of HeLa cells.  Evidence of 
direct interaction was established by co-immunoprecipitation and fluorescence resonance 
energy transfer analysis.  Co-expression of the two proteins resulted in accumulation of 
triacylglycerol levels above what was observed when either protein was expressed individually 
(Man et al., 2006).  Interaction with fatty acid transport protein 1, an acyl-CoA synthetase, was 
identified at the interface of the ER and lipid droplet and was found to facilitate lipid droplet 
expansion (Xu et al., 2012).  Recently, DGAT2 has been reported to interact with MGAT2, an 
enzyme responsible for producing diacylglycerol, particularly in the intestine.  Interaction was 
found to be dependent on the DGAT2 TMDs.  It was also discovered that incubation of McA-
RH7777 cells with 2-monoacylglycerol caused DGAT2 to localize to, and produce, large lipid 
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droplets.  This suggests that diacylglycerol produced by MGAT2 can be utilized by DGAT2 
(Jin et al., 2014)  
DGAT activity has been divided into overt and latent fractions from studies in liver 
microsomes (Waterman et al., 2002; Owen et al., 1997; Abo-Hashema et al., 1999).  Overt 
activity is believed to represent catalysis on the cytosolic face of the ER, corresponding to 
storage of triacylglycerols in cytosolic lipid droplets.   Latent activity is detected after 
membrane permeabilization and is thought to denote triacylglycerols synthesized in the ER 
lumen and destined for secretion.  Elucidating the precise role of each DGAT in their 
contribution to triacylglycerol storage and secretion has yielded interesting and sometimes 
contradictory results.  Based on the topologies, it would suggest that latent activity is that of 
DGAT1 while overt activity is provided by DGAT2.  Evidence from transgenic mouse models 
suggests that over expression of DGAT1 or DGAT2 increases triacylglycerol production and 
storage in lipid droplets (Monetti et al., 2007).  Overexpression of DGAT1 in McA-RH7777 
cells increased intracellular triacylglycerols and their secretion (Liang et al., 2004).  In vivo, 
short-term adenoviral overexpression of DGAT1 increased liver triacylglycerol abundance and 
secretion.  DGAT2 overexpression increased liver triacylglycerols to a greater level than was 
observed for DGAT1 but had no effect on secretion (Yamazaki et al., 2005).  A similar study 
found that while both isoforms increased triacylglycerol levels in hepatocytes, overexpression 
of neither DGAT1 nor DGAT2 altered triacylglycerol secretion (Millar et al., 2006).  Studies 
utilizing antisense oligonucleotides directed against DGAT2 in the liver reduced hepatic 
triacylglycerol levels and triacylglycerol secretion (Yu et al., 2005; Liu et al., 2008).  Recent 
work characterizing the effects of DGAT1 and DGAT2 inhibitors in mouse hepatocytes found 
that while DGAT1 and DGAT2 can compensate for one another in triacylglycerol synthesis, 
triacylglycerols produced by DGAT1 are primarily utilized for oxidation while those made by 
DGAT2 are directed towards secretion (Li et al., 2015).  It was also observed that inhibition of 
DGAT2, but not DGAT1, significantly reduced triacylglycerol secretion; tandem inhibition 
essentially abolished secretion.  It is possible that interfering with the activity of one DGAT 
isoform could artificially impact the typical physiological processes of the other. 
The beneficial effects observed in homozygous and heterozygous knockout mice made 
DGAT1 an attractive candidate for therapeutic intervention in the treatment of hyperlipidemias, 
obesity and type II diabetes.  Several companies including Pfizer, Astrazeneca and Novartis 
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produced inhibitors that progressed to clinical trials (Maciejewski et al., 2013; Denison et al., 
2013; Novartis, 2011; Serrano-Wu et al., 2012).  Unfortunately, not only was the efficacy of 
these compounds underwhelming but significant gastrointestinal side effects were noted.  For 
this reason, as well as results obtained in the studies of DGAT2 directed antisense 
oligonucleotides in mice (detailed above), there has been renewed interest in targeting DGAT2.  
While several DGAT2 inhibitors have been developed, they have exhibited relatively weak 
potency - in vitro and in vivo effects are unknown (Qi et al., 2012; Wurie et al., 2012; Lee et 
al., 2013; Kim et al., 2013; Naik et al., 2014; Kim et al., 2014).  A recent report detailed 
synthesis of several DGAT2 inhibitors; the most promising of which, compound 9 (PF-
06424439), reduced plasma triacylglycerol levels by greater than 50% in rats (Futatsugi et al., 
2015).  Moreover, in low-density lipoprotein receptor knockout mice fed a high fat and high 
cholesterol diet, 3 days of compound 9 treatment reduced plasma triacylglycerol by 61% and 
plasma cholesterol by 34% relative to control. 
Recently, DGAT1 and DGAT2 associated diseases have been identified in humans.  A 
case study detailed three children born from parents heterozygous for a DGAT1 splice variant 
in which exon 8 was skipped, resulting in an in-frame deletion of 75 base pairs; a 25 amino acid 
deletion in a highly conserved domain present in members of the membrane-bound O-
acyltransferase family (Haas et al., 2012).  While the deletion did not affect the putative active 
site, the protein was rapidly degraded and inactive, culminating in an autosomal recessive 
congenital diarrheal disorder.  Both parents exhibited elevated fasting triacylglycerol levels and 
total cholesterol.  The first child (boy) was heterozygous for the mutant allele and was 
unaffected.  The second child (girl), homozygous for the mutant allele, presented with 
hyperlipidemia, vomiting, colicky pain, diarrhea and associated protein-losing enteropathy - 
starting 3 days after birth.  She was severely underweight despite tube-feeding and died at 17 
months from malnutrition and sepsis.  The third child (boy) presented similarly with 
hyperlipidemia, diarrhea and protein-losing enteropathy.  The child was responsive to 
nutritional support and by 13 months the diarrhea had improved.  At 46 months of age he was 
healthy and on an unrestricted diet.  The authors determined that DGAT1, but not DGAT2, is 
expressed highly in the humnan intestine.  This is contrary to tissue expression in mice where 
both DGAT1 and DGAT2 are present (Cases et al., 1998, 2001).  The authors hypothesized that 
diarrhea and protein-losing enteropathy may be caused by the accumulation of toxic DGAT1 
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substrates, diacylglycerol and fatty acids, or by bile acid malabsorption.  Moreover, 
hyperlipidemia observed in both children and parents could be due to overcompensation by 
hepatic DGAT2 through secretion of triacylglycerols packaged as VLDL.   The survival of the 
third child suggests the possibility of age or sex related differences in intestinal DGAT2 
expression, compensating for defective DGAT1. 
 Aberrant DGAT2 was very recently reported to cause autosomal dominant early-onset 
axonal Charcot-Marie-Tooth Disease (Hong et al., 2016).  The report described a male, who as 
early as 8 years old, suffered from weakness in the lower limbs, ataxia and frequent falling.  
The disease progressed as the individual experienced hand tremors at 12 years and difficulty 
walking at 37 years of age.  Analysis was undertaken at age 38.  Serum triacylglycerol levels 
were mildly depressed while serum total cholesterol and low-density lipoprotein-cholesterol 
were average.  The patient’s son exhibited similar weakness of the lower limbs, ataxia, and 
frequent falling as early as 5 years of age.    The cause was determined to stem from mutation 
of tyrosine 223 to histidine (Y223H).  Overexpression of the mutant protein inhibited 
proliferation in NSC34 mouse motor neuron cells.  Moreover, overexpression in zebrafish 
decreased axon branching as well as axon fasciculation in neurons of the neuromuscular 
junction.  While the mechanism of pathology was unclear, reduced ER stress was noted, 
suggesting that DGAT2 Y223H does not trigger an unfolded protein response. 
 
1.3.7 The monoacylglycerol pathway 
In addition to the Kennedy pathway, the monoacylglycerol pathway is another prominent 
mechanism by which triacylglycerols are synthesized in mammals.  The MGAT pathway 
describes the transfer of an acyl group from fatty acyl-CoA to 2-monoacylglycerol, forming 
1,2-diacylglycerol (Fig. 1.5) (Kennedy, 1957; Bell and Coleman, 1980; Lehner and Kuksis, 
1996; Ellis et al., 2010; Coleman et al., 2002).  The MGAT and Kennedy pathways converge as 
1,2-diacylglycerol is converted to triacylglycerol by DGATs (Cases et al., 1998; Yen et al. 
2008).  The MGAT pathway is important for the absorption of dietary fat.  Triacylglycerols are 
highly non-polar and cannot be absorbed intact; they must first be broken down to 2-
monoacylglycerol by lipases.  Monoacylglycerol is transported into enterocytes where 
triacylglycerols are re-synthesized by the MGAT pathway  (Johnson and Rao, 1967).   
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The acylation of 2-monoacylglycerol is catalyzed by MGAT.  There are three MGAT 
isoforms, MGAT1-3, encoded by genes MOGAT1-3 respectively (Cases et al., 2001).  All three 
isoforms have been found to localize to the ER and demonstrate broad substrate specificity for 
monoacylglycerols and fatty-acyl CoA.  Variation in MGAT tissue expression has been noted 
among isoforms.  MGAT1 is expressed highly in the stomach and kidney of mice. It is also 
detectable in liver, uterus and adipose tissue but is absent in the intestine (Yen et al., 2002).  
This expression pattern is conserved in humans but at reduced levels (Yen and Farese, 2003).  
Murine MGAT2 is expressed highly in the small intestine and at low levels in kidney and 
adipose tissue.  Human MGAT2 is expressed highly in the intestine, stomach, liver and kidneys.  
It is detectable in mammary glands and adipose tissue as well (Yen and Farese, 2003; Cao et al. 
2003b).  MGAT3 is not present in mice but is expressed highly in the human intestine, 
particularly in the ileum (Yue et al., 2011; Cheng et al., 2003).  Structural information on 
MGAT isoforms is very limited, however, MGAT2 appears to be an integral membrane ER 
protein with two TMDs - the second of which dictates ER targeting.  Topology studies indicate 
that the short N-terminal region is partially embedded in the ER membrane bilayer.   The 
extended C-terminal region faces the cytosol, while a short sequence containing the putative 
HPHG active site, is embedded in the cytosolic face of the membrane (McFie et al., 2016).  
Very little is known about the physiological role of MGAT1.  A recent study found 
MGAT1 is highly expressed in fatty liver relative to normal liver; MGAT1 suppression is 
effective at blocking the fatty liver phenotype (Lee et al., 2012).  Moreover, MOGAT1 gene 
activation is directly induced by PPARγ (Lee et al., 2012).  Evidence suggests that MGAT2 is 
the major intestinal MGAT in mice.  Global MGAT2 knockout mice (Mogat2-/-) appear to 
develop normally, however, they gain less weight than wild-type mice when fed a high fat diet, 
accordant with MGAT2’s role in fat absorption.  Mogat2-/- mice are also resistant to glucose 
intolerance, hypercholesterolemia, and hepatic steatosis induced by high-fat diet.  Interestingly, 
MGAT2 knockout mice absorb sufficient dietary fat, even when fat accounts for 60% of caloric 
intake, such that levels of fecal fat and vitamin A and E are normal.  This suggests that MGAT2 
is not essential for absorbing typical fat quantities.  Nevertheless, Mogat2-/- mice exhibit 
impaired triacylglycerol synthesis, slowed gastric emptying and perturbed fat absorption 
kinetics (Yen et al., 2009).  MGAT3 is only present in humans and higher mammals.  While it 
functions as an MGAT, it shares higher sequence identity with DGAT2 (49%), than with 
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MGAT1 (44%) or MGAT2 (46%) (Cheng et al., 2003).  Also, like MGAT2, MGAT3 is 
upregulated in the liver of humans with nonalcoholic fatty liver disease; expression is greatly 
reduced following weight loss (Denison et al., 2014).  Analysis of MGAT3 found that it is 
present in the ER and may also function as a DGAT (Cheng et al., 2003; Cao et al., 2007; 
Brandt et al., 2016a).  Overexpression of MGAT3 in oleate treated COS-7 cells increased lipid 
droplet size and number; yet, MGAT3 did not traffick to lipid droplets (Brandt et al., 2016a)  
 
 
 
 
 
 
Figure 1.5.  The monoacylglycerol pathway - In the monoacylglycerol pathway, 2-
monoacylglycerol is acylated to produce 1,2-diacylglycerol.  This reaction is catalyzed by the 
endoplasmic reticulum localized, MGAT, of which there are three isoforms (MGAT1-3).  
MGAT isoforms differ in tissue expression and substrate specificity.  Diacylglycerol can be 
converted to triacylglycerol by the DGAT enzymes.   
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1.4 Digestion and transport of lipids  
 Triacylglycerol is the primary component of ingested animal fat and plant oils, and 
represents ~95% of dietary fat; the remaining 5% consists of phospholipids, sterols and fat-
soluble vitamins (Yen et al., 2015).  Intestinal absorption of triacylglycerol is very efficient, 
allowing for almost complete assimilation of dietary fats even following a high fat meal 
(Kasper, 1970; Mansbach and Dowell, 2000).  Also, processing of dietary fat and its transition 
to body fat requires less energy compared to carbohydrate or protein (Swaminathan et al., 1985; 
Maffeis et al., 2001).   
Fat digestion is initiated in the stomach by lingual and gastric lipases, which 
preferentially hydrolyze medium chain triacylglycerols at the sn-3 position, producing 1,2-
diacylglycerol (Carey and Hernell, 1992; Armand et al., 1996).  Emulsification, or the 
breakdown of large fat globules into smaller fat particles, begins in the stomach by mechanical 
contractions.  The stomach regulates transition into the duodenum where food is mixed with 
bile acids and pancreatic secretions containing lipases.  Bile acids function as detergents and are 
crucial in the solubilization of dietary fats, cholesterol and lipid-soluble vitamins (Zhou and 
Hylemon, 2014).  The pancreas produces several lipases such as pancreatic lipase, carboxyl 
ester lipase, and phospholipase A2, in addition to pancreatic lipase-related protein-1 and -2 
(Wang et al., 2013).  In the duodenum, emulsion particles consist of a core of triacylglycerol 
and diacylglycerol covered by a monolayer of polar lipids, phospholipids and fatty acids.  On 
the surface, small quantities of triacylglycerols and cholesterol are present - along with 
denatured dietary proteins, oligosaccharides and a bile salt coat (Carey and Hernell, 1992).  
Pancreatic lipase is a soluble enzyme and catalyzes hydrolysis at the interface between 
emulsion-oils and the aqueous phase (Verger, 1997; Roussel et al., 1998). Pancreatic lipase 
hydrolyzes triacylglycerol primarily at sn-1 and sn-3 positions to produce monoacylglycerol 
and fatty acids.  It can also hydrolyze monoacylglycerol, yielding glycerol and a fatty acid 
(Patton and Carey, 1979).  Digestion of dietary phospholipids and cholesterol also occurs in the 
small intestine.  Phospholipids are hydrolyzed by phospholipase A2 at the sn-2 position, 
releasing fatty acids while lysophospholipids are integrated into micelles prior to uptake by 
mucosal cells (Wang et al., 2013).  Dietary cholesterol must be unesterified by cholesterol 
esterase, carboxylic ester lipase and sterol ester hydrolase before incorporation into micelles 
(Wang et al., 2013).  
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 Fatty acids released during digestion are taken up by enterocytes through passive 
diffusion and protein transport (Stahl et al., 1999; Mashek and Coleman, 2006; Abumrad and 
Davidson, 2012).  Passive diffusion via fatty acid “flip-flop” across the plasma membrane is 
believed to account for a large percentage of fatty acid uptake (Niot et al., 2009).  Several 
protein transporters have also been identified including, fatty acid transport protein 4, fatty acid 
binding proteins (FABP) and fatty acid translocase (Grevengoed et al., 2014; Stremmel et al., 
1985; Abumrad and Davidson, 2012; Chen et al., 2001).  Monoacylglycerol is absorbed by the 
intestinal brush border membrane through passive diffusion (Schulthess et al., 1994).   As 
monoacylglycerol absorption can be saturated, the existence of a protein transporter has also 
been hypothesized (Ho and Storch, 2001).  After uptake by enterocytes, fatty acids and 
monoacylglycerol are transported through the cytosol to the ER, likely by FABPs (Storch and 
Corsico, 2008). These include liver-type FABP, which is also expressed in the liver and kidney, 
and intestine-type FABP (Storch and McDermott, 2009).  In addition to fatty acids, liver-type 
FABP binds monoacylglycerol and acyl-CoA (Lagakos et al., 2013; Storch and Thumser, 
2000).  Data from liver-type FABP and intestine-type FABP knockout mice suggest that for 
triacylglycerol synthesis, fatty acids are channeled by intestine-type and monoacylglycerol by 
liver-type.  Liver-type FABP may also play a role in fatty acid oxidation (Lagakos et al., 2013).   
Prior to triacylglycerol synthesis, fatty acids must be activated by an acyl-CoA 
synthetase, of which thirteen isoforms have been identified.  Activation is achieved by 
thioesterification of the long-chain fatty carboxyl group (≥ 16 carbons) with CoA (Grevengoed 
et al., 2014).  The acyl-CoA synthetase 5 isoform is the most abundant in the intestinal mucosa 
and accounts for 60% of total intestinal acyl-CoA synthetase activity in mice (Meller et al., 
2013).  In the intestine, the most prominent mechanism for triacylglycerol synthesis is via the 
MGAT pathway.  It is estimated that >75% of intestinal triacylglycerol is produced via this 
route (Johnston and Rao, 1967).  Interestingly, an alternate DGAT mechanism for 
triacylglycerol synthesis has been reported in rat intestine.  In this reaction, an unidentified 
diacylglycerol transacylase catalyzes acyl-group transfer between two molecules of 
diacylglycerol to form triacylglycerol and monoacylglycerol (Lehner and Kuksis, 1993; Cases 
et al., 2001). 
 It is believed that synthesized triacylglycerols are released into the phospholipid bilayer 
of the ER (Wilfling et al., 2014a).  These triacylglycerols either become incorporated into 
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cytosolic lipid droplets or enter the ER lumen for secretion (Thiam et al., 2013; Demignot et 
al., 2014; Lehner et al., 2012; Martin and Parton, 2006; Murphy and Vance, 1999; Ohsaki et 
al., 2009; Sturley and Hussain, 2012).  In hepatocytes and enterocytes, cells responsible for the 
production of lipoproteins, accumulated triacylglycerols primarily partition into the ER lumen 
for secretion (Hussain, 2014).  These accumulations are known as chylomicrons in the small 
intestine and very low-density lipoproteins in hepatocytes.  For chylomicrons, the surface 
consists of a phospholipid monolayer and free cholesterol surrounded by apolipoprotein B48.  
Other proteins present on the surface of chylomicrons include apolipoprotein AI, apolipoprotein 
AIV and apolipoprotein C.  The interior of chylomicrons primarily consists of triacylglycerol 
and cholesteryl esters.  Chylomicrons are transported to the Golgi for modification prior to 
release into the circulation via the thoracic duct (Mansbach and Siddiq, 2010; Tso et al., 2001).  
Chylomicrons function to transport triacylglycerol to peripheral tissues, especially skeletal 
muscle and adipose tissue.  Triacylglycerol is subjected to hydrolysis by lipoprotein lipase in 
the blood vessel capillaries prior to entering tissues (Young and Zechner, 2013).  Hydrolyzed 
chylomicrons are known as chylomicron remnants, which ultimately are taken up by the liver 
(Redgrave, 1970; Ji et al., 1997).  Following a lipid rich meal, when intake of fatty acids and 
monoacylglycerol surpasses the enterocytes ability to produce and secrete chylomicrons, 
triacylglycerol is stored in cytosolic lipid droplets (Nevin et al., 1995).  Triacylglycerol stored 
in lipid droplets can be liberated for secretion by adipose triglyceride lipase (Yang et al., 1995; 
Obrowsky et al., 2013; Xie et al., 2014; Zhang et al., 2014). 
  
1.5 Lipid droplets  
Originally viewed as inert deposits of intracellular lipids, lipid droplets are now 
recognized as functional organelles with a variety of roles (Fujimoto and Parton, 2011).  
Droplets in non-adipocytes range from 0.1-5 µm in diameter while those found in white 
adipocytes can be greater than 100 µm (Tauchi-Sato et al., 2002).  The exterior phospholipid 
monolayer consists of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, 
lysophosphatidylcholine and lysophosphatidylethanolamine (Tauchi-Sato et al. 2002; Leber et 
al. 1994; Bartz et al. 2007a).  Phosphatidylcholine is the primary phospholipid in the 
monolayer, possibly because its cylindrical shape reduces surface tension (Thiam et al., 2013).  
Free cholesterol is also present on the lipid droplet surface (Prattes et al., 2000).  The interior is 
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composed of stored triacylglycerols and cholesterol esters in varying ratios, depending on cell-
type.  Cryoelectron microscopy has revealed segregation between triacylglycerols and 
cholesterol esters in the droplet core (Czabany et al. 2008; Chang et al. 2009).  Proteins are 
known to associate with the lipid droplet surface through insertion into, or interaction with, the 
phospholipid monolayer and have also been detected in the droplet core (Dvorak et al., 1992; 
Bozza et al., 1997; Robenek et al., 2004, 2005).  How proteins are inserted into the 
phospholipid monolayer remains an important question.  Caveolin, a scaffold protein with 
several functions, is known to interact with the plasma membrane and lipid droplets.  
Topological evidence indicates cytosolic localization of the N- and C-termini with the presence 
of a long central hydrophobic membrane helix that is embedded in the membrane (Glenney and 
Soppet, 1992; Ostermeyer et al., 2004).  This is very similar to DGAT2 (Stone et al., 2006; 
McFie et al., 2014).  Possibly, these long internal hydrophobic sequences are central in 
facilitating embedment in both membrane bilayers and the lipid droplet monolayer.  
 Triacylglycerol synthesized by DGATs and deposited in the ER membrane bilayer has 
limited solubility, leading to the formation of lipid droplets (Wang et al., 2010).  There are 
three prominent hypotheses for how lipid droplets are formed. The first of which suggests that 
lipid esters accumulate in the ER bilayer, leading to bulging of the cytosolic monolayer.  The 
cytosolic leaflet eventually buds off to form an enclosed lipid droplet.  Whether this is driven 
solely by the accumulation of neutral lipids in the ER or by cytosolic proteins that bind to the 
ER and induce budding, is unknown  (Fig. 1.6A) (Murphy and Vance, 1999; Walther and 
Farese, 2009).  The bicelle formation model is very similar. Lipid esters accumulate between 
the ER membranes prior to both leaflets of the membrane being excised (Fig. 1.6B) (Ploegh, 
2007).  One issue with this model is that excision of the droplet would create a hole in the ER 
membrane, allowing release of segregated calcium and altering the redox environment of the 
ER (Walther and Farese, 2009).  Finally, the vesicular budding model describes accumulation 
of triacylglycerols in bilayer vesicles produced by vesicle machinery of the secretory pathway 
(Fig. 1.6C) (Walther and Farese, 2009; Walther et al., 2009).  The vesicle, which remains 
tethered or in close proximity to the ER, has neutral lipids deposited into the intermembrane 
space, causing the vesicle lumen to either fuse with the outer membrane or form an inclusion 
within the droplet interior.  
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Figure 1.6.  Theories of lipid droplet formation – (A) The monolayer budding theory 
suggests that triacylglycerol s accumulate in the ER membrane, causing bulging of the cytosolic 
leaflet, which eventually pinches off into the cytosol.  (B) The bilayer budding model differs in 
that both the ER and cytosolic faces of the bilayer form the lipid droplet.  (C) The vesicular 
budding model posits that triacylglycerols accumulate in the membrane bilayer of vesicles that 
are in close proximity to the ER membrane. 
 
 Following droplet formation, lipid droplets grow through coalescence, ripening and in 
situ expansion (Thiam et al., 2013).  Coalescence is driven by increasing surface tension 
brought on by the incorporation of lipids with negative curvature such as cholesterol, 
diacylglycerol, phosphatidylethanolamine and fatty acids.  Insufficient levels of 
phosphatidylcholine also drives coalescence of lipid droplets, reducing surface tension by 
decreasing surface-to-volume ratio (Fujimoto and Parton, 2011). This has been shown in 
Drosophila and mammalian cells (Guo et al., 2008; Jacobs et al., 2008).  Droplet ripening 
refers to transfer of neutral lipids from one lipid droplet to another.  Triacylglycerols flow from 
the smaller droplet to the larger droplet, down the Laplace pressure gradient. Laplace pressure 
describes pressure differences between the inside and outside of a curved surface.  Fat-specific 
protein 27 is known to induce ripening in adipose tissue during adipogenesis (Gong et al., 2011; 
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Sun et al., 2013).  Finally, in situ expansion describes triacylglycerol synthesis on the formed 
droplet and is facilitated by localization of triacylglycerol synthesis enzymes to the lipid droplet 
surface. Isoforms of acyl-CoA synthetase, GPAT4, AGPAT3 and DGAT2 have all been found 
to traffic to lipid droplets (Wilfling et al., 2014b).    
 The PAT protein family consists of perilipin, adipophilin/adipose differentiation-related 
protein and tail-interacting protein of 47 kDa - recently renamed perilipin-1, perilipin-2 and 
perilipin-3 respectively - along with S3-12 (perilipin-4) and OXPAT/MLDP/LSDP5 (perilipin-
5) (Londos et al., 2005; Kimmel et al., 2010).  These proteins localize to lipid droplets and play 
crucial structural and regulatory roles.  They differ slightly in tissue expression and cellular 
localization.  Perilipin-1 is expressed in adipocytes and steroidogenic cells (Greenberg et al., 
1991).  Following feeding, when insulin levels are high, perilipin-1 is dephosphorylated.  
Perilipin-1 sequesters comparative gene identification 58 (CGI58), an activator of adipose 
triglyceride lipase, and also inhibits hormone-sensitive lipase interaction with lipid droplets - 
promoting triacylglycerol storage (Brasaemle, 2007; Lass et al., 2011).  Deletion of perilipin-1 
in mice decreased WAT and increased ectopic fat deposition (Martinez-Botas et al., 2000; 
Tansey et al., 2001).  Moreover, loss of function in humans causes partial lipodystrophy, 
dyslipidemia and type II diabetes (Gandotra et al., 2011).  Perilipin-1 is typically found on large 
lipid droplets (Grahn et al., 2013).  Perilipin-2 is expressed most highly in the liver, heart, and 
skeletal muscle, but it ubiquitous in tissues  (Jiang and Serrero, 1992; Heid et al., 1998).  
Similar to perilipin-1, it reduces adipose triglyceride lipase induced lipolysis but cannot 
compensate for loss of perilipin-1 activity in adipose tissue (Listenberger et al., 2007).  
Perilipin-3 is elevated in small intestine, liver and macrophages but is detectable in all tissues 
(Grasselli et al., 2010).  Data suggests that perilipin-3 functions in the organization of the lipid 
droplet phospholipid monolayer and knockdown in hepatic tissue inhibits triacylglycerol 
storage (Sztalryd et al., 2006).  Perilipin-4 is expressed in WAT, heart and skeletal muscle; 
expression is controlled by PPARγ (Wolins et al., 2006; Dalen et al., 2004; Nagai et al., 2004; 
Shimizu et al., 2006).  Its role in adipose tissue is unknown but loss of perilipin-4 in cardiac 
tissue correlated with attenuated triacylglycerol storage (Chen et al., 2013).  Perilipin-5 is 
largely found in organs with prominent fatty acid oxidation, like liver, muscle and brown 
adipose tissue (Fujimoto and Parton, 2011).  Overexpression of perilipin-5 has been found to 
promote cardiac steatosis by blocking lipolysis (Pollak et al., 2013).  Accordantly, reduced 
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perilipin-5 expression correlated with reduced storage of triacylglycerols. 
It is believed that PAT proteins may bind lipid droplets using a similar mechanism to 
that of apolipoprotein E, which utilizes a four-helix bundle of amphipathic helixes capable of 
binding the monolayer surface (Wilson et al., 1991).  A very similar four-helix bundle has been 
identified in perilipin-3 (Lu et al., 2000).  Additionally, a sequence of N-terminal 11-mer 
repeats forming an amphipathic helical structure is common to all PAT proteins and is likely 
involved in lipid droplet interaction (Hickenbottom et al., 2004).  Interestingly, PAT proteins 
demonstrate preferential binding based on lipid droplet size.  In adipocytes, perilipin-3 and 
perilipin-4 localize to small droplets while perilipin-2 and perilipin-1 are found on medium and 
large droplets respectively (Wolins et al., 2005).  The mechanism for this is unknown, however, 
PATs may preferentially bind lipid droplets of a certain curvature, or interact with certain 
proteins or phospholipid head groups more abundant on or in droplets of a given size (Walther 
and Farese, 2009). 
 
1.6 Triacylglycerol catabolism 
 Stored triacylglycerols can be liberated from cytosolic lipid droplets to meet cellular 
energy requirements through fatty acid catabolism, for thermogenesis, or for the assembly of 
lipoproteins and intracellular signaling molecules (Walther and Farese, 2009).  Lipolysis can 
occur in the cytosol, ER and in late endosomes (Hornick et al., 1992; Lass et al., 2011).  This 
process is largely modulated by lipases; the location and substrate specificity dictates which 
pathway fatty acids are directed to.  All lipases belong to the α/β hydrolase superfamily of 
serine esterases (Duncan et al., 2007).  While there are some examples of integral membrane 
lipases, most are soluble proteins and act at the interface of the lipid droplet and the cytosol.   
In WAT, insulin present in the fed-state inhibits lipolysis, however, during fasting, 
increased catecholamines and stress hormones stimulate lipolysis - utilizing triacylglycerol to 
meet energy requirements (Fain and Garcija-Sainz, 1983; Arner, 2005).  Stimulation of β-
adrenergic signaling by catecholamines increases cAMP, thereby activating protein kinase A 
(Fain and Garcija-Sainz, 1983; Carmen and Victor, 2006).  Protein kinase A phosphorylates 
perilipin-1 and hormone sensitive lipase.  Perilipin-1 phosphorylation inhibits its ability to 
interact with and sequester CGI58, an activator of adipose triglyceride lipase (Tansey et al., 
2001; Sztalryd et al., 2003; Yamaguchi et al., 2006).  It also allows hormone sensitive lipase to 
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interact with lipid droplets, promoting hydrolysis (Tansey et al., 2003).  Adipose triglyceride 
lipase is abundant in adipose tissue but is also expressed in heart, intestine, muscle, liver and 
pancreas (Ahmadian et al., 2011; Chandak et al., 2010; Haemmerle et al., 2006, 2011; Ong et 
al., 2011; Wu et al., 2012).  It catalyzes hydrolysis of triacylglycerol at sn-1 and sn-2, 
producing sn-1,3-diacylglycerol or sn-2,3-diacylglycerol respectively (Zimmerman et al., 2004, 
2009).  Hormone sensitive lipase is present mainly in white and brown adipocytes as well as 
steroid producing tissues (Holm et al., 1988; Kraemer et al., 1993; Holm, 2003).  It functions 
primarily as a diacylglycerol lipase, exhibiting a preference for fatty acids at the sn-3 position, 
while it also demonstrates cholesteryl ester- and retinyl ester-lipase activity (Rodriguez et al., 
2010; Cook et al., 1982; Wei et al., 1997).  Triacylglycerol lipase activity has been noted in 
vitro, yet hormone sensitive lipase is not sufficient to rescue adipose triglyceride lipase loss in 
vivo (Morak et al., 2012).  Protein kinase A phosphorylates and activates hormone sensitive 
lipase (Anthonsen et al., 1998; Su et al., 2003).  In addition, phosphorylated perilipin-1 binds 
and recruits hormone sensitive lipase to the lipid droplet surface (Wang et al., 2009a; Krintel et 
al., 2009).  Monoacylglycerol lipase localizes to the cytosol and lipid droplets, catalyzing the 
hydrolysis of monoacylglycerol (Karlsson et al., 1997).  Little is known regarding the 
mechanisms governing monoacylglycerol lipase but mice with aberrant monoacylglycerol 
lipase-activity display reduced fatty acid and glycerol release in WAT (Taschler et al., 2011).  
Throughout this sequence, it is believed that diacylglycerol and monoacylglycerol are 
constantly being re-acylated by DGATs and MGATs (Salter et al., 1998).  In rats, 57% of free 
fatty acids released by lipolysis are re-esterified into triacylglycerols (Kalderon et al., 2000).  
This futile cycle is believed to allow for rapid change and fine tuning of fatty acid oxidation in 
response to fluctuating energy demands (Wolfe et al., 1990; Newsholme and Crabtree, 1976).  
Finally, FABP4 binds free fatty acids and transports them to the plasma membrane prior to 
albumin-facilitated distribution to other tissues via circulation (Coe et al., 1999). 
 Oxidation of fatty acids to produce energy, also known as β-oxidation, requires 
sequential cleavage of two-carbon units from a fatty acid as a molecule of acetyl-CoA (Fig. 
1.7).  Acetyl-CoA is then oxidized to CO2 in the citric acid cycle.  NADH and FADH2 
produced through these processes drive the electron transport chain to generate ATP.  β-
oxidation takes place in the mitochondrial matrix.  Fatty acids of ≤ 12 carbons are able to pass 
through the mitochondrial membrane unassisted.  However, the more prevalent fatty acids of ≥ 
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14 carbons must use the carnitine shuttle (Nelson and Cox, 2008).  This involves ATP 
dependent activation of fatty acids by acyl-CoA synthetases in the outer mitochondrial 
membrane to form fatty acyl-CoAs (Nelson and Cox, 2008).  Fatty acyl-CoAs can be utilized 
by mitochondrial GPATs to produce lysophosphatidate in the glycerol-3-phosphate pathway, or 
can be processed by carnitine acyltransferase I, replacing the CoA group with a molecule of 
carnitine (Nelson and Cox, 2008).  Fatty-acyl carnitine passes through the inner mitochondrial 
membrane via the acyl-carnitine/carnitine transporter, where carnitine is immediately replaced 
with a CoA group by carnitine acyltransferase II (Nelson and Cox, 2008).  Carnitine-dependent 
trafficking of acyl groups into the matrix forms the rate-limiting step of β-oxidation (Nelson 
and Cox, 2008).  Through the coordinated processing by enzymes, acyl-CoA dehydrogenase, 
enoyl-CoA hydratase, β-hydroxyacyl-CoA dehydrogenase and ketoacyl-CoA thiolase - a two-
carbon unit is removed to form one acetyl-CoA, one FADH2, one NADH and a proton (Nelson 
and Cox, 2008).  The fatty acid goes through successive rounds of this sequence.  For example, 
palmitic acid (16-carbons) passes through this cycle 7 times, generating: 8 acetyl-CoA, 7 
FADH2, 7 NADH and 7 protons.  Acetyl-CoA formed through fatty acid oxidation is further 
oxidized to CO2 in the citric acid cycle (Nelson and Cox, 2008).  Electrons generated by β-
oxidation and carried by FADH2/NADH are used to drive the electron transport chain, 
producing ATP.  Complete oxidation of palmitate results in the production of 129 ATP (Nelson 
and Cox, 2008).  
The glycerol backbone remaining after hydrolysis of the fatty-acyl groups can be 
released into the circulation and taken up by the liver where it is phosphorylated by glycerol 
kinase to produce glycerol-3-phosphate.  This can be oxidized to dihydroxyacetone phosphate 
by glycerol-3-phosphate dehydrogenase.  Triose phosphate isomerase can then convert 
dihydroxyacetone phosphate to the glycolytic intermediate, glyceraldehyde-3-phosphate 
(Nelson and Cox, 2008).   
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Figure 1.7.  The β-oxidation pathway – Energy is released from fatty acids through β-
oxidation as two-carbon units in the form of acetyl-CoA; electrons are transferred to carriers 
FAD and NAD+.  Acetyl-CoA can enter the citric acid cycle while electrons are delivered to the 
electron transport chain. 
 
   Regulation of β-oxidation enables efficient transition between triacylglycerol 
anabolism and catabolism in order to respond to cellular energy requirements.  There are 
several key regulatory steps in this process.  Malonyl-CoA, the first intermediate in long-chain 
fatty acid biosynthesis, inhibits carnitine acyltransferase I - blocking transport of fatty acids into 
the mitochondria (Nelson and Cox, 2008).  An additional layer is present in this mechanism as 
high AMP (low ATP) levels activate AMP-activated protein kinase, which inhibits several 
lipogenic enzymes via phosphorylation.  These targets include acetyl-CoA carboxylase 1 and 2, 
which converts acetyl-CoA to malonyl-CoA (Nelson and Cox, 2008).  Reduction in malonyl-
CoA alleviates inhibition of carnitine acyltransferase I, allowing β-oxidation to restore ATP 
levels (Nelson and Cox, 2008).  β-oxidation is also inhibited by elevated energy levels in the 
form of NADH/NAD+ ratio.  Elevated NADH levels indicate abundant energy and inhibit β-
hydroxyacyl-CoA dehydrogenase, which catalyzes the conversion of hydroxyacyl-CoA to α-
ketoacyl-CoA in the third reaction of β-oxidation (Nelson and Cox, 2008).  Finally, regulation 
at the transcriptional level is mediated by PPARα and cAMP responsive element binding 
protein (CREB).  During fasting, PPARα upregulates the expression of acetyl-CoA synthetase 
I, carnitine acyltransferase I and II, and acyl-CoA dehydrogenase - increasing ATP production 
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in oxidative tissues such as liver, brown adipose tissue and muscle.  CREB is activated through 
cAMP signaling (Nelson and Cox, 2008).  This is triggered by glucagon released due to low 
blood glucose.  CREB also activates genes that promote β-oxidation, such as sirtuin 1 (Li, 
2013) 
 
1.7 Ubiquitin and the ubiquitin proteasome system 
Ubiqutin is an 8.5 kDa regulatory protein expressed in all eukaryotes.  Covalent linkage 
of ubiquitin to a target protein is achieved through the concerted action of three types of 
enzymes: ubiquitin activating enzymes (E1), ubiquitin conjugating enzymes (E2) and ubiquitin 
ligating enzymes (E3).  E1 catalyzes the ATP dependent activation of ubiquitin C-terminal 
Gly76, conjugating ubiquitin to the E1 by a high energy thioester bond (Haas et al., 1982).  
Ubiquitin is then transferred to a cysteine residue located in the active site of an E2 enzyme.  
Transfer of ubiquitin to the target protein is achieved through different mechanisms depending 
on the class of E3 enzyme involved.  E3 enzymes are the most important element of the 
ubiquitination machinery in determining substrate specificity.  There are three classes of E3s, 
characterized by the presence of one of two general domains – really interesting new gene 
(RING)/RING-like and homologous to E6AP carboxyl terminus (HECT).  RING and RING-
like E3s bind to both the E2 and the ubiquitination target and catalyze the direct transfer from 
E2 to target protein.  In contrast, HECT E3s catalyze the transfer of the thioester bonded 
ubiquitin from E2 to a conserved cysteine residue in the HECT domain before being conjugated 
to the target protein (Ravid and Hochstrasser, 2008).  The third class of E3s are known as 
RING-between-RING E3 ligases (Aguilera et al., 2000).  They consist of a standard RING 
domain (RING1) that is responsible for recruiting the ubiquitin bound E2, while a second RING 
domain (RING2), containing a catalytic cysteine, transfers ubiquitin to the substrate - similar to 
HECT E3s (Wenzel et al., 2011; Duda et al., 2013). 
Post-translational linkage of ubiquitin to a target molecule is most often achieved through 
the formation of an amide bond between Gly76 of ubiquitin and the ε-NH2 of an internal lysine 
residue.  While less common, ubiquitin can also be linked to the substrate N-terminal residue α-
NH2 group (Ciechanover and Ben, 2004).  In addition, recent studies have documented 
ubiquitin linkages to cysteine via a thioester bond as well as to serine and threonine residues by 
an oxyester bond (Fig. 1.8) (Wang et al., 2012b).  The linkage of a single ubiquitin molecule to 
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an amino acid residue is termed monoubiquitination.  However, additional ubiquitins can be 
covalently attached to the first, creating a polyubiquitin chain.  Each subsequent ubiquitin can 
be linked to any of seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, Lys63) or 
the amino-terminal methionine (Met1) of the preceding ubiquitin in the chain.  Therefore eight 
different homotypic polyubiquitin chains and variety of atypical chains consisting of 
heterologous, forked and/or mixed linkages are possible (Ye and Rape, 2009; Ikeda and Dicik, 
2008; Iwai and Tokunaga, 2009).  In some cases E4 enzymes, which support chain elongation, 
are necessary for polyubiquitin chain formation (Koegl et al., 1999).   
Ubiquitin signaling has been implicated in several cellular processes including protein 
degradation, DNA repair, endoplasmic reticulum-associated degradation (ERAD), receptor 
endocytosis, apoptosis and autophagy (Ravid and Hochstrasser, 2008; Finley, 2009; Ulrich and 
Walden, 2010; Hirsch et al., 2009; Raiborg and Stenmark, 2009; Wertz and Dixit, 2010; Kirkin 
et al., 2009).  Specialized proteins containing ubiquitin-binding domains recognize specific 
ubiquitin chain linkages in order to differentially activate signaling pathways (Dikic et al., 
2009). 
 
 
 
 
Figure 1.8.  Protein ubiquitination - Ubiquitination is most often achieved through the 
formation of an amide bond between Gly76 of ubiquitin and the ε-NH2 of an internal lysine 
residue.  Ubiquitin can also be linked by peptide bond to the N-terminal α-NH2, to cysteine via 
a thioester bond or to serine and threonine residues by an oxyester bond.  
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The most extensively studied branch of ubiquitin signaling is the ubiquitin-proteasome 
system (Fig. 1.9).  A ubiquitin chain consisting of at least four Lys48 linked ubiquitin 
monomers represents a tag, targeting the protein to which it is linked for degradation by the 26S 
proteasome (Ikeda and Dikic, 2008; Thrower et al., 2000).  The signal presented by a protein, 
rendering it recognizable as a proteasomal substrate, is known as a degron. Degrons include the 
presence of hydrophobic or basic amino acids at the N-terminus of the protein (N-end rule) and 
phosphorylation at serine and/or threonine residues (phosphodegron) (Rao et al., 2001; Orlicky, 
2003).   
The 26S proteasome consists of an inner 20S core particle flanked on either side by a 
19S regulatory subunit.  Ubiquitin mediated protein targeting to the proteasome can be achieved 
through either a direct or indirect recognition pathway.  Direct targeting refers to recognition of 
the ubiquitin chain by one of two subunits in the 19S regulatory particle.  The regulatory 
particle non-ATPase (Rpn) 10 (S5A in mammals) subunit contains one-to-three ubiquitin 
interaction motifs (dependent on species) while the Rpn13 (ADRM1 in mammals) contains a 
ubiquitin-binding domain known as pleckstrin homology receptor for ubiquitin (Finley, 2009; 
Husnjak et al., 2008; Schreiner et al., 2008).  Indirect targeting refers to ubiquitin chain 
recognition by proteasomal shuttle factor proteins such as radiation gene 23, dominant 
suppressor of Kar2 and DNA-damage inducible homolog 1 (Glickman and Raveh, 2005; 
Grabbe and Dikic, 2009).  These factors utilize their ubiquitin-associated domains to bind 
ubiquitinated substrates followed by their N-terminal ubiquitin-like domain in order to dock to 
subunits Rpn10, Rpn13 or Rpn1 (PSMD2 in mammals) of the 19S base (Dikic et al., 2009; 
Finley, 2009).  The function of proteasomal shuttle factors is critical as they provide a means of 
recognition and transport for ubiquitin marked proteins distant from the proteasome. 
Prior to translocation of the ubiquitinated protein into the 20S proteolytic cavity, 
proteins in the base of the 19S cap are responsible for ATP-dependent unfolding and 
deubiquitination of the target.  Entrance to the 20S cavity is regulated by the cap protein, 
regulatory particle ATPase 2 (Kohler et al., 2001).  Protein degradation within the 20S cavity is 
achieved through threonine-dependent nucleophilic attack, reducing the protein to short 7-9 
amino acid peptides (Voges et al., 1999).  
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Figure 1.9.  The ubiquitin proteasome system – The covalent attachment of an ubiquitin tag 
to a target protein is accomplished by the concerted effort of E1- ubiquitin activating enzymes, 
E2- ubiquitin conjugating enzymes and E3- ubiquitin ligases.  A chain of at least four Lys48 
linked ubiquitin molecules is sufficient for recognition by subunits of the 19S regulatory 
particle or shuttle factors.  ATP-dependent unfolding and deubiquitination occurs at the 19S cap 
prior to threonine-dependent nucleophilic attack in the 20S proteolytic cavity.   
 
1.8 Endoplasmic reticulum-associated degradation  
 ERAD is an indispensable process in maintaining ER homeostasis in eukaryotic 
organisms.  Polypeptides entering the ER through the translocon achieve their native state by 
chaperone assistance and commonly, the acquisition of post-translation modifications 
(Rapoport, 2007; Braakman and Hebert, 2013).  However, due to factors such as mutation and 
insufficient chaperone levels, a portion of these proteins fail to achieve the proper folded 
conformation (Hartl and Hayer-Hartl, 2009).  The accumulation of misfolded proteins in the 
lumen and membrane of the ER results in ER stress and proteotoxicity.  A variety of diseases 
have been linked to retarded ERAD function including Wilson disease, Hirschprung disease 
and severe congenital neutropenia (Walter and Ron, 2011; Guerriero and Brodsky, 2012).  
 ERAD substrates appear to be detected by the exposure of hydrophobic regions 
normally inaccessible in the native structure.  Recognition factors complexed to multi-pass 
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integral membrane RING E3 ligases are responsible for substrate recognition. These 
recognition factor/ligase complexes appear to demonstrate specificity dependent on the location 
of the misfolded domain, whether cytosolic, intramembrane, or luminal (Plemper et al., 1999, 
1999; Bhamidipati et al., 2005; Kim et al., 2005; Szathmary et al., 2005; Carvalho et al., 2006; 
Denic et al., 2006; Gauss et al., 2006).  There are nine confirmed ER-membrane localized E3 
ligases functioning in the ERAD pathway: 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase 
degradation homolog 1 (HRD1), autocrine motility factor receptor (AMFR), tripartite motif 
containing protein 13 (TRIM13), membrane-associated RING finger protein 6, and RING 
finger proteins- 5, 103, 139, 170, and 204 (Nakatsukasa and Brodsky, 2008; Ravid and 
Hochstrasser, 2008; Hirsch et al., 2009).  Furthermore, there are an additional 15 ER-membrane 
localized E3 ligase candidates that may play a role in ERAD and while less common, a host of 
cytoplasmic E3 ligases such as Parkin and carboxy terminus of heat-shock 70-interacting 
protein (CHIP), involved in ERAD of some substrates (Neutzner et al., 2011; Imai et al., 2002; 
Meacham et al., 2001).   
 Following substrate recognition, the misfolded protein is retrotranslocated across the ER 
membrane to the cytosol.  How the targeted protein crosses the membrane is not fully 
understood.  Current lines of evidence implicate the Sec61 complex, degradation in 
endoplasmic reticulum protein-1 and/or intrinsic retrotranslocation function of the ERAD E3 
ligases (Wiertz et al., 1996; Ye et al., 2001; Lilley and Ploegh, 2004; Kalies et al., 2005; Kreft 
et al., 2006; Scott and Schekman, 2008; Wang et al., 2008a; Horn et al., 2009; Carvalho et al., 
2010; Mehnert et al., 2014).  Upon partial exposure of the protein to the cytosol, it can be 
ubiquitinated by an E3 ligase, permitting detection by a homohexameric complex of the valosin 
containing protein (mammals, VCP/p97; yeast, Cdc48) ATPase complex and cofactors 
ubiquitin fusion degradation 1 like protein and nuclear protein localization 4 homolog (Bays et 
al., 2001; Ye et al., 2001, 2003; Jarosch et al., 2002; Rabinovich et al., 2002).  Targeting of this 
complex to the ER membrane is modulated by the ubiquitin-binding domain of fas-associated 
factor family member 2 in mammals (Neuber et al., 2005; Schuberth and Buchberger, 2005; 
Mueller et al., 2008).  The VCP/p97 complex also facilitates interaction of de-ubiquitinating 
enzymes with the ubiquitinated substrate (Rumpf and Jentsch, 2006; Jentsch and Rumpf, 2007; 
Ernst et al., 2009). Disruption of deubiquitinating enzymes YOD1 or ataxin-3 inhibits 
retrotranslocation.  This suggests that cycles of ubiquitination and de-ubiquitination are 
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necessary for ERAD (Wang et al., 2006; Ernst et al., 2009; Zhang et al., 2013).  It appears that 
dislocation of the ubiquitinated substrate from the membrane is coupled to ATP hydrolysis by 
VCP/p97; the precise mechanism is currently unknown (Ye et al., 2003).  Following membrane 
dislocation, cytosolic chaperones such as B-cell CLL/lymphoma-2-associated athanogene 6 or 
proteasomal shuttle factors Rad23 and Dsk2 maintain substrate solubility and mediate transfer 
to the proteasome for degradation (Medicherla et al., 2004; Claessen and Ploegh, 2011; Wang 
et al., 2011; Xu et al., 2012). 
 Mammalian ERAD, for the majority of substrates, appears to involve RING E3 ligases 
HRD1 and/or AMFR (Nadav et al., 2003; Kikkert et al., 2004; Fang et al., 2001). The activities 
of other known E3 ligases are implicated in the destruction of a smaller group of substrates.  
Based on current data, it appears that there is a high level of cooperativity among E3 ligases of 
ERAD and that processing by several ligases is required for complete ERAD.  Several versions 
of cooperativity have been proposed: 1) several E3s working in parallel, demonstrating equal 
specificity to a given substrate; 2) E3s simultaneously targeting a substrate with specificity to 
different sites on said substrate; 3) monoubiquitination by one E3 coupled to chain extension E4 
activity of another E3; 4) sequential rounds of ubiquitin conjugation and removal (Olzmann et 
al., 2013a).  Joint activity of AMFR and ring finger protein 139, specific to different sites on 
the protein, has been documented in the degradation of HMG-CoA reductase while ring finger 
protein 5 has been found to accompany cytoplasmic E3, CHIP, in directing the degradation of 
cystic fibrosis transmembrane conductase regulator ΔF508 (Jo et al., 2011; Younger et al., 
2006).  Ring finger protein 5 may also monoubiquitinate certain substrates, serving to prime 
chain elongation by AMFR (Morito et al., 2008).  While Hrd1p has reportedly been found to 
form dimers in yeast, E3s have yet to be observed forming heteromeric complexes of multiple 
E3s (Horn et al., 2009; Carvalho et al., 2009).  Several groups postulate that ERAD E3s can 
ubiquitinate each other (Morito et al. 2008; Shmueli et al. 2009; Ballar et al., 2010; Jo et al., 
2011).  It is possible that inter-ubiquitination among ERAD E3s could function as a mechanism 
to regulate ERAD function - monoubiquitination of a single or set of E3s altering activity, while 
polyubiquitination controls E3 degradation (Olzmann et al., 2013a). 
 
1.8.1 ERAD of native proteins and its role in lipid metabolism 
While ERAD is predominantly thought of as a “garbage removal” process in the cell, it 
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has also been implicated in the regulation of many native proteins.  Moreover, several of these 
proteins are involved in lipid synthesis pathways.  ERAD of functional proteins is a highly 
specific process appearing to require a diverse set of signals that prompt identification by the 
recognition factor/E3 ligase complex.  Perhaps the best characterized of native ERAD 
substrates is HMG-CoA reductase, which catalyzes the rate-limiting step in the conversion of 
HMG-CoA to mevalonate in the synthesis of cholesterol and non-sterol isoprenoids (Goldstein 
and Brown, 1990).  A complex feedback mechanism is utilized in order to target HMG-CoA 
reductase for ERAD.  As cholesterol synthesis proceeds, an intermediate, 24,25-
dihydrolanosterol, accumulates, triggering binding of ER-membrane proteins known as insulin 
induced genes (INSIG) to the membrane domain of HMGR (Song et al., 2005).  Interactions 
between a subset of INSIG proteins with E3 ligase AMFR results in ubiquitination at lysine 
residues 89 and 248, subsequently triggering proteasomal degradation (Song et al., 2005; Lee et 
al., 2007; Sever et al., 2003).   
 Additional examples of functional proteins regulated through ERAD include: 
cytochrome P450 3A4, cyclooxygenase-2, apolipoprotein B-100 and SCD1.  Interestingly, there 
appears to be diversity in signaling to E3 ligases that a particular protein is an ERAD substrate.  
For example, cytochrome P450 3A4 requires phosphorylation at residues Ser478, Thr264 and 
Ser420 by protein kinase A and protein kinase C in order to be degraded through ERAD by the 
concerted effort of the E2 conjugase, ubiquitin conjugating enzyme E2G 2, and E3 ligase, 
AMFR (Wang et al., 2001; Wang et al., 2009b).  Further research using mass spectrometry 
revealed additional protein phosphorylation sites as well as eight ubiquitinated lysine residues 
tagged by ubiquitin conjugating enzyme E2G 2/AMFR and/or non-ERAD associated E2/E3 
ubiquitin conjugating enzyme E2D1/CHIP (Wang et al., 2012a).  Conversely, cyclooxygenase-
2, an integral membrane protein of the ER responsible for catalyzing the committed step in 
prostanoid biosynthesis, is targeted for ERAD by a 19 amino acid cassette near its C-terminus, 
which contains an N-glycosylation site at Asn594.  While substitution of Asn594 stabilizes 
cyclooxygenase-2 mutants glycosylated at Asn594, a mutant containing glycosylated Asn594 
yet lacking the rest of the 19-amino acid cassette is also stable (Mbonye et al., 2006). 
 Like HMG-CoA reductase, SCD1 and apolipoprotein B-100 are involved in lipid 
synthesis pathways and degraded by ERAD.  Mammalian SCD1 is an integral membrane 
protein in the ER and is involved in the catalysis of mono-unsaturated fatty acids (Shimakata et 
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al., 1972; Strittmatter et al., 1974).  In this case, detection by recognition factors/E3 ligase 
appears to be dependent on an N-terminal 66-residue PEST sequence.  Rich in Pro, Glu, Ser 
and Thr residues, the PEST sequence is typical of short-lived proteins in which degradation 
appears to be facilitated by the ubiquitin-proteasome system or non-lysosomal cysteine 
protease, calpain (Reverte et al., 2001; Spencer et al., 2004; Shumway et al., 1999).  
Proteasomal inhibition by MG132 results in the accumulation of polyubiquitinated SCD1 in the 
ER that is found to interact with VCP/p97, suggesting ERAD.  Deletion of the N-terminal 
PEST sequence increases SCD1 stability.  Likewise, fusion of the PEST sequence to a normally 
stable ER membrane protein results in its degradation by the proteasome (Kato et al., 2006).   
 In contrast, apolipoprotein B-100 ERAD is regulated by lipidation.  Apolipoprotein B-
100 is the primary constituent of very low-density lipoprotein produced by hepatocytes, playing 
an integral role in lipoprotein transport.  It contains prominent hydrophobic regions that must be 
lipidated during synthesis in order to avoid ERAD (Lapierre et al., 2004).  Co-translational 
lipidation is facilitated by microsomal triglyceride transfer protein (Hussain et al., 2003).  
Insufficient lipidation of the nascent peptide causes delay of co-translational entry through the 
Sec61 translocon, resulting in regions of apolipoprotein B-100 being exposed to the cytosol 
(Mitchell et al., 1998).  The E3 ligase AMFR is responsible for apolipoprotein B-100 
ubiquitination (Fisher et al., 1997, 2008).   
 While the main trends and players in the ERAD pathway appear to be consistent, the 
diversity in signaling mechanisms responsible for targeting a native protein for ERAD appears 
extensive; this is highlighted by comparing the examples outlined above.  Sterol sensitive 
INSIG proteins are responsible for the turnover of HMG-CoA reductase, while phosphorylation 
by protein kinases A and C is necessary for destruction of cytochrome P450 3A4.  Finally, 
apolipoprotein B-100 degradation is triggered by its insufficient co-translational lipidation.  
While the mechanisms are very dissimilar, all of these proteins are ubiquitinated by the same 
E3 ligase, AMFR.   A complex network of recognition factors allows for this heterogeneity in 
signaling mechanisms. 
 It has been proposed that there may be a functional link between ERAD and lipid 
droplets.  This is based on the inference that a traditional protein-based channel is unlikely to 
accommodate the size of folded ERAD substrates, many of which may have large post-
translational modifications such as glycosylations (Ploegh, 2007).  In addition, ERAD 
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components fas-associated factor family member 2, VCP/p97, ancient ubiquitous protein 1 and 
ubiquitin-conjugating enzyme E2G 2 - as well as ERAD substrates HMG-CoA reductase and 
apolipoprotein B-100 - are isolated in a lipid droplet-enriched fraction following proteasomal 
inhibition (Hartman et al., 2010; Ohsaki et al., 2006).  Also, HMG-CoA reductase is stabilized 
when droplet formation is inhibited via acyl-CoA synthetase inhibitor, triacsin c (Hartman, 
2010).  Further findings illustrate that sterol treatment caused relocation of HMG-CoA 
reductase to buoyant lipid droplet-associated ER membranes, preceding dislocation to the 
cytosol.  Moreover, chemical inhibition of lipid droplet formation reduced cytosolic dislocation 
of native ERAD targets (Hartman et al., 2010; Klemm et al., 2011).  This suggests that lipid 
droplets may play a role in substrate dislocation or possibly serve as a waypoint for substrates 
traveling to the proteasome (Ploegh, 2007).  Contrasting evidence in S. cerevisiae revealed that 
lipid droplets are not necessary for ERAD, illustrating differences between mammalian and 
yeast ERAD pathways (Olzmann and Kopito, 2011). 																		
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CHAPTER 2: Hypothesis and objectives 
Hypothesis 
A principle mechanism of DGAT2 and DGAT2 family regulation is through post-translational 
ubiquitination and degradation by the proteasome.  Moreover, DGAT2 exists in a multi-protein 
triacylglycerol synthesis complex and interaction with members of this assembly further 
influence DGAT2 regulation. 
 
 Objectives 
1. Identify ubiquitinated residues of DGAT2. 
2. Determine the role of protein ubiquitination in regulating DGAT2 stability, 
triacylglycerol synthesis and storage. 
3. Identify proteins interacting with DGAT2. 
4. Examine the role(s) of proteins interacting with DGAT2. 																		
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CHAPTER 3: Materials and methods 
3.1 Reagents 
 Names of reagents and their corresponding supplier are listed in Table 3.1.  Supplier 
addresses are shown in Table 3.2.  Table 3.3 outlines cDNA and expression vectors.    The 
sequences of mutagenic primers used in this work are detailed in Table 3.4.  
 
Table 3.1. Reagents and suppliers 
General reagents and consumables Supplier 
Anti-FLAG M2 affinity gel Sigma-Aldrich 
Ezview HA agarose Sigma-Aldrich 
BODIPY 493/503 Invitrogen 
Bovine serum albumin - fatty acid free Sigma-Aldrich 
Coumaric acid Sigma-Aldrich 
Cycloheximide Sigma-Aldrich 
Dimethyl sulfoxide Sigma-Aldrich 
1,2 Dioleoyl-sn-glycerol Sigma-Aldrich 
Eeyarestatin I Santa Cruz 
3X-FLAG peptide Sigma-Aldrich 
HRV 3C protease Novagen 
Hyblot Cl film Denville Scientific 
Insulin Sigma-Aldrich 
2x Laemmli sample buffer Bio-Rad 
Luminol Sigma-Aldrich 
MG132 Sigma-Aldrich 
NBD-palmitoyl CoA Avanti 
Oleic acid Sigma-Aldrich 
PfuUltra DNA polymerase Stratagene 
10x PfuUltra DNA polymerase buffer Stratagene 
Polyethylenimine Polysciences 
Polyvinylidene difluoride membrane Bio-Rad 
Trypsin Sigma-Aldrich 
Tunicamycin Sigma-Aldrich 
Bacterial cell culture reagents Supplier 
Ampicillin Fisher 
Bacto agar Difco 
DH5α Competent E. coli Invitrogen 
NZ-Amine A from bovine milk Sigma-Aldrich 
Tryptone EMD 
XL10-Gold Ultracompetent E .coli Agilent 
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Yeast extract EMD 
Mammalian cell culture reagent Supplier 
Antibiotic-Antimycotic 100x Gibco 
Dulbecco's modified eagle's medium  Lonza 
Fetal bovine serum Gibco 
Commercial kits Supplier 
Duolink® In Situ Proximity Ligation Assay Sigma-Aldrich 
Primary antibodies Supplier 
Mouse anti-ADRP/perilipin-2 (10R-A117ax) Fitzgerald 
Rabbit anti-calnexin (ADI-SPA-865) Enzo 
Rabbit anti-DGAT2 C-term (N/A) Invitrogen 
Mouse anti-FLAG (F3165) Sigma-Aldrich 
Rabbit anti-FLAG (F7425) Sigma-Aldrich 
Mouse anti-HA (H9658) Sigma-Aldrich 
Mouse anti-Hsp70 (MA3-028) Thermo Pierce 
Rabbit anti-lamin (A+C) (ab108922) Abcam 
Mouse anti-Myc (N/A) N/A 
Rabbit anti-Myc (C3956) Sigma-Aldrich 
Mouse anti-ubiquitin (sc-8017) Santa Cruz 
Mouse anti-VCP/p97 (MA3-004) Thermo Pierce 
Secondary antibodies Supplier 
Goat anti-mouse 594 (A11005) Invitrogen 
Donkey anti-rabbit 594(A21207) Invitrogen 
Goat anti-mouse 488 (A11001) Invitrogen 
Donkey anti-rabbit 488 (A21206) Invitrogen 
Donkey anti-rabbit 405(ab175651) Abcam 
Goat anti-mouse horseradish peroxidase (170-6516) Bio-Rad 
Goat anti-rabbit horseradish peroxidase (170-65-15) Bio-Rad 
 
Table 3.2.  Reagent supplier addresses 
Supplier Location 
Abcam Cambridge, UK 
Agilent Santa Clara, California, USA 
Bio-Rad Mississauga, Ontario, Canada 
Denville Scientific Holliston, Massachusetts, USA 
Difco Franklin Lakes, New Jersey, USA 
EMD Chicago, Illinois, USA 
Enzo Farmingdale, New York, USA 
Fisher Waltham, Massachusetts, USA 
Fitzgerald Acton, Massachusetts, USA 
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Gibco Waltham, Massachusetts, USA 
Invitrogen Waltham, Massachusetts, USA 
Lonza Basel, Switzerland 
Polysciences Washington, Pennsylvania, USA 
Sigma Aldrich St. Louis, Missouri, USA 
Stratagene San Diego, California, USA 
Thermo Pierce Waltham, Massachusetts, USA 
 
Table 3.3.  cDNA and expression vectors 
cDNA Vector Promoter 
FL-DGAT2 pcDNA3 CMV 
FL-DGAT2 3C Mutants 1-4 pcDNA3 CMV 
FL-DGAT2 K-to-R Mutants pcDNA3 CMV 
FL-Lys-less-DGAT2 pcDNA3 CMV 
FL-Lys-less-DGAT2 R-to-K Mutants pcDNA3 CMV 
FL-Lys-less-DGAT2-HA pcDNA3 CMV 
Lys-less-DGAT2-HA pcDNA3 CMV 
Lys-Less-DGAT2 (untagged) pcDNA3 CMV 
FL-DGAT2/Δ2-30 pcDNA3 CMV 
FL-DGAT2/Δ30-67 pcDNA3 CMV 
FL-DGAT2/Δ66-115 pcDNA3 CMV 
FL-DGAT2/Δ2-119 pcDNA3 CMV 
FL-DGAT2/Δ327-388 pcDNA3 CMV 
FL-DGAT2/Δ2-35 pcDNA3 CMV 
FL-DGAT2/HA-insert pcDNA3 CMV 
Myc-DGAT2 pcDNA3 CMV 
DGAT2-HA pcDNA3 CMV 
LacZ pcDNA3 CMV 
FL-Lipin1 pcDNA3 CMV 
FL-MGAT2 pCMV6 CMV 
MGAT2-Myc-FL pCMV6 CMV 
MGAT2-Myc pCMV6 CMV 
FL-MGAT3 pcDNA3.1+ CMV 
MGAT3-Myc-FL C265Y pCMV6 CMV 
HA-Ubiquitin pRK5 CMV 
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Table 3.4.  Mutagenic primers 
Primer name Primer sequence 
FL-DGAT2 3C protease mutants 
Mutant 1 F 5’-CTGGAAGTTCTGTTTCAGGGGCCCAAGACCCTCATCGCCGCC-3’ 
Mutant1 R 5’-GGGCCCCTGAAACAGAACTTCCAGATCATCATCATCTTTGTAAT CTCCCATGC-3’ 
Mutant 2 F 5’-CTGGAAGTTCTGTTTCAGGGGCCCCTGGTGAAGACACACAACC TG-3’ 
Mutant 2 R 5’-GGGCCCCTGAAACAGAACTTCCAGCTGGATGGGAAAGTAGTCT CG-3’ 
Mutant 3 F 5’-CTGGAAGTTCTGTTTCAGGGGCCCGCTGATCTGGTTCCCACTTA TTCCTTTGG-3’ 
Mutant 3 R 5’-GGGCCCCTGAAACAGAACTTCCAGTCCATGGCGCAGGGCCAGC TT C-3’ 
Mutant 4 F 5’-CTGGAAGTTCTGTTTCAGGGGCCCCCCAAGCTGGAGCACCCGA CC-3’ 
Mutant 4 R 5’-GGGCCCCTGAAACAGAACTTCCAGGACAGTGATGGGCTCCCCC AC-3’ 
FL-DGAT2 Lys-to-Arg mutants 
K2R F 5'-GGAGATTACAAAGATGATGATGATAGGACCCTCATCGCCGCC-3' 
K2R R 5'-GGCGGCGATGAGGGTCCTATCATCATCATCTTTGTAATCTCC-3' 
K26, 28R F 5'-GCCCGCAGCGAAAACAGGAATAGAGGATCTGCCCTG-3' 
K26, 28R R 5'-CAGGGCAGATCCTCTATTCCTGTTTTCGCTGCGGGC-3' 
K63, 66R F 5'-GGCTCAACAGATCTAGGGTGGAAAGACAGCTGCAGGTC-3' 
K63, 66R R 5'-GACCTGCAGCTGTCTTTCCACCCTAGATCTGTTGAGCC-3' 
K118, 119R F 5'-GACTGGAACACGCCCAGGAGAGGTGGCAGGAGATCGC-3' 
K118, 119R R 5'-GCGATCTCCTGCCACCTCTCCTGGGCGTGTTCCAGTC-3' 
K146R F 5'-CCAGCTGGTGAGGACACACAACCTGCTG-3' 
K146R R 5'-CAGCAGGTTGTGTGTCCTCACCAGCTGG-3' 
K183, 184R F 5'-GCTACTGAAGTCAGCAGGAGGTTTCCTGGCATAAGGCCC-3' 
K183, 184R R 5'-GGGCCTTATGCCAGGAAACCTCCTGCTGACTTCAGTAGC-3' 
K227R F 5'-GACTACTTGCTCTCCAGGAATGGGAGTGGC-3' 
K227R R 5'-GCCACTCCCATTCCTGGAGAGCAAGTAGTC-3' 
K286, 301, 
302, 305R F 
5'-GTATACAGGCAGGTGATCTTTGAGGAGGGTTCCTGGGGCCGAT 
GGGTCCAGAGGAGGTTCCAGAGGTATATTGG-3' 
K286, 301, 
302, 305R R 
5'-CCAATATACCTCTGGAACCTCCTCTGGACCCATCGGCCCCAGG 
AACCCTCCTCAAAGATCACCTGCCTGTATAC-3' 
K251R F 5'-CCCTGAGCTCCATGCCTGGCAGGAACGCAGTCACCC-3' 
K251R R 5'-GGGTGACTGCGTTCCTGCCAGGCATGGAGCTCAGGG-3' 
K257R F 5'-CGCAGTCACCCTGAGGAACCGC-3' 
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K257R R 5'-GCGGTTCCTCAGGGTGACTGCG-3' 
K260R F 5'-CCGCAGAGGCTTTGTG-3' 
K260R R 5'-CACAAAGCCTCTGCGG-3' 
K264R F 5'-GGCTTTGTGAGGCTGGCCCTGCGCC-3' 
K264R R 5'-GGCGCAGGGCCAGCCTCACAAAGCC-3' 
K332, 346, 
353R F 
5'-GCCCTACTCCAGGCCCATCACCACCGTCGTGGGGGAGCCCATC 
ACTGTCCCCAGGCTGGAGCACCCGACCCAGAGAGACATCGACC-3' 
K332, 346, 
353R R 
5'-GGTCGATGTCTCTCTGGGTCGGGTGCTCCAGCCTGGGGACAGT 
GATGGGCTCCCCCACGACGGTGGTGATGGGCCTGGAGTAGGGC-3' 
K368, 374, 
376R F 
5'-GGAGGCCCTGGTGAGGCTCTTTGACAATCACAGGACCAGATTT 
GGCCTTCC-3' 
K368, 374, 
376R F 
5'-GGAAGGCCAAATCTGGTCCTGTGATTGTCAAAGAGCCTCACCA 
GGGCCTCC-3' 
FL-Lys-less-DGAT Arg-to-Lys mutants 
R2K F 5'-GGAGATTACAAAGATGATGATGATAAGACCCTCATCGCCGCC-3' 
R2K R 5'-GGCGGCGATGAGGGTCTTATCATCATCATCTTTGTAATCTCC-3' 
R26, 28K F 5'-GCCCGCAGCGAAAACAAGAATAAAGGATCTGCCCTG-3' 
R26, 28K R 5'-CAGGGCAGATCCTTTATTCTTGTTTTCGCTGCGGGC-3' 
R63, 66K F 5'-GGCTCAACAGATCTAAGGTGGAAAAACAGCTGCAGGTC-3' 
R63, 66K R 5'-GACCTGCAGCTGTTTTTCCACCTTAGATCTGTTGAGCC-3' 
R118, 119K F 5'-GACTGGAACACGCCCAAGAAAGGTGGCAGGAGATCGC-3' 
R118, 119K R 5'-GCGATCTCCTGCCACCTTTCTTGGGCGTGTTCCAGTC-3' 
R146K F 5'-CCAGCTGGTGAAGACACACAACCTGCTG-3' 
R146K R 5'-CAGCAGGTTGTGTGTCTTCACCAGCTGG-3' 
R183, 184K F 5'-GCTACTGAAGTCAGCAAGAAGTTTCCTGGCATAAGGCCC-3' 
R183, 184K R 5'-GGGCCTTATGCCAGGAAACTTCTTGCTGACTTCAGTAGC-3' 
R227K F 5'-GACTACTTGCTCTCCAAGAATGGGAGTGGC-3' 
R227K R 5'-GCCACTCCCATTCTTGGAGAGCAAGTAGTC-3' 
R251, 257, 
260,264K F 
5'-CCTGGCAAGAACGCAGTCACCCTGAAGAACCGCAAAGGCTTT 
GTGAAGCTGGCC-3' 
R251, 257, 
260,264K R 
5'-
GGCCAGCTTCACAAAGCCTTTGCGGTTCTTCAGGGTGACTGCGTTCTTGCCAGG-
3' 
R286K F 5'-GAGGTATACAAGCAGGTGATCTTTGAGGAGGG-3' 
R286K R 5'-CCCTCCTCAAAGATCACCTGCTTGTATACCTC-3' 
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R301K F 5'-CCGATGGGTCCAGAAGAGGTTCCAGAGG-3' 
R301K R 5'-CCTCTGGAACCTCTTCTGGACCCATCGG-3' 
R302K F 5'-CCGATGGGTCCAGAGGAAGTTCCAGAGG-3' 
R302K R 5'-CCTCTGGAACTTCCTCTGGACCCATCGG-3' 
R305K F 5'-GGAGGTTCCAGAAGTATATTGGTTTCGCCCCC-3' 
R305K R 5'-GGGGGCGAAACCAATATACTTCTGGAACCTCC-3' 
R332K F 5'-GCCCTACTCCAAGCCCATCACCACC-3' 
R332K R 5'-GGTGGTGATGGGCTTGGAGTAGGGC-3' 
R346K F 5'-CCCATCACTGTCCCCAAGCTGGAGCACCCG-3' 
R346K R 5'-CGGGTGCTCCAGCTTGGGGACAGTGATGGG-3' 
R353K F 5'-CCGACCCAGAAAGACATCGACCTG-3' 
R353K R 5'-CAGGTCGATGTCTTTCTGGGTCGG-3' 
R368K F 5'-GAGGCCCTGGTGAAGCTCTTTGAC-3' 
R368K R 5'-GTCAAAGAGCTTCACCAGGGCCTC-3' 
R374K F 5'-GACAATCACAAGACCAGATTTGGCC-3' 
R374K R 5'-GGCCAAATCTGGTCTTGTGATTGTC-3' 
R376K F 5'-GACAATCACAGGACCAAATTTGGCC-3' 
R376K R 5'-GGCCAAATTTGGTCCTGTGATTGTC-3' 
FL-Lys-less-DGAT tag change 
Remove N-
Term FL F 5'-CATCTAGATGACCCAATATG_AGGACCCTCATCG-3' 
Remove N-
Term FL R 5'-CGATGAGGGTCCT_CATATTGGGTCATCTAGATG-3'  
Add C-Term 
HA F 
5'-GGATACCCATACGATGTTCCAGATTACGCTTGAGACCCAATAT 
CGGATCCCGGGC-3'   
Add C-Term 
HA R 
5'-AGCGTAATCTGGAACATCGTATGGGTATCCGTTCACCTCCAGC 
ACCTCAGTCTC-3'  
 
3.2 Site directed mutagenesis 
 Mutations and epitope tags were introduced into cDNA by PCR with PfuUltra DNA 
polymerase.  Mutagenic primers are detailed in Table 3.4.  PCR reactions were conducted in a 
final volume of 50 µL containing the following reagents: 29 µL cross-linked ultrapure water, 5 
uL 10x Pfu buffer, 0.2 mM dNTPs, 10% dimethyl sulfoxide (DMSO), 125 ng of each 
mutagenic primer (forward and reverse), 50 ng of template DNA and 1 µL of PfuUltra DNA 
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polymerase.  The general thermal cycler protocol used was: 1) 1 min. at 95oC. 2) 18 cycles: 50 
sec. at 95oC, 50 sec. at 60oC and 1 min./kilobase at 68oC. 3) 7 min. at 68oC.  Methylated DNA 
was digested with 20 units of DpnI for 2 h at 37oC.       
FL-Lys-less-DGAT2, in which all of 25 DGAT2 lysines were mutated to arginine, was 
manufactured by GenScript.  
 The cDNA of all constructs was verified by sequencing prior to use. 
 
3.3 Bacterial strains and media preparations 
 XL10-Gold Ultracompetent E. coli were used for the amplification of PCR products 
following mutagenesis.  Transformation was conducted according to manufacturers 
instructions.  Transformation required the use of NZY+ broth consisting of 10 g NZ-amine, 5 g 
yeast extract and 5 g NaCl in 1 L of double-distilled water.  The broth was adjusted to pH 7.5 
and autoclaved for 20 min at 15 psi.  Prior to use, filter sterilized components were added at 
final concentrations of: 12.5 mM MgCl2, 12.5 mM MgSO4 and 0.4% glucose.  The bacterial 
transformation mixture was plated onto Luria-Bertani (LB) broth agar plates.  LB broth, 
consisting of 10 g tryptone, 5 g yeast extract and 10 g of NaCl in 1 L of double-distilled water, 
was supplemented with 15 g of agar and autoclaved as previously described.  Once cooled, 
ampicillin was added at 100 µg/mL and the LB agar solution was transferred into petri dishes. 
 DH5α Competent E. coli were used for bulk amplification of plasmid DNA.  
Transformation was conducted according to manufacturer specifications.  Transformation 
required the use of LB broth.  The bacterial transformation mix was again transferred to LB 
agar plates containing ampicillin at a final concentration of 100 µg/mL.  Colonies were cultured 
in Terrific broth, composed of 2.4 g tryptone, 4.8 g yeast extract and 0.8 mL glycerol - brought 
to a final volume of 200 mL with double-distilled water.  The solution was autoclaved for 20 
min at 15 psi, before the addition of a 20 mL solution containing 0.17 M KH2PO4 and 0.72 M 
K2HPO4.  Ampicillin was added at a final concentration of 100 µg/mL. 
 
3.4 Mammalian cell culture 
 HEK-293T and COS-7 (American Type Culture Collection) cells were grown in 
Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) in a 37oC incubator (5% CO2).  Cells were grown in the presence of 1x antibiotic-
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antimycotic.  Triacylglycerol synthesis and lipid droplet formation was stimulated by treatment 
with 0.5 mM oleic acid complexed to 0.67% fatty acid-free bovine serum albumin (BSA).   
 
3.5 Cell transfection 
 For HEK-293T transfection, 20 µg of plasmid DNA was added to 430 µL of 0.15 M 
NaCl and 120 uL of 0.1% polyethylenimine (pH 7.0).  For transfection of COS-7 cells, 
polyethylenimine volume was reduced to 60 µL.  The transfection solution was incubated 10 
min. at room temperature prior to drop-wise addition to a 100 mm culture dish (containing 10 
mL of media) with cells at ~50% confluency.  After 4 h, cells were washed with phosphate 
buffered saline (PBS) and re-fed fresh media.  Experiments were conducted 20-48 h post-
transfection. 
 
3.6 Immunoprecipitation 
 FLAG or human influenza hemagglutinin (HA) epitope containing proteins were 
expressed in HEK-293T cells.  Approximately 20 h post-transfection, cells were washed with 
PBS, pelleted at 600 x g for 2 min. and resuspended in a 0.5% CHAPS, 1x PBS (pH 7.4) 
solution.  Cells were disrupted by 20 passages through a 27 gauge needle.  Insoluble material 
was pelleted at 20,800 x g for 10 min. and solubilized material transferred to a new tube.  
Samples were incubated with 10 µL of anti-FLAG or anti-HA agarose in 0.5% CHAPS, 1x PBS 
(pH 7.4) in a final volume of ~1mL and rotated for 2-3 h at room temperature.  Alternatively, 
samples were rotated overnight at 4oC.  Agarose was pelleted for 30 sec. at 5000 x g and 
washed three times with 0.5% CHAPS in 1x PBS (pH 7.4).  FLAG-tagged proteins were eluted 
from beads by incubation with 3x FLAG peptide or by boiling in an equal volume of 2x SDS-
PAGE sample buffer containing 5% β-mercaptoethanol.  HA-tagged proteins were displaced by 
boiling in an equal volume of 2x SDS-PAGE sample buffer (+5% β-mercaptoethanol). 
 Some experiments were conducted using total cell extracts in a solution of 8 M Urea, 1x 
PBS (pH 7.4).  Immunoprecipitation of epitope tagged proteins was carried out at a final urea 
concentration of 1 M urea, 1x PBS (pH 7.4).  Urea was removed from immunoprecipitates 
through washing in 1x PBS.  Tagged proteins were eluted by boiling in 2x SDS-PAGE sample 
buffer containing 5% β-mercaptoethanol. 
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3.7 3C protease assay 
Approximately 20 h post-transfection, cells were washed twice with PBS prior to 
harvest by scraping.  Cells were pelleted at 600 x g for 2 min. and resuspended in a 0.5% 
CHAPS, 1x PBS (pH 7.4) solution.  Cells were disrupted by 20 passages through a 27 gauge 
needle.  Insoluble material was pelleted at 20,800 x g for 10 min. and solubilized material was 
transferred to a new tube.  An aliquot was taken to determine protein concentration.  
Immunoprecipitation was conducted in a solution of 0.5% CHAPS in 1x PBS, using anti-FLAG 
agarose as described in section 3.6.  Total cell extracts or anti-FLAG immunoprecipitates were 
incubated with 5 units of human rhinovirus (HRV) 3C protease for 16 h at 4oC. Anti-FLAG 
agarose and bound N-terminal fragments were pelleted by centrifugation at 600 x g for 2 min., 
the supernatant fraction containing C-terminal fragments was transferred to a fresh tube.  An 
equal volume of 2x SDS-PAGE sample buffer (+5% β-mercaptoethanol) was added to total cell 
extracts as well as to pelleted and supernatant fractions of the immunoprecipitation.  Samples 
were boiled for 5 min.  The pelleted immunoprecipitation fraction was centrifuged 20,800 x g 
for 1 min. to pellet anti-FLAG agarose, and the supernatant, containing displaced N-terminal 
fragments, was transferred to a fresh tube. Samples were analyzed by SDS-PAGE and 
immunoblotting. 
 
3.8 Standard protein degradation assay  
 Approximately 20 h post-transfection, cells were washed with PBS and re-fed 100 
µg/mL cycloheximide (CHX) diluted in DMEM (+10% FBS).  Time zero samples were 
harvested immediately at the onset of CHX incubation and received no treatment.  Samples 
were harvested at various time intervals of CHX treatment. Cells were washed twice with PBS 
prior to harvest by scraping.  Cells were pelleted at 600 x g for 2 min. and suspended in 8M 
urea, 1x PBS (pH 7.4).  Cells were disrupted by 20 passages through a 25 gauge needle 
followed by 15 passages through a 27 gauge needle.  Insoluble material was pelleted at 20,800 
x g for 10 min. and solubilized material was transferred to a new tube.  Samples were incubated 
in 2x SDS-PAGE sample buffer (+5% β-mercaptoethanol) for 30 min. at 37oC.  Samples were 
not boiled due to the presence of urea.  Protein degradation was observed by SDS-PAGE and 
immunoblotting.   
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3.9 Protein degradation assay under lipogenic conditions 
HEK-293T cells were transfected with FL-DGAT2.  Four hours after transfection, cells 
were re-fed DMEM (+10% FBS) in the presence or absence of 0.5 mM oleic acid.  
Approximately 18 h later, cells were washed with PBS and re-fed in the presence or absence of 
0.5 mM oleic acid with 100 µg/mL CHX in DMEM (+10% FBS).  Time zero samples were 
harvested immediately after the 18 h incubation and received no CHX.  Cells were washed 
twice with PBS and harvested by scraping after 0-6 h of CHX treatment.  Cells were pelleted at 
600 x g for 2 min. and resuspended in 0.5% Triton X-100, 1x PBS (pH 7.4).  Cells were 
disrupted by 20 passages through a 27 gauge needle.  Insoluble material was pelleted at 20,800 
x g for 10 min. and solubilized material transferred to a new tube.  An aliquot was removed for 
lipid extraction (3.10).  Samples were boiled in 2x SDS-PAGE sample buffer with 5% β-
mercaptoethanol for 5 min. Protein degradation was observed by SDS-PAGE and 
immunoblotting.  
Alternatively, lipogenesis was stimulated with insulin treatment.  Four hours post-
transfection, cells were re-fed DMEM (+10% FBS) in the presence or absence of 5 µg/mL 
insulin.  One hour later, cells were washed with PBS and re-fed in the presence or absence of 5 
µg/mL insulin with 100 µg/mL CHX in DMEM (+10% FBS).  Time zero samples were 
harvested immediately after the 18 h incubation and received no CHX.  Cells were washed 
twice with PBS and harvested by scraping after 0-6 h of CHX treatment. Cells were pelleted at 
600 x g for 2 min. and resuspended in 8 M urea, 1x PBS (pH 7.4).  Cells were disrupted by 20 
passages through a 25 gauge needle, followed by 15 passages through a 27 gauge needle.  
Insoluble material was pelleted at 20,800 x g for 10 min. and solubilized material was 
transferred to a new tube.  Samples were incubated in 2x SDS-PAGE sample buffer with 5% β-
mercaptoethanol for 30 min. at 37oC.  Samples were not boiled due to the presence of urea.  
Protein degradation was observed by SDS-PAGE and immunoblotting. 
 
3.10 Lipid extraction 
 Sample total cell extracts prepared in a buffer of 0.5% Triton X-100, 1x PBS (pH 7.4) 
were brought to a final volume of 1 mL with double-distilled water in 16 x 100 mm glass tubes.  
Four mL of CHCl3:MeOH (2:1, v/v) was added and samples were vortexed for 30 sec. prior to 
centrifugation at 775 x g for 5 min.  The aqueous supernatant was discarded and the lower 
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organic phase was evaporated.  Air-dried samples were resuspended in 65 µL of CHCl3:MeOH 
(2:1, v/v), vortexed and applied to a channeled silica gel G60 thin layer chromatography plate.  
The plate was developed in a hexane:ethyl ether:acetic acid (80:20:1, v/v/v) solvent system.  
Plates were air-dried and then briefly submerged in a solution of 10% cupric sulfate (w/v) and 
8% phosphoric acid.  Lipids were observed by charring at approximately 180oC until bands 
appeared.  Pictures were taken using a VersaDoc 4000 molecular imaging system (Bio-Rad 
Laboratories, Inc.) and Quantity One software (Bio-Rad Laboratories, Inc.).   
 
3.11 Co-immunoprecipitation 
 Approximately 20 h post-transfection, HEK-293T cells were washed with PBS.  Cells 
were pelleted at 600 x g for 2 min. and resuspended in a 0.5% CHAPS, 1x PBS (pH 7.4) 
solution.  To reduce non-specific interactions, a detergent to protein ratio of approximately 10:1 
was used, representing the critical micelle concentration for CHAPS.  Cells were disrupted by 
20 passages through a 27 gauge needle.  Insoluble material was pelleted at 20,800 x g for 10 
min. and solubilized material was transferred to a new tube.  An aliquot was taken to determine 
protein abundance.  The detergent to protein ratio was then adjusted to 10:1.  Samples were 
incubated with 10 µL of anti-FLAG or anti-HA agarose in 0.5% CHAPS, 1x PBS (pH 7.4) at a 
final volume of ~1mL and rotated for 2-3 h at room temperature.  Alternatively, samples were 
rotated overnight at 4oC.  Anti-FLAG agarose was pelleted for 30 sec. at 5000 x g and washed 
three times with 0.5% CHAPS, 1x PBS (pH 7.4).  Proteins were eluted from beads by boiling in 
an equal volume of 2x SDS-PAGE sample buffer containing 5% β-mercaptoethanol. 
 
3.12 Isolation of crude mitochondria and lipid droplet fractions 
 Approximately 20 h post-transfection, HEK-293T were washed with PBS.  Cells were 
pelleted at 600 x g for 2 min. and resuspended in 1x PBS (pH 7.4).  Cells were disrupted by 20 
passages through a 27 gauge needle followed by centrifugation 2 min. at 1000 x g to pellet 
cellular debris and nuclei.  The supernatant was centrifuged for 10 min. at 10,000 x g (4oC) to 
pellet crude mitochondria (containing mitochondria and mitochondria-associated membranes).  
Crude mitochondria were resuspended in a solution of 50 mM Tris-HCl (pH 7.4), 250 mM 
sucrose.   
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 The supernatant obtained following the 10,000 x g centrifugation was adjusted to 20% 
sucrose and dispensed onto a 1 mL sucrose cushion of 60 % sucrose, 20 mM Tris-HCl (pH 7.4), 
1 mM EDTA.  Six mL of 5% sucrose, 20 mM Tris-HCl (pH 7.4), 1 mM EDTA was then 
layered on top of the sample; 20 mM Tris-HCl (pH 7.4) 1 mM EDTA was added until the tube 
was nearly brimmed.  The sample was then centrifuged at 200,000 x g for 30 min (4oC).  The 
floating fat layer, containing lipid droplets, was isolated and diluted with 20 mM Tris-HCl (pH 
7.4), 1 mM EDTA.  
 
3.13 SDS-PAGE and Western blotting 
 Samples were incubated in an equal volume of 2x SDS sample buffer (+5% β-
mercaptoethanol) and boiled for 5 min. (unless indicated otherwise), to denature and solubilize 
proteins.  SDS-PAGE was carried out on a polyacrylamide gel (8 – 12%) in a running buffer of 
25 mM Tris-HCl, 192 mM glycine, and 0.1 % (w/v) SDS at approximately 160 volts for 1 h.  
Proteins were transferred to a polyvinylidene difluoride membrane in a buffer of 62 mM boric 
acid (pH 8.0) at 360 mA for a period of 1.5 h.  Alternatively, transfer was conducted overnight 
at 25 volts and 4oC.  Membranes were blocked for 30 min. in 10 % skim milk powder (w/v), 1x 
PBST to reduce non-specific binding.  Primary antibody was diluted in 1x PBST (1:50 – 4000).  
Membranes were incubated with primary antibody for approximately 2 h at room temperature 
or overnight at 4oC.  Membranes were incubated with species-specific secondary antibody 
conjugated to horseradish peroxidase (1:10,000) for 40 min. at room temperature.  Proteins 
were detected by incubation in a solution of 100 mM Tris-HCl (pH 8.6), 1.25 mM luminol, 
0.225 mM p-coumaric acid and 9.0 x10-3 % (w/w) hydrogen peroxide for 1 min. and exposed to 
Hyblot Cl film.       
  
3.14 DGAT activity assay 
 The activity assay reaction mixture consisted of: 100 mM Tris-HCl (pH 7.6), 20 mM 
MgCl2, 0.625 mg/mL of BSA (fatty acid free), 200 µM 1,2 dioleoyl-sn-glycerol, 25 µM N-[(7-
nitro-2-1,3-benzoxadiazol-4-yl)-methyl]amino (NBD)-palmitoyl CoA, 100 mM sucrose, 
brought to a final volume of 150 µL with double-distilled water.  Aliquots of reaction mixture 
were pre-heated at 37oC for 2 min.  The reaction was initiated upon the addition 50 µg of total 
cell extract (diluted to 1 µg/µL in 50 mM Tris-HCl pH 7.6, 250 mM sucrose) and incubated at 
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37oC for 10 min.  The reaction was terminated by the addition of 4 mL CHCl3/methanol (2:1, 
v/v) and mixed by brief vortex.  Water, at a volume of 800 µL was added, followed by a 10 sec. 
vortex at top speed.  Samples were centrifuged at room temperature for 5 min. at 775 x g.  The 
upper aqueous layer was aspirated followed by air-drying of the organic phase. Sixty-five µL of 
CHCl3 was added to each sample tube prior to brief vortex and application to a channeled 20 x 
20 cm thin layer chromatography plate.  The plate was developed in a solvent system of ethyl 
ether/hexane/methanol/acetic acid (55:45:5:1, v/v/v/v).  The plate was then allowed to air dry 
for 1 h prior to NBD-triacylglycerol quantification using a VersaDoc 4000 molecular imaging 
system (Bio-Rad Laboratories, Inc.) and Quantity One software (Bio-Rad Laboratories, Inc.).   
 
3.15 Immunofluorescence microscopy 
 COS-7 cells were cultured in 6-well plates containing glass coverslips.  Cells were fixed 
for 10 min. in 4% paraformaldehyde, 1x PBS (pH 7.4) and permeabilized for 5 min. in 0.2% 
Triton X-100, 1x PBS (pH 7.4).  Blocking, in 3% BSA, 1x PBS (pH7.4) for 5 min. was 
conducted to reduce non-specific binding.  Primary antibodies specific to protein or epitope 
tags were diluted (1:50 – 300) and applied to cells for 1 h.  Fluorescent secondary antibodies 
(1:200) and neutral lipid stain BODIPY 493/503 (1:50-100) were incubated with samples for 30 
min.  All incubation steps were carried out at 37oC in a humidity chamber.  Images were 
obtained using Leica SP5 and Zeiss LSM700 laser scanning confocal microscopes.  Image 
processing was conducted using ImageJ 
 
3.16 Lipid droplet counting and size analysis 
The size and number of lipid droplets were assessed in COS-7 cells expressing DGAT2 
or DGAT2 mutant constructs.  Cells were prepared for immunofluorescence microscopy (3.15) 
and images were taken with a Leica SP5 laser scanning confocal microscope.  Lipid droplet 
analysis was conducted using ImageJ analysis software. All analysis was conducted on fourteen 
cells per construct; lipid droplets with an area of ≥ 0.2 micron2 were counted. 
 Variation among groups was analyzed using a one-way analysis of variance test and 
Tukey test. 
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3.17 Proximity ligation assay (PLA) 
 Approximately 20 h post transfection, COS-7 cells were fixed and permeabilized as 
outlined under section 3.15.  Blocking was conducted for 30 min at 37oC in a pre-heated 
humidity chamber in a solution of 3% BSA, 1x PBS (pH 7.4).  Primary antibodies were diluted 
to 1:50 – 1:300 in 3% BSA, 1x PBS (pH 7.4).  Cells were incubated with primary antibody for 
30 min at 37oC in a pre-heated humidity chamber.  Duolink® in situ proximity ligation assay 
was conducted according to manufacturer’s instructions.  Cell nuclei were visualized with 
DAPI containing mounting medium.  Images were obtained using Leica SP5 and Zeiss 
LSM700 laser scanning confocal microscopes.  Image processing was conducted with ImageJ 
 In some experiments, cells were “co-stained” with protein or epitope specific primary 
antibody.  Chemical staining of lipid droplets by BODIPY 493/503 was also carried out.   This 
was done after the completion of the proximity ligation assay protocol and was conducted as 
described in section 3.15.  
 
3.18 Protein identification by mass spectrometry 
HEK-293T cells were transfected with FL-DGAT2 or control Myc-DGAT2 and 
incubated for approximately 18 hours in 0.5 mM oleic acid to stimulate lipogenesis.  Cells were 
harvested in 0.5% CHAPS, 1x PBS (pH 7.4) and the detergent to protein ratio adjusted to 10:1.  
Co-immunoprecipitations were conducted using anti-FLAG agarose beads in a 0.5% CHAPS, 
1x PBS (pH 7.4) solution.  Proteins were dissociated from anti-FLAG agarose by boiling in 2x 
SDS-PAGE sample buffer (+5% β-mercaptoethanol).  Sample preparation and analysis by mass 
spectrometry was conducted in collaboration with Dr. George Katselis’ Lab at the University of 
Saskatchewan.  Samples were buffered in 100 mM ammonium bicarbonate prior to addition of 
an equal volume of tetrafluoroethylene.  Samples were then reduced in 10 mM dithiothreitol 
and alkylated in 55 mM indole-3-acetic acid.  Tetrafluoroethylene was removed by SpeedVac 
and proteins were precipitated using acetone.  The precipitant was re-suspended in ammonium 
bicarbonate buffer and trypsinized before drying and re-suspension in 0.1% formic acid in 
water/acetonitrile (97:3) for liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
Samples were analyzed by 6550 iFunnel Q-TOF (Agilent Technologies) equipped with a chip 
cube interface and with 1260 infinity nano and cap pumps.  The liquid chromatography 
separation of peptides was carried out on a chip consisting of a 160 nL trapping column and 75 
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µL × 150 mm analytical column.  Columns were packed with Zorbax 300SB-C-18 5 µm using 
a gradient solvent system comprised of 0.1% formic acid in water and 0.1% formic acid in 
acetonitrile. Data extractor, SpectrumMill Proteomics Workbench Version B.04.00.127 
(Agilent Technologies) was used for identification of MS/MS spectra.  Data were searched 
against the SWISS-PROT Homo sapiens database with fixed cysteine carbamidomethylation 
and variable methionine oxidation parameters.   
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CHAPTER 4:  Identification of ubiquitinated residues on DGAT2 
4.1. Introduction 
 DGAT2 regulation has not been extensively studied, especially at the post-translational 
level.  Recent research has demonstrated that DGAT2 is rapidly degraded by the ubiquitin 
proteasome system via the ERAD pathway (Choi et al., 2014).  
 DGAT2 is present on the long arm of chromosome 11 (11q13), a region linked to body 
mass index and obesity-associated phenotypes in humans (Saar et al., 2003; Norman et al., 
1997; Pratley et al., 1998; Watanabe et al., 2000; Hirschhorn et al., 2001).  As the enzyme 
responsible for bulk triacylglycerol synthesis, it is reasonable to hypothesize that genomic 
variance in DGAT2 could correlate with predisposition or resistance to elevated adiposity and 
related conditions.  Currently, studies have not found a link between DGAT2 genetic variants 
and total body fat in humans (Friedel et al., 2007). However, a single nucleotide polymorphism 
(SNP), rs1944438, has been linked to liver fat levels  (Kantartzis et al., 2009).  Additionally, 
DGAT2 SNPs have been found to affect fat deposition in pigs (Yin et al., 2012; Renaville et 
al., 2015). 
 We were interested in identifying ubiquitinated residues of DGAT2 responsible for 
modulating DGAT2 destruction.   If SNPs are present at or surrounding ubiquitin acceptor sites, 
the turnover rate of DGAT2 could be altered, potentially affecting triacylglycerol synthesis.  
There are examples of proteins such as elongator complex protein 3 in S. cerevisiae, which is 
ubiquitinated at only 1 of its 42 lysine residues (Peng et al., 2003).  Other proteins contain 
multiple ubiquitinated lysines.  In the case of yeast cell cycle regulating protein, SIC1, the six 
N-terminal-most of its twenty lysines are involved in ubiquitin dependent degradation.  
Interestingly, in vitro, the kinetics of degradation differ up to five-fold depending on the lysine 
chosen as acceptor (Petroski and Deshaies, 2003).  Conversely, proteins such as cyclins A and 
B1 are also ubiquitinated on several lysine residues, yet degradation rate does not vary with the 
acceptor lysine  (Fung et al., 2005; Kirkpatrick et al., 2006). As DGAT2 has 25 lysines, 
identifying residues important in dictating protein turnover was challenging and several 
different approaches were taken (see Fig 9.1 for the position of lysine residues in DGAT2 
orthologs). 
 Attempts to examine endogenous DGAT2 turnover were unsuccessful.  Numerous “in 
house” and commercial antibodies specific to N-terminal, C-terminal and internal regions were 
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evaluated.  Cell lines tested include adipocytes (3T3-L1 and OP9), liver (HepG2) and kidney 
(HEK-293T).  Other researchers recently reported degradation of endogenous DGAT2 by the 
ubiquitin-proteasome system in HEK-293T cells using a commercial antibody (Choi et al., 
2014).  We have since acquired this antibody and do not believe that the band detected is 
endogenous DGAT2, as the size does not align with our positive control; a positive control was 
not included in the aforementioned study.  For these reasons, an overexpression system was 
used for the characterization of DGAT2 post-translational regulation. 
 
4.2. Results 
4.2.1. The 3C protease assay was ineffective at identifying ubiquitinated DGAT2 residues 
 In order to map ubiquitinated lysine residues of DGAT2, we employed a method 
previously utilized in ubiquitin mapping of tumor protein p53 (p53) (Chan et al., 2006).  This 
approach requires the production of several mutants, each containing a single protease cleavage 
site.  DGAT2 mutant constructs were produced through PCR based insertion of a 3C protease 
recognition site (amino acid sequence: LEVLFQGP). This method of ubiquitin mapping relies 
on the use of HRV 3C protease to cleave (between Gln and Gly residues) the inserted 3C sites 
in mutant constructs bound to anti-FLAG agarose.  The agarose bound fraction is then pelleted 
while the fragment is released into the supernatant  (Fig. 4.1).  Through SDS-PAGE and 
immunoblotting, comparison of the ubiquitin signal generated from the N- and C-terminal 
fragments of each mutant can reveal ubiquitinated regions of the protein. 	
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Figure 4.1. The 3C protease method – HEK-293T cells were transfected with FL-DGAT2 or 
a FL-DGAT2 3C mutant construct.  Cells were harvested and subjected to immunoprecipitation 
with anti-FLAG agarose.  Isolates bound to anti-FLAG agarose were incubated with HRV 3C 
protease prior to centrifugation.  FL-DGAT2 and N-terminal fragments of 3C mutants bound to 
anti-FLAG agarose would be pelleted while fragments C-terminal of the cleave site would be 
present in the supernatant.  Samples were analyzed by SDS-PAGE and immunoblotting with 
anti-FLAG and anti-DGAT2 (C-terminus) to demonstrate efficient cleavage.  Subsequent 
immunoblotting with anti-ubiquitin antibody was conducted to identify ubiquitinated regions of 
DGAT2. 
 
Four mutants were designed, each containing a single 3C encoding site inserted 
strategically into the DNA sequence - avoiding regions of predicted secondary structure (Fig. 
4.2).  HEK293T cells were transfected with 3C mutants (Section 3.5) and expression of all 
mutants was confirmed (Fig. 4.3A). Protease efficiency was confirmed on total cell extracts of 
FL-DGAT2 and FL-DGAT2 3C Mutant 1 transfected HEK-293T cells (Fig. 4.3B).  Protease 
incubation with FL-DGAT2 3C Mutant 1 lysates resulted in cleavage of the 3C site and 
removal of the FLAG-tag as was detected by immunoblotting with anti-FLAG antibody.  
Conversely, incubation of the 3C protease with FL-DGAT2 lysates had no effect. 
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Figure 4.2.  DGAT2 3C mutant constructs - Mutants were produced through PCR insertion 
of a 3C protease recognition sequence (LEVLFQGP), denoted “3C”.  Included are the positions 
of lysine residues within FL-DGAT2 and FL-DGAT2 mutants, as well as the size in kDa of N- 
and C-terminal fragments following cleavage by HRV 3C protease.  Black bars represent the 
relative position of TMDs (amino acids 66–87 and 93–116).  
 
A.                B. 
 
 
Figure 4.3.  The 3C mutant 1 protease site is effectively cleaved in total cell extracts  – 
HEK-293T cells were transfected with FL-DGAT2 or 3C mutants as indicated.  (A) Mutant 
expression in total cell extracts was confirmed by SDS-PAGE and anti-FLAG immunoblotting.  
(B) Total cell extracts were incubated for 16 h in the presence or absence of HRV 3C protease 
to demonstrate protease efficiency and specificity.  Samples were separated by SDS-PAGE and 
immunoblotted with anti-FLAG antibody. 
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In order to identify ubiquitinated regions of DGAT2, subsequent cleavage reactions were 
carried out on FL-DGAT2 and 3C mutants conjugated to anti-FLAG beads (Section 3.6).  
Following protease incubation, the pellet fraction (anti-FLAG beads and associated N-terminal 
bound protein fragment) was separated from the supernatant fraction (containing protein 
fragments C-terminal of the 3C cleavage site).  Cleavage efficiency was evaluated by 
immunoblotting with an anti-DGAT2 C-terminus specific antibody.  The ubiquitination status 
of N- and C-terminal fragments was to be evaluated with an anti-ubiquitin antibody.  
Experiments using 3C Mutants 1-3 in the presence of the protease yielded results of limited 
success (Fig. 4.4).  It was noted that following protease incubation, C-terminal fragments of 
approximately the correct size were detected for all mutants.  However, a significant amount of 
the construct was not cleaved as the full-size ~46 kDa band was readily detectable in the pellet 
fractions.  In addition, the majority of the C-terminal fragment for each mutant was detected in 
the pellet rather than in the supernatant.  Attempts to examine the ubiquitination of C-terminal 
fragments successfully released into the supernatant fractions were ineffective (data not 
shown), likely due to insufficient quantities of these ubiquitinated fragments to be detected by 
anti-ubiquitin immunoblotting.  Numerous buffers, detergents, 3C protease brands and 
incubation conditions were evaluated in order to optimize this process, however, no conditions 
were effective at solubilizing 3C mutants while still remaining conducive to 
immunoprecipitation and protease digestion.  For these reasons, this approach was abandoned.  
	
Figure 4.4. Cleavage of 3C mutant immunoprecipitates was incomplete – 
Immunoprecipitates derived from HEK293T cells transfected with FL-DGAT2 and FL-DGAT2 
3C mutants 1-3 were incubated with HRV 3C protease for 16 h. Samples were centrifuged, 
separating the supernatant (S) from the pelleted (P) beads.  Cleavage efficiency was evaluated 
by SDS-PAGE and immunoblotting with an anti-DGAT2 C-terminus specific antibody.  
Expected fragment sizes can be found in Fig. 4.2. 
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4.2.2. Conservative substitution of all DGAT2 lysine residues to arginine abolished 
DGAT2 degradation 
We sought to confirm that degradation of DGAT2 is a lysine dependent process.  While 
ubiquitin mediated degradation is most commonly associated with internal lysine residues, 
several proteins have been shown to be ubiquitinated at the N-terminal residue or at serine, 
threonine and/or cysteines (Johnson et al., 1995; Tait et al., 2007; Shimizu et al., 2010).  To 
address this possibility, we designed a FL-DGAT2 construct in which all lysine residues, with 
the exception of one lysine present in the middle of the FLAG-tag, were mutated to arginine 
(FL-Lys-less-DGAT2). The FL-DGAT2 and FL-Lys-less-DGAT2 constructs were transfected 
into HEK-293T cells and protein stability was assessed via CHX protein degradation assay 
(Section 3.8).  CHX binds to the E-site of the 60S ribosomal subunit, inhibiting translation 
elongation and thereby protein synthesis (Schneider-Poetsch et al., 2010; Klinge et al., 2011; 
Pestova and Hellen, 2003).  Protein degradation was examined by treating cells with CHX and 
harvesting at several time intervals.  Samples were separated by SDS-PAGE and analyzed by 
immunoblotting (Fig. 4.5).  We found that mutation of all twenty-five lysines was sufficient to 
abrogate DGAT2 degradation, suggesting that DGAT2 turnover is lysine dependent.  Blotting 
for calnexin was conducted to demonstrate that assay conditions did not induce general protein 
degradation and that sample protein concentrations were consistent.   
 
 
Figure 4.5.  Lys-less-DGAT2 is not degraded - HEK-293T cells expressing either FL-
DGAT2 or FL-Lys-less-DGAT2 were treated with CHX for 0–4 h.  Samples were separated by 
SDS-PAGE and immunoblotted with anti-FLAG and anti-calnexin antibodies.  
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4.2.3. Lys-less-DGAT2 remained polyubiquitinated, likely through N-terminal 
ubiquitination 
Having shown that Lys-less-DGAT2 is stable, we expected that it was no longer 
ubiquitinated.  FL-DGAT2 and FL-Lys-less-DGAT2 were expressed in HEK-293T cells and 
isolated by anti-FLAG immunoprecipitation prior to SDS-PAGE and immunoblotting (Fig. 
4.6A).  Unexpectedly, Lys-less-DGAT2 was still ubiquitinated at a similar level to DGAT2.  As 
the running buffer contained 5% β-mercaptoethanol, which would remove ubiquitin chains 
conjugated through a thioester linkage, cysteine ubiquitination would not be detected.  To test 
for serine/threonine ubiquitination, immunoprecipitates were treated with sodium hydroxide 
(Fig. 4.6A).  Ubiquitin linkage to these residues, via an oxyester bond, is sensitive to mild 
alkaline hydrolysis.  Sodium hydroxide treatment had no effect on the intensity of the ubiquitin 
signal, ruling out conjugation at serine or threonine residues.  As one lysine residue is 
remaining in the middle of the FLAG-tag, we generated FL-Lys-less-HA and Lys-less-HA 
(containing no lysines) constructs to examine whether this lysine is a potential ubiquitin 
acceptor site.  The aforementioned constructs, along with untagged Lys-less-DGAT2, were 
transfected in HEK-293T cells and proteins were isolated with anti-FLAG agarose.  Blotting for 
ubiquitin revealed signals of approximately equal intensity for FL-Lys-less-HA and Lys-less-
HA while controls showed no ubiquitin signal (Fig. 4.6B).  By process of elimination, 
ubiquitination through peptide bond formation at the α-NH2 is the most likely scenario.  As this 
modification does not appear to effect stability, its function is unknown.  It is unclear whether 
N-terminal ubiquitination occurs on native DGAT2 or is merely an artifact related to the 
mutation of 25 lysine residues. 
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B. 
 
Figure 4.6.  Lys-less-DGAT2 is ubiquitinated, likely at the N-terminus - (A) FL-DGAT2 
and FL-Lys-less expressed in HEK-293T cells were immunoprecipitated with anti-FLAG 
agarose. Proteins were eluted by boiling in an equal volume of 2x Laemmli buffer containing 
5% β-mercaptoethanol. Eluted proteins were incubated with or without 100 mM NaOH at 37oC 
for 2 h.  NaOH treated samples were neutralized with HCl while those that did not receive 
NaOH were treated with an equal volume of 1x PBS.  Immunoprecipitates were analyzed by 
immunoblotting with anti-FLAG and anti-ubiquitin antibodies. (B) FL-Lys-less-HA and Lys-
less-HA expressed in HEK-293T cells were immunoprecipitated with anti-HA. Untagged Lys-
less was included as a negative control. Immunoprecipitates were then separated by SDS-PAGE 
and probed with anti-HA, anti-DGAT2 and anti-ubiquitin antibodies. HC denotes heavy chains.  
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4.2.4. Deletion of amino acids 327-388 increased DGAT2 stability 
As the 3C protease method was ineffective at identifying regions of DGAT2 that were 
ubiquitinated, we chose to evaluate the turnover and ubiquitination status of several DGAT2 
deletion mutants (Fig. 4.7).  HEK-293T cells were transfected with each construct and their 
stability was assessed.  We identified that the N-terminus had little-to-no role in dictating 
DGAT2 stability as none of these deletion mutants - including a deletion of residues 2-119, 
removing the first 5 lysine residues - had an appreciable effect in reducing turnover (Fig. 4.8A).  
Notably, a deletion of amino acids 327-388, lacking the 6 C-terminal most lysines, was greatly 
stabilized.  Further highlighting the importance of the DGAT2 C-terminus, a mutant in which 
all 20 lysines C-terminal of the TMDs (FL-DGAT2 K118-376R) were conservatively 
substituted to arginine, demonstrated little degradation over the course of the experiment (Fig. 
4.8B).  
 In addition to analyzing degradation of DGAT2 deletion mutants, we examined their 
ubiquitination.  Each construct was expressed in HEK-293T cells and isolated by anti-FLAG-
immunoprecipitation.  Samples were then subjected to SDS-PAGE and immunoblotting with 
anti-FLAG and anti-ubiquitin antibodies (Fig. 4.8C). While ubiquitination in deletion mutants 
Δ2-119 and Δ66-115 was reduced relative to other constructs, the abundance of the unmodified 
protein was also less than that of other mutants.  Additionally, Δ2-30, Δ30-67 and Δ327-388 - 
while expressed at levels at or below that of FL-DGAT2 - they demonstrated increased 
ubiquitination.  Ultimately, no deletion was sufficient to abolish DGAT2 ubiquitination, 
consistent with the CHX degradation results (Fig. 4.8A).   
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Figure 4.7.  DGAT2 deletion mutants - DGAT2 mutants used to identify regions of DGAT2 
that have a role in mediating its degradation. Black circles represent individual lysine residues 
present in DGAT2. Black boxes represent the transmembrane domains of DGAT2 (amino acids 
66–87 and 93–116).	
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 A.      B. 
 
 C. 
  
 
Figure 4.8. Lysine residues in the C-terminal half of DGAT2 are important for its 
degradation - (A and B) HEK-293T cells expressing FL-DGAT2 and the DGAT2 mutants 
shown in Fig. 4.7 were exposed to 100 µg/mL CHX for the time indicated.  Samples were 
separated by SDS-PAGE and analyzed by immunoblotting with anti-FLAG and anti-calnexin 
antibodies.  An asterisk denotes the position of a non-specific band.  (C) HEK-293T cells were 
transfected with DGAT2 deletion mutants.  Samples were subjected to anti-FLAG 
immunoprecipitation.  Immunoprecipitates were displaced by 3X FLAG peptide prior to SDS-
PAGE and subsequent immunoblotting with anti-ubiquitin primary antibody.  Re-blotting with 
anti-FLAG antibody was conducted to confirm mutant isolation.  
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4.2.5. Identification of lysines involved in regulating DGAT2 stability by systematic 
restoration in Lys-less-DGAT2 
 In order to identify specific lysine residues important for DGAT2 degradation signaling, 
we took a site directed mutagenesis approach.  Early experiments found that mutations of single 
lysine residues to arginines had little effect in reducing DGAT2 degradation (data not shown).  
This suggested that many lysines might be involved.  In addition, it was challenging to interpret 
which lysines were important as it relied on detecting slight differences in mutant stability for 
rapidly degraded proteins.  For these reasons, we chose to use the Lys-less construct and 
systematically restore lysine residues.  Detecting changes in degradation was much simpler 
with the stable Lys-less-DGAT2 as a baseline.  Constructs were transfected into HEK-293T 
cells and analyzed by CHX degradation assay.  Samples were harvested and subjected to SDS-
PAGE and immunoblotting with anti-FLAG and anti-calnexin antibodies (Fig. 4.9).  Notably, 
as identified with the Δ327-388 deletion mutant, the 6 C-terminal lysines were important in 
regulating DGAT2 degradation as individual restoration resulted in ~60-90% degradation 
following 6 h of CHX treatment.  Tandem restoration of K63 and K66, as well as K183 and 
K184, also strongly increased degradation - as did lysines K302 or K305.  All remaining 
lysines, apart from K2, K26 and K28, which had no effect on degradation, triggered an 
intermediate rate of turnover.  
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Figure 4.9.  Addition of specific lysine residues back to a lysine-less mutant of DGAT2 
promoted its degradation - Individual or clusters of lysine residues were added back to FL-
Lys-less-DGAT2.  HEK-293T cells expressing FL-DGAT2, FL-Lys-less-DGAT2, or FL-Lys-
less-DGAT2 lysine restoration mutants were exposed to 100 µg/mL CHX for the time 
indicated. Samples were separated by SDS-PAGE and analyzed by immunoblotting with anti-
FLAG and anti-calnexin antibodies.  
4.3. Discussion 
 The 3C protease method of ubiquitin mapping originally described by Chen et al. 
(2006) is advantageous as it streamlines ubiquitinated lysine detection by grouping lysines into 
clusters of those N-terminal or C-terminal to an engineered protease site.  By comparing the 
ubiquitination of the N- and C-terminal fragments of 3C mutants, it is possible to pinpoint 
candidate acceptor lysines.  Ideally, this should eliminate exhaustive mutagenesis in which 
every lysine must be individually examined.  In the original study, the authors used this method 
to determine that of the 20 lysines present in p53, five situated in the DNA binding domain 
were potentially ubiquitinated; mutation of all five lysines abolished ubiquitination (Chen et al., 
2006).  While ultimately effective, the authors identified several caveats to this method.  First, 
the fragment C-terminal to the protease site was consistently isolated along with the N-terminal 
fragment during immunoprecipitation.  This becomes problematic upon anti-ubiquitin 
immunoblotting as a ubiquitin signal detected in the pellet could be provided by contamination 
from the C-terminal fragment rather than ubiquitination of the N-terminal immunoprecipitated 
fragment.  Therefore, only the supernatant fraction, containing the successfully released C-
	 70	
terminal fragment, is reliable.  Secondly, this method is only ideal for mapping ubiquitinated 
lysines in those proteins with either few ubiquitinated lysines or those in which they are closely 
grouped.  A protein with several ubiquitinated residues spread throughout the length of the 
protein would be a poor candidate for analysis by this method.  Unfortunately both of these 
issues made this method a poor tool to examine DGAT2.  We found that not only was a 
significant portion of the C-terminal fragment isolated along with the immunoprecipitated N-
terminal fragment, but the overall cleavage efficiency at the 3C protease site was weak.  We 
postulate this occurred because DGAT2 molecules interact with each other to form a 
multimeric complex stabilized by disulfide bonds (Man et al., 2006; McFie et al., 2011).  We 
believe that incomplete cleavage was most likely caused by interaction of 3C mutant proteins 
physically obstructing the 3C site, and was likely compounded by the presence of the anti-
FLAG agarose.  In addition, it is likely that C-terminal fragments were interacting with 
uncleaved constructs still bound to anti-FLAG beads and thus remained in the pellet fraction 
following centrifugation.  Several alterations to the protocol were evaluated in order to resolve 
these issues, however, detergents and other reagents necessary to solubilize DGAT2 and reduce 
interactions were not conducive to maintaining protease activity.  Ultimately, through 
mutagenesis, we found that DGAT2 also fell victim to caveat two as it contained multiple 
ungrouped ubiquitinated residues and therefore was not a suitable candidate for analysis by the 
3C protease method. 
 To show that DGAT2 degradation was lysine dependent, we utilized a construct in 
which all 25 lysine residues were mutated to arginine.  As expected, this mutant was not 
degraded, yet surprisingly, it was still polyubiquitinated.  We identified that peptide bond 
formation at the α-NH2 was the most likely site of ubiquitin conjugation.  The significance of 
N-terminal ubiquitination is not well understood.  It has been found to function as a degradation 
signal, forming a distinct pathway dubbed the ubiquitin fusion degradation pathway (Johnson et 
al., 1995).  While degradation of Lys-less-DGAT2 was not apparent, it might occur over a 
longer time period as the longest CHX assay conducted was six hours.  Additionally, N-
terminal ubiquitination found on the Lys-less construct could be an artifact of mutating all 
lysine residues in the protein. 
 Analysis of pre-existing DGAT2 deletion mutants demonstrated the importance of the 
C-terminus in dictating DGAT2 stability.  Deletion of the C-terminal-most residues (Δ327-388) 
	 71	
greatly stabilized DGAT, suggesting the six lysine residues in this region may be of 
importance.  A previous report implicated the first TMD as a degradation signal (Choi et al., 
2014).  Our findings demonstrated that deletion of the TMDs (amino acids 66-116 in mutants 
FL-Δ66-115 and FL-Δ2-119) had no significant effect on DGAT2 stability.  One possible 
explanation for this disparity is that the previous study utilized a fusion protein containing the 
N-terminal 398 amino acids of firefly luciferase linked to the N-terminus of DGAT2. Thus, the 
sizable tag could elicit significant structural changes in DGAT2.  While this fusion protein, 
when intact, is rapidly degraded, it is possible that deletions in the TMD region cause structural 
rearrangements that mask normal DGAT2 degradation signals.  
 In agreement with the finding that no deletion mutant was invulnerable to degradation, 
all DGAT2 deletion mutants were polyubiquitinated.  Polyubiquitination of FL-Δ327-388 was 
greater than that of FL-DGAT2 despite reduced abundance of the unmodified protein.  This 
suggested that a larger fraction of this mutant was in the polyubiquitinated form.  However, the 
FL-Δ327-388 mutant exhibited increased stability.  It is possible that deletion of this region 
caused improper folding that targets the mutant to degradation through a quality control 
mechanism, which facilitates turnover at a lesser rate.  While the ubiquitin signal was reduced 
in FL-Δ2-119 and FL-Δ66-115, the monomeric form of the mutant was also less abundant.  
 Early attempts at mutating individual lysines to arginines in DGAT2 and assessing 
stability were largely unsuccessful.  The rapid rate of DGAT2 degradation made fine 
distinctions in turnover time difficult to discern.  Only when larger groups of lysines were 
mutated simultaneously could a noticeable reduction in turnover be elicited (ex. mutant FL-
K118-376R).  As identifying the contribution of individual lysine residues in dictating DGAT2 
stability was not possible, we used the Lys-less-DGAT2 mutant – which was stable over a 6 h 
CHX degradation assay.  Therefore, restoration of lysines in Lys-less-DGAT2 allowed us to 
distinguish those that facilitated degradation.  In agreement with data from the deletion mutants, 
the N-terminal most lysines (K: 2, 26 and 28) did not trigger turnover in the Lys-less construct.  
However, restoration of lysines directly flanking the TMDs (K: 63, 66, 118 and 119) (TMD1: 
66-87; TMD2: 93-116) was sufficient to induce turnover.  Moreover, re-introduction of lysines 
K346, K353, K368, K374 or K376 - all removed in the degradation resistant Δ327-388 mutant - 
served as potent turnover signals.  All remaining lysines - excluding K2, K26 and K28 - also 
facilitated degradation to varying degrees.  Mass spectrometry was attempted in order to 
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confirm these findings, but was unsuccessful due to poor sequence coverage.   As there are so 
many potential ubiquitin acceptor sites, it is unsurprising that the substitution of individual 
lysines in DGAT2 had little effect.  Moreover, the rapid turnover of DGAT2 could simply be a 
function of the abundance of ubiquitin chain acceptor sites, therby increasing the likelihood that 
DGAT2 is recognized and targeted for destruction.  
 All lysine residues of DGAT2 are present on the cytosolic face of the ER membrane, 
potentially exposing them to ubiquitination by E3 ligases localized to the ER membrane or 
cytosol (Stone et al., 2006; McFie et al., 2014).  It is possible that substitution of 25 lysine 
residues in the Lys-less-DGAT2 construct causes significant structural changes.  Moreover, 
when the lysines are reintroduced into the Lys-less construct they may be present in regions 
with significantly different structure than is observed in the native protein.  This could lead to 
ubiquitination of lysines that are not normally accessible for post-translational modification; 
knowledge of DGAT2 structural domains could identify these residues.  It is also possible that 
Lys-less-DGAT2 is ubiquitinated by a different group E3 ligases.  This would likely be 
dependent on whether the degron(s) of DGAT2 that are traditionally identified are substantially 
altered in the mutant protein. 
 Notably, a mass spectrometry based study of ubiquitination patterns in mouse tissues 
revealed greater than 20,000 unique ubiquitination sites (Wagner et al., 2012).  DGAT2, 
ubiquitinated at Lys264 in heart tissue, was detected.  Incidentally, we found that restoration of 
the K251, K257, K260 and K264 cluster of lysines induced degradation in the Lys-less 
construct. 
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CHAPTER 5: Examining the role of lysines in triacylglycerol synthesis and 
the effects of lipogenesis on DGAT2 stability and ubiquitination 
5.1. Introduction 
 For some time there has been debate as to whether DGAT2 is capable of trafficking 
from the ER to lipid droplets.  An alternative hypothesis is that it may remain in the ER with its 
cytoplasmic domains interacting with lipid droplets via the close proximity of the two 
membranes.  Recent evidence suggests that DGAT2 does in fact exist on the lipid droplet 
(Jacquier et al. 2011; Xu et al., 2012; Wilfling et al., 2013; McFie et al., 2014). One of the 
preeminent unresolved aspects of DGAT2 is elucidating the events that allow this transition to 
the droplet.  It may move to the lipid droplet in a manner similar to that of GPAT4, which 
diffuses on membrane bridges that connect the ER and lipid droplets (Wilfling et al., 2013).    
Post-translational modification of DGAT2 during lipogenesis could be a crucial factor in 
DGAT2 relocalization.   
Lysine is the most commonly post-translationally modified amino acid (Zhang et al., 
2011).  Potential modifications include: methylation, acetylation, biotinylation, propionylation, 
butylation, succinylation, ubiquitination and ubiquitin-like modification.  Post-translational 
modifications can have a variety of implications in cell signaling, including dictating changes in 
protein localization.  Notably, the role of ubiquitination in affecting protein localization has 
been detailed in many cases.  For example, p53 requires multi-monoubiquitination for nuclear 
export (Li et al., 2003) 
 Lipid concentrations have been shown to affect the turnover rate of multiple proteins 
involved in triacylglycerol metabolism, such as perilipin-2, apolipoprotein B, lipoprotein (a), 
and apolipoprotein E (Xu et al., 2005, 2006; Taghibiglou et al., 2000; White et al., 1999; 
Wenner et al., 2001).  Supplementation with fatty acids stabilizes these proteins, increasing the 
efficiency of triacylglycerol storage in lipid droplets.  Conversely, as fatty acid levels fall, these 
proteins are ubiquitinated and degraded by the proteasome.  As DGAT2 is rapidly degraded 
under basal conditions, it is possible that lipogenesis and lipolysis prompt alterations in stability 
(Choi et al., 2014). 
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5.2. Results 
5.2.1. Lys-less-DGAT2 retained in vitro DGAT activity 
We were interested to see if Lys-less-DGAT2, containing 25 lysine substituted 
arginines, was active and able to efficiently catalyze the acylation of diacylglycerol to 
triacylglycerol.  FL-DGAT2 and FL-Lys-less-DGAT2 were expressed in HEK-293T cells and 
total cell extracts were isolated.  Triacylglycerol synthesis activity of cell lysates was assessed 
by measuring the incorporation of fluorescent NBD-palmitoyl-CoA, producing NBD-
triacylglycerol (Fig. 5.1) (Section 3.14) (McFie and Stone, 2011).  We identified that Lys-less-
DGAT2 retained in vitro activity equal to that of DGAT2.  This suggests that lysines are not 
necessary for DGAT2 activity.  
 
 
 
 
Figure 5.1.  Lys-less-DGAT2 is active in vitro – In vitro DGAT activity of total cell extracts 
isolated from HEK-293T cells transiently expressing FL-DGAT2, FL-Lys-less-DGAT2 or 
untransfected control were analyzed as described in Section 3.14.  Fifty micrograms of total cell 
extract was used for each reaction.  DGAT2 and FL-Lys-less-DGAT2 were expressed at similar 
levels (data not shown).  Results shown represent the average values obtained from duplicate 
samples in one experiment; the experiment was repeated, yielding similar results.  
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5.2.2. Lys-less-DGAT2 exhibited altered localization and reduced the average size of 
lipid droplets in COS-7 cells 
 Having identified that Lys-less-DGAT2 was stable and retained in vitro activity 
comparable to DGAT2, we were particularly interested to examine the effect of the Lys-less 
mutant on triacylglycerol synthesis in situ.  We expected the degradation resistance of the Lys-
less construct to translate to increased triacylglycerol synthesis and elevated lipid droplet size 
and/or number.  COS-7 cells were transfected with FL-DGAT2 or FL-Lys-less-DGAT2 and 
treated with oleic acid to stimulate lipid droplet formation.  Analysis was conducted by 
immunofluorescence microscopy (Section 3.15).  We found that Lys-less-DGAT2 exhibited 
altered localization (Fig. 5.2).  While some cells showed Lys-less-DGAT2 localization to the 
ER, typical of DGAT2, a population of cells also displayed strong staining in or around the 
nucleus with distinct punctate structures.  Additionally, Lys-less-DGAT2 did not localize to the 
surface of lipid droplets when triacylglycerol synthesis was stimulated by the addition of oleic 
acid.  As DGAT2 localization to the lipid droplet aids in droplet expansion, a lack of large lipid 
droplets was apparent in Lys-less-DGAT2 transfected cells (Monetti et al., 2007; Stone et al. 
2004).  
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Figure 5.2.  Lys-less-DGAT2 exhibited altered localization and reduced the size of lipid 
droplets - COS-7 cells transiently expressing FL-DGAT2 or FL-Lys-less-DGAT2 were treated 
with 0.5 mM oleate for 12 h and then stained with anti-FLAG.  BODIPY 493/503 was used to 
visualize lipid droplets. Two different staining patterns for FL-Lys-less-DGAT2 are shown. 
Scale bars, 10 µm.  
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5.2.3. Mutation of two DGAT2 lysine clusters caused mislocalization of DGAT2 and 
perturbed lipid droplet formation 
Having noted that Lys-less-DGAT2 exhibited altered localization and produced smaller 
lipid droplets, we chose to screen our DGAT2 Lys-to-Arg mutant library to identify regions 
which may be responsible.  A cluster of Lys residues - K251, K257, K260, K264 - that when 
mutated to Arg (FL-DGAT2 K251, 257, 260, 264R) was sufficient to cause nuclear/perinuclear 
localization, similar to Lys-less-DGAT2 (Fig. 5.3).  Conversely, reintroduction of these four 
lysines into the Lys-less construct (FL-Lys-less-DGAT2 R251, 257, 260, 264K) was not able to 
correct mislocalization, suggesting that additional regions may be able to produce this 
phenotype.  
Lipid droplet analysis was conducted on confocal images of FL-DGAT2, FL-DGAT2 
K251, 257, 260, 264R, FL-Lys-less-DGAT2 and FL-Lys-less-DGAT2 R251, 257, 260, 264K 
transfected COS-7 cells (Section 3.16).  Lipid droplet number in cells expressing DGAT2 
K251, 257, 260, 264R was significantly higher post-oleate treatment than in those expressing 
other constructs (Fig. 5.4A).  Examination of mean droplet area revealed that DGAT2 
transfected cells produced larger droplets than those observed with the DGAT2 mutants (Fig. 
5.4B).  In addition, DGAT2 and DGAT2 K251, 257, 260, 264R transfected cells exhibited a 
greater total lipid droplet area per cell than the Lys-less mutants (Fig. 5.4C).  While DGAT2 
K251, 257, 260, 264R appeared to result in an overall increase in total droplet area relative to 
DGAT2, this finding was not statistically significant.  To summarize, substitution of lysine 
residues 251, 257, 260 and 264 for arginine caused cells to produce an elevated number of lipid 
droplets with a lower mean area relative to DGAT2.  Ultimately, the total lipid droplet area was 
relatively similar when comparing cells expressing each construct.  While restoration of the 
251-264 cluster of lysines in the Lys-less construct appeared to increase the mean droplet area 
above that of Lys-less, the mean sum of total lipid droplet area remains similar.  Likely, there 
are additional regulatory lysine residues important in the production of lipid droplets.   
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Figure 5.3.  Lipid droplet analysis of cells expressing DGAT2 lysine mutants - COS-7 cells 
transiently expressing FL-DGAT2, FL-Lys-less-DGAT2, FL-DGAT2 K251, 257, 260, 264R or 
FL-Lys-less-DGAT2 R251, 257, 260, 264K were treated with 0.5 mM oleate for 18 h and then 
stained with anti-FLAG and BODIPY 493/503 to visualize lipid droplets.  Scale bar, 10 µm 
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A.             B. 
       
 
C. 
	                     
 
Figure 5.4.  DGAT2 lysines 251-257 are important in normal lipid droplet formation - 
COS-7 cells were transfected with FL-DGAT2, FL-DGAT2 K251, 257, 260, 264R, FL-Lys-
less-DGAT2 or FL-Lys-less-DGAT2 R251, 257, 260, 264K prior to 18 h treatment with 0.5 
mM oleic acid (18:1).  Samples were stained with anti-FLAG and BODIPY 493/503 to 
visualize lipid droplets.  Images were taken with a confocal system and analyzed using ImageJ 
analysis software. All analysis was conducted on fourteen cells per construct.  Lipid droplets 
with an area of ≥ 0.2 micron2 were counted.  (A) Mean lipid droplet number was calculated.  *, 
**, ***, p < 0.05 versus DGAT2, Lys-less-DGAT2 and Lys-less-DGAT2 R251, 257, 260, 264 
transfected cells respectively. (B) Mean lipid droplet area was calculated.  *, **, ***, p < 0.05 
versus DGAT2 K251, 257, 260, 264R, Lys-less-DGAT2 and Lys-less-DGAT2 R251, 257, 260 
,264K transfected cells respectively.  ****, p <0.05 versus Lys-less-DGAT2 transfected cells. 
(C) Mean sum of lipid droplet area was calculated *, **, p < 0.05 versus Lys-less-DGAT2 and 
Lys-less-DGAT2 R251, 257, 260, 264K transfected cells respectively.  ***, ****, p < 0.05 
versus Lys-less-DGAT2 and Lys-less-DGAT2 R251, 257, 260, 264K transfected cells 
respectively. 
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Through further screening of our mutant library, we identified that mutation of the six 
C-terminal lysines - 332, 346, 353, 368, 374 and 376 - to Arg caused a similar nuclear pattern 
to that observed in the Lys-less and K251, 257, 260, 264R mutants (Fig. 5.5).  We previously 
identified these six residues as strong promoters of DGAT2 degradation (Chapter 4.2.5).  
Unfortunately, re-establishment of these ten residues in the Lys-less construct was insufficient 
to restore typical DGAT2 localization (data not shown).  
 
 
 
 
 
 
Figure 5.5. Mutation of the six C-terminal DGAT2 lysines caused nuclear localization - 
COS-7 cells transiently expressing FL-DGAT2 or FL-DGAT2 K332, 346, 353, 368, 374, 376R 
(FL-DGAT2 K332-376R) were treated with 0.5 mM oleate for 12 h and then stained with anti-
FLAG and BODIPY 493/503 to visualize lipid droplets.  Scale bar, 10 µm.   
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5.2.4. Stimulation of lipogenesis did not reduce DGAT2 turnover 
We were interested in determining if DGAT2 stability is altered by the stimulation of 
lipogenesis.  It is possible that when the cell is producing triacylglycerols, DGAT2 turnover 
could be reduced in order to increase the rate of triacylglycerol synthesis.  Two separate 
methods of lipogenic induction were evaluated (Section 3.9).  Treatment with oleic acid, a 
DGAT2 substrate, drives the acylation of 1,2-diacylglycerol to form triacylglycerol.  HEK-
293T cells were transfected with FL-DGAT2 and cultured in the presence or absence of oleic 
acid followed by re-feeding a solution of CHX with or without oleic acid (Fig. 5.6A).  DGAT2 
was rapidly degraded independent of oleic acid.  Examination of triacylglycerol levels revealed 
a large increase in triacylglycerol synthesis in oleate treated cells, which remained relatively 
constant throughout the CHX time course (Fig. 5.6B).  While DGAT2 is reduced over this 
period, a fall in triacylglycerol levels is not necessarily expected, as the bulk of triacylglycerol 
would be formed over the 18 h oleic acid incubation.  Thus, variations in triacylglycerol 
abundance over the 6 h CHX treatment would be heavily influenced by the rate of 
triacylglycerol breakdown, which may happen at a lesser rate.    
 DGAT2 turnover was also analyzed under insulin-induced lipogenesis.  Treatment with 
insulin stimulates lipogenesis through the activation of pyruvate dehydrogenase and acetyl-
CoA carboxylase.   Pyruvate dehydrogenase is responsible for the conversion of pyruvate into 
acetyl-CoA, a substrate for acetyl-CoA carboxylase.  Acetyl-CoA carboxylase then converts 
acetyl-CoA to malonyl-CoA, providing the two-carbon units in the production of long chain 
fatty acids.  FL-DGAT2 transfected cells were treated in the presence or absence of insulin, 
preceding co-treatment with CHX (Fig. 5.6C).  Samples were harvested, isolating total cell 
extracts, and DGAT2 protein levels were analyzed by anti-FLAG-immunoblotting.  The data 
showed that stimulation of lipogenesis, triggered by insulin, did not affect the rate of DGAT2 
turnover.  
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 A. 
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Figure 5.6. Neither oleic acid nor insulin stabilized DGAT2 - (A) HEK-293T cells 
expressing FL-DGAT2 were incubated with or without 0.5 mM oleate for 18 h. Cells were then 
treated with 100 µg/mL CHX in the presence or absence of 0.5 mM oleate for 0–6 h. Time zero 
refers to cells harvested after the 18 h incubation, in the presence or absence of oleate, without 
any CHX. (B) Lipids were extracted from equal amounts of cellular protein from the samples in 
Fig. 2A and separated by thin layer chromatography. (C) Cells were treated with or without 5 
µg/mL insulin for 1 h. The growth media was replaced with media containing 100 µg/mL CHX 
with or without 5 µg/mL insulin and cells were harvested at the indicated time points. Time 
zero refers to cells harvested after the 1 h insulin treatment with no CHX. Samples were 
separated by SDS-PAGE and immunoblotted with anti-FLAG and anti-calnexin.  TG represents 
triacylglycerol. 
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5.2.5. Polyubiquitinated DGAT2 was detected in mitochondrial and fat fractions 
Stimulation of lipogenesis did not appear to alter DGAT2 degradation, however, we 
chose to use subcellular fractionation to examine whether lipid droplet localized DGAT2 was 
ubiquitinated.  HEK-293T cells were transfected with FL-DGAT2 and HA-ubiquitin or a Myc-
DGAT2 and HA-ubiquitin negative control.  Through differential- and sucrose gradient-
centrifugation, crude mitochondria and the lipid droplet/fat fractions were isolated (Section 
3.12). MAM, in which DGAT2 is enriched, is present in the crude mitochondria fraction.  
DGAT2 was immunoprecipitated with anti-FLAG agarose and analyzed by SDS-PAGE and 
immunoblotting (Fig. 5.7).   Relative fraction purity was assessed by the presence of marker 
proteins.  Heat shock protein 70 (Hsp70) was detectable only in the crude mitochondria input 
fraction while lipid droplet protein, perilipin-2, was observed only in the fat input fraction.  FL-
DGAT2 was detected in crude mitochondria and fat fractions.  The Myc-DGAT2 control, not 
bound by anti-FLAG agarose, was only detected in fraction inputs and not isolated in the anti-
FLAG immunoprecipitates.  Detection of HA-ubiquitin conjugates with an anti-HA primary 
antibody revealed DGAT2 polyubiquitination in both crude mitochondria and fat fraction 
immunoprecipitations.  No ubiquitin signal was detected in anti-FLAG immunoprecipitates of 
fractions derived from Myc-DGAT2 transfected cells.  This demonstrates that DGAT2 isolated 
from MAM and lipid droplets is polyubiquitinated. 
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Figure 5.7. DGAT2 localized to both MAM and lipid droplets is ubiquitinated - HEK-293T 
cells expressing either FL-DGAT2 or Myc-DGAT2 along with HA-ubiquitin were incubated 
with 0.5 mM oleate for 43 h to stimulate triacylglycerol synthesis.  Crude mitochondria and 
floating fat fractions were then isolated by ultracentrifugation. Purity of the crude mitochondrial 
membrane and floating fat fractions were assessed by sequential immunoblotting with anti-
Hsp70 (mitochondria) and perilipin-2 (lipid droplet) antibodies.  FL-DGAT2, but not Myc-
DGAT2, was immunoprecipitated with anti-FLAG agarose from detergent solubilized material.  
Immunoprecipitates (IP) were separated by SDS-PAGE and were then probed with anti-FLAG 
and anti-HA antibodies.  HC and LC represent antibody heavy and light chains respectively.  
5.2.6.  Inhibiting lipid droplet localization did not affect DGAT2 degradation 
Having identified that DGAT2 on the ER and lipid droplets is ubiquitinated, we chose to 
determine whether DGAT2 localization to the lipid droplet has an impact on its turnover.  This 
was examined using a mutant that is retained in the ER, FL-DGAT2-HA-insert, which has an 
artificially extended lumenal loop between its TMDs.  The extended region is comprised of 22 
amino acids, containing an HA-tag flanked by additional primary sequence normally present in 
the loop.  This mutant has been shown to retain full catalytic activity in vitro, but does not 
migrate from the ER following oleate loading (McFie et al. 2014).  HEK-293T cells transiently 
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expressing FL-DGAT2 or the ER anchored mutant were pre-treated in the presence or absence 
of oleic acid prior to CHX assay.  Samples were analyzed by SDS-PAGE and anti-FLAG 
immunoblotting (Fig. 5.8).  In the absence and presence of oleic acid, the HA-insert mutant was 
rapidly degraded at a rate very similar to DGAT2.  This suggests that DGAT2 degradation is 
not dependent on localization to lipid droplets. 
 
 
 
 
Figure 5.8.  Inhibiting lipid droplet localization did not affect DGAT2 degradation - HEK-
293T cells expressing FL-DGAT2 or FL-HA-insert were treated with or without 0.5 mM oleate 
for 18 h.  Cells were then treated with 100 µg/mL CHX in the presence or absence of 0.5 mM 
oleate for 0–6 h.  Samples were analyzed by immunoblotting with anti-FLAG and anti-calnexin 
antibodies.  LD denotes a lipid droplet. 
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5.2.7. DGAT2 is ubiquitinated in situ under basal and lipogenic conditions 
Stimulation of lipogenesis did not have an effect on DGAT2 turnover.  Similarly, a 
DGAT2 mutant confined to the ER was rapidly degraded at a rate closely resembling that of 
DGAT2.  However, the ubiquitination status of DGAT2 may be altered during lipogenesis, 
possibly playing a role in migration to the lipid droplets during triacylglycerol synthesis.  We 
were interested in identifying which cellular pools of DGAT2 were ubiquitinated, as well as 
any differences in the ubiquitination of DGAT2 populations under basal and lipogenic 
conditions.  COS-7 cells were co-transfected with FL-DGAT2/HA-ubiquitin or control Myc-
DGAT2/HA-ubiquitin and incubated with or without oleic acid prior to Duolink® In Situ 
Proximity Ligation Assay (PLA) analysis (Fig. 5.9) (Section 3.17). Anti-FLAG and anti-HA 
primary antibodies were detected by species specific PLUS and MINUS PLA probes.  Addition 
of the ligation mixture results in hybridization of the oligonucleotide tails if the PLUS and 
MINUS PLA probes are within 40 nm of each other.  The hybridized circular DNA is then 
amplified and detected with a fluorescent probe.   
Following completion of the PLA, cells were co-stained with BODIPY 493/503 to 
visualize ubiquitinated DGAT2 relative to lipid droplet position.  Alternatively, cells were co-
stained using anti-DGAT2 specific antibody in order to compare ubiquitinated DGAT2 to the 
total DGAT2 population.  A strong interaction signal was detected in cells expressing FL-
DGAT2 and HA-ubiquitin in both oleate treated and untreated samples - signifying 
ubiquitinated DGAT2.  The population of ubiquitinated DGAT2 appeared to align very closely 
with total DGAT2 population, independent of oleate treatment (Fig. 5.10A).  Ubiquitinated 
DGAT2 was also observed closely associated with BODIPY stained lipid droplets (Fig. 5.10B), 
confirming our subcellular fractionation findings (Fig. 5.7).  Whether the ubiquitination of lipid 
droplet localized DGAT2 functions as a lipid droplet targeting signal, in DGAT2 degradation, 
or in both, is unknown.   
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Figure 5.9.  Duolink® in situ proximity ligation assay – In situ identification of protein-
protein interactions or post-translational modifications using PLA requires primary antibodies 
specific to each target.  Species-specific secondary antibody PLA probes bind to the primary 
antibodies.  Oligonucleotide tails on the PLA probes hybridize with connector oligonucleotides 
if the two target proteins are within 40 nm, forming a complete circularized oligonucleotide that 
is ligated together.  Addition of polymerase replicates the circular oligonucleotide to amplify 
the interaction signal.  Fluorescent probes hybridize to the amplified sequence allowing for 
detection.  A d protocol is described in Section 3.17.  This figure has been adapted from 
product literature produced by Sigma Aldrich. 
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A. 
 
 
B. 
 
Figure 5.10. DGAT2 ubiquitination patterns are not affected by oleic acid - COS-7 cells 
were co-transfected with FL-DGAT2/HA-ubiquitin or control Myc-DGAT2/HA-ubiquitin and 
incubated approximately 18 h in the presence or absence of 0.5 mM oleic acid prior to PLA 
analysis.  In order to visualize ubiquitinated DGAT2 relative to the total population of DGAT2 
and lipid droplet position, cells were co-stained with (A) anti-DGAT2 or (B) BODIPY 493/503 
respectively.  Cover slips were mounted with DAPI containing medium and visualized using a 
confocal system.  Scale bar, 10 µm.   
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5.3. Discussion 	 We	used	Lys-less-DGAT2 to determine if lysine residues play a catalytic role in DGAT 
activity.  From our in vitro assay, it is clear that lysines are dispensable for triacylglycerol 
synthesis.  More interesting were the effects in situ, in which the Lys-less mutant exhibited 
aberrant localization and disrupted typical lipid droplet formation.  The nuclear foci observed in 
Lys-less-DGAT2 transfected cells are most likely accumulations of degradation resistant 
DGAT2.  This conclusion is bolstered by similar findings from mutants DGAT2 K251, 257, 
260, 264R and DGAT2 K332, 346, 353, 368, 374, 376R which contain mutation of lysines 
shown to induce degradation when restored in the Lys-less construct (Chapter 4.2.5.)   Why 
DGAT2 accumulates in or around the nucleus is unclear.  However, like the ER, the nucleus is 
enriched in components of the ubiquitin-proteasome system (Palmer et al., 1996).  Moreover, 
DGAT2 was recently discovered in intranuclear membranes and on nuclear lipid droplets, thus, 
it is possible there is a nuclear pathway for DGAT2 degradation (Ohsaki et al., 2016).  Our 
findings did not clearly distinguish whether the Lys-less mutant was present as insoluble 
aggregates in the nucleoplasm, in nuclear membranes, or in closely apposed ER membranes.  
This could be resolved through examining co-localization with known nuclear proteins or by 
isolation and analysis of nuclear fractions. 
How the Lys-less-DGAT2 mutant has such a dramatic effect on triacylglycerol 
synthesis and lipid droplet formation in situ, yet retains normal in vitro activity is difficult to 
reconcile.  Analysis clearly revealed that lipid droplet size and number were altered in Lys-less-
DGAT2 expressing cells.  Interestingly, mutation of lysines 251, 257, 260 and 264 in DGAT2 
caused a significant reduction in the average size of lipid droplets, with a corresponding 
increase in average number of droplets.  This did not affect total lipid droplet area within the 
cell, suggesting that some or all of these lysines may be involved in targeting DGAT2 to 
expanding droplets.  Restoration of these residues in the Lys-less construct did not elevate total 
cellular lipid droplet area, again implying that additional lysines play a role in regulating 
DGAT activity in situ. 
 As mentioned previously, lipid concentrations have been shown to affect the turnover 
rate of multiple proteins involved in triacylglycerol metabolism.  We identified that stimulating 
triacylglycerol synthesis through substrate loading or insulin treatment did not alter DGAT2 
turnover.  These results suggest that DGAT2 degradation is held relatively constant and 
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DGAT2 levels are likely controlled primarily at the level of transcription.  However, it is 
possible that at the time of the degradation assay, after sustained treatment with oleic acid, the 
cells were no longer lipogenic.  This was recently re-evaluated, using tandem treatment with 
CHX and oleic acid while omitting the oleic acid pre-treatment; DGAT2 degradation was still 
not inhibited (data not shown).  SCD1 is another protein involved in triacylglycerol synthesis 
that is rapidly degraded by the ubiquitin-proteasome system independent of lipid 
concentrations.  Incidentally, SCD1 and DGAT2 have been shown to interact when co-
expressed, elevating triacylglycerol synthesis above levels when either protein was transfected 
individually (Man et al., 2006).  This cooperation could indicate similarities in post-
translational regulation. 	 As stimulation of triacylglycerol synthesis, which triggers DGAT2 movement to lipid 
droplets does not stabilize DGAT2, DGAT2 situated on droplets must still be vulnerable to 
degradation.  Consistent with this notion, DGAT2 isolated from both crude mitochondria and 
lipid droplet fractions was polyubiquitinated.  Several questions still remain.  For one, does 
ubiquitin have a role in targeting DGAT2 to lipid droplets?  Use of linkage-specific antibodies 
to detect chains not typically associated with degredation may be useful in determining this.  
The inability of the Lys-less-DGAT2 construct to migrate to droplets provides some evidence 
that the process is at least lysine dependent.  Secondly, can DGAT2 on lipid droplets be sent 
directly to the proteasome or must it first move back to the ER?  Oleosins and PAT-domain 
containing proteins are reportedly degraded on lipid droplets (Deruyffelaere et al., 2015; 
Kaushik and Cuervo, 2015).  Multiple proteins involved in protein degradation, such as ancient 
ubiquitous protein 1, are present on droplets and could facilitate this process (Jo et al., 2013; 
Klemm et al., 2011; Spandl et al., 2011; Olzmann et al., 2013b).  Yeast DGAT2 ortholog, 
Dga1, shuttles back to the ER under lipolytic conditions (Jacquier et al., 2011).  A similar 
mechanism could be present for DGAT2 degradation.  Unfortunately, analysis of DGAT2 
degradation using an ER anchored mutant provided little insight.  Moreover, PLA analysis 
revealed that ubiquitinated DGAT2 is abundant under basal and lipogenic conditions.  Also, it 
appeared that all DGAT2 can be potentially ubiquitinated rather than a specifically localized 
sub-population.  Linkage specific poly-ubiquitin antibodies could again be useful in identifying 
traditionally non-degradative linkages. 
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 These findings point to a protein that is constitutively ubiquitinated and rapidly 
degraded independent of its location or metabolic signals.  As DGAT2 transcript levels have 
been shown to fall during fasting and increase upon refeeding, it is possible that regulation is 
imposed primarily at the transcriptional level (Meegalla et al., 2002).  This study is limited by 
reliance on an overexpression system; the ability to monitor endogenous DGAT2 would be 
beneficial.  Recent findings in our lab, indirectly measuring DGAT2 turnover, support the 
conclusions of our overexpression system in that it is a rapidly degraded protein.  3T3-L1 
adipocytes were pre-treated with DMSO or MG132 for 30 min., CHX was added to the culture 
media and cells were incubated for two hours.  In vitro DGAT assays were conducted in the 
presence of a DGAT1 inhibitor to observe triacylglycerols produced only by DGAT2.  We 
found that lysates obtained from cells treated with MG132, blocking DGAT2 degradation, 
produced significantly more triacylglycerols.  This indicates that over the two hour CHX 
incubation, DGAT2 proteins levels fell considerably (Brandt et al., 2016b).  Repeating this 
experiment in cells treated with oleic acid or insulin would be valuable in validating our 
findings that DGAT2 is degraded independent of lipogenic stimuli.	 	Additionally, it must be 
acknowledged that DGAT2 regulation could vary widely between tissues and what applies in 
human kidney cells may not be replicated in hepatocytes or adipocytes – tissues exhibiting 
prominent DGAT2 expression and activity.	
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CHAPTER 6:  Identification of proteins interacting with DGAT2  
6.1. Introduction 
 Very little is known about the identity of proteins interacting with DGAT2.  Until 
recently, the only experimentally validated interacting partners included SCD1, MGAT2, fatty 
acid transport protein 1 and GPAT8 (Man et al., 2006; Jin et al., 2014; Xu et al., 2012; Gidda et 
al., 2011).  These interactions suggest that DGAT2 is part of a large triacylglycerol synthesis 
complex.  Identification of other binding partners could be valuable in understanding the 
regulatory network of DGAT2. 
MGAT2 is responsible for producing diacylglycerol in the MGAT pathway, which is 
particularly prominent in the intestine (Johnston and Rao, 1967).  Interaction of DGAT2 with 
MGAT2 was recently discovered (Jin et al., 2014). This interaction was found to be dependent 
on DGAT2 TMDs.  Moreover, diacylglycerol produced by MGAT2 may be utilized by 
DGAT2.  Like MGAT2, MGAT3 exhibits a high degree of sequence similarity with DGAT2 
(Cheng et al., 2003).  In addition to MGAT activity, MGAT3 also appears to possess significant 
DGAT activity (Cheng et al., 2003; Cao et al., 2007; Brandt et al., 2016a).  Association of 
DGAT2 with MGAT3, and the possible metabolic implications have yet to be studied. 
 Calnexin is an integral membrane protein of the ER (Schrag et al., 2001).  It functions 
as a lectin, binding monoglucosylated glycans covalently attached to proteins undergoing 
folding in the ER (Hammond and Helenius, 1993, Hammond et al., 1994; Helenius, 1994).  The 
glycan acts as a tag, the composition of which signals the folding status of the protein to which 
it is attached.  Calnexin interaction with a protein undergoing folding occurs until the glucose 
molecule is removed, at which point it is either properly folded or structural aberrations trigger 
re-glucosylation, signaling further chaperone assistance by calnexin (Hammond and Helenius, 
1993, Hammond et al., 1994; Helenius, 1994).  Persistent interaction with lectin chaperones 
leads to ERAD of the improperly folded protein (Tannous et al., 2015; Hebert and Molinari, 
2007).  Inhibition of the proteasome causes calnexin to accumulate in regions of the ER 
enriched in several ERAD factors and substrates (Frenkel et al., 2003; Benyair et al., 2015).  
Interestingly, calnexin has also been found to bind non-glycosylated proteins (Danilczyk and 
Williams, 2001).  In vitro, calnexin binding to non-glycosylated proteins appears to inhibit 
aggregation (Saito et al., 1999).  
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6.2. Results 
6.2.1. Identification of DGAT2 interacting proteins by LC-MS/MS  
 To identify proteins interacting with DGAT2, we chose to take an unbiased mass 
spectrometry proteomics-based approach.  HEK-293T cells were transfected with FL-DGAT2 
or control Myc-DGAT2 and incubated with oleic acid to stimulate lipogenesis.  Co-
immunoprecipitation was conducted on total cell extracts using anti-FLAG agarose.  Sample 
preparation and analysis by mass spectrometry was conducted in collaboration with Dr. George 
Katselis’ Lab at the University of Saskatchewan.  Samples were trypsinized prior to analysis by 
LC-MS/MS.  Data were searched against the SWISS-PROT Homo sapiens database (Table 
9.1).  Data extractor, SpectrumMill Proteomics Workbench Version B.04.00.127 (Agilent 
Technologies) was used for identification of MS/MS spectra.  Peptide identifications were 
accepted if they could be established at greater than 90.0% probability.  Additionally, protein 
identifications were accepted if they could be established at greater than 99.0% probability and 
contained at least one identified peptide.  Proteins identified in Myc-DGAT2 transfected 
samples were judged to interact non-specifically with the anti-FLAG agarose and excluded 
from further analysis.  DGAT2 was successfully identified in the FL-DGAT2 transfected 
sample with 3 unique peptides and 3 unique spectra detected  (Fig. 6.1 A, B).  DGAT2 
sequence coverage was 5.15% (Table 9.1).  DGAT2 was not identified in the Myc-DGAT2 
transfected control.  
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A.  
Sequence Observed Actual Mass Charge Intensity 
(K)THNLLTTR(N) 319.18 954.51 3 1.64E+06 
(R)DTIDYLLSK(N) 534.27 1066.53 2 4.17E+07 
(K)YIGFAPCIFHGR(G) 719.35 1436.68 2 6.84E+06 
  
B. 
 
 
Figure 6.1.  DGAT2 was successfully detected by LC-MS/MS - HEK-293T cells were 
transfected with FL-DGAT2 or control Myc-DGAT2 and incubated for approximately 18 h in 
0.5 mM oleic acid to stimulate lipogenesis.  Cells were harvested and total cell extracts 
prepared for co-immunoprecipitation with anti-FLAG agarose.  Proteins were dissociated from 
anti-FLAG agarose by boiling in 2x SDS-PAGE sample buffer (+5% β-mercaptoethanol).  
Samples were trypsinized prior to analysis by LC-MS/MS.  Data extractor, SpectrumMill 
Proteomics Workbench Version B.04.00.127 (Agilent Technologies) was used for identification 
of MS/MS spectra.  Data were searched against the SWISS-PROT Homo sapiens database. (A) 
Three unique peptides from DGAT2 were isolated from trypsinized co-immunoprecipitation 
samples.  Included are values for observed and actual mass, as well as peptide charge and 
intensity. (B) Representative spectrum identifying DGAT2 in co-immunoprecipitation samples. 
 
One hundred thirty-three proteins were isolated along with DGAT2.  This list was 
compared against The Contaminant Repository for Affinity Purification Mass Spectrometry 
Database.  This database contains the frequency of identification for ~4500 different proteins 
isolated across 334 separate mass spectrometry experiments, aiding in the discrimination of 
common contaminants from genuine interactions (Mellacheruvu et al., 2013).  Frequency of 
identification was included for proteins present in the database (Table 9.1).  Twenty of the 134 
proteins identified by LC-MS/MS had a frequency of greater than 25% when scanned against 
the Contaminant Repository database; other proteins were also present in the database but at 
lower frequency (Table 9.1).   
DGAT2 immunoprecipitated with several components of the proteasome, including: 
26S proteasome non-ATPase regulatory subunits 11 and 14 as well as 26S protease regulatory 
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subunit 7.  Interestingly, the E3 ubiquitin ligase, TRIM13, was isolated.  Co-
immunoprecipitation of these proteins with DGAT2 provides further evidence of DGAT2 
regulation by the ubiquitin-proteasome system.   
We were interested in the identification of calnexin in the DGAT2 immunoprecipitates 
(Fig. 6.2 A, B).  Two unique peptides of calnexin were detected, representing 2.53% sequence 
coverage. In this chapter, experiments focus on confirming DGAT2 interaction with calnexin 
and gaining insight into the functional significance of this relationship. 
 
  
A. 
Sequence Observed Actual Mass Charge Intensity 
(K)AEEDEILNR(S) 544.75 1087.50 2 1.98E+06 
(R)KIPNPDFFEDLEPFR(M) 621.97 1862.88 3 1.31E+05 
 
B. 
 
 
Figure 6.2.  Calnexin was detected by LC-MS/MS in DGAT2 co-immunoprecipitates - 
HEK-293T cells were transfected with FL-DGAT2 or control Myc-DGAT2 and incubated for 
approximately 18 h in 0.5 mM oleic acid to stimulate lipogenesis.  Cells were harvested and 
total cell extracts prepared for co-immunoprecipitation with anti-FLAG agarose.  Proteins were 
dissociated from anti-FLAG agarose by boiling in 2x SDS-PAGE sample buffer (+5% β-
mercaptoethanol).  Samples were trypsinized prior to analysis by LC-MS/MS.  Data extractor, 
SpectrumMill Proteomics Workbench Version B.04.00.127 (Agilent Technologies) was used 
for identification of MS/MS spectra.  Data were searched against the SWISS-PROT Homo 
sapiens database. (A) Two unique peptides from calnexin were isolated from trypsinized co-
immunoprecipitation samples.  Included are values for observed and actual mass, as well as 
peptide charge and intensity.  (B) Representative spectrum identifying calnexin in co-
immunoprecipitation samples. 
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6.2.2. DGAT2 co-immunoprecipitated with MGAT2 and MGAT3 
MGAT2 and MGAT3 are members of the DGAT2 family.  They also exhibit substantial 
sequence similarity with DGAT2 (Fig. 6.3).  Knowing that DGAT2 and MGAT2 interact, we 
also expected MGAT3 to interact with DGAT2.  HEK-293T cells were transfected with 
DGAT2-HA, MGAT2-Myc-FL, MGAT3-Myc-FL, Lipin1 or LacZ.  Reciprocal anti-HA and 
anti-FLAG immunoprecipitations were conducted on total cell extracts.  Samples were 
separated by SDS-PAGE and analyzed by immunoblotting (Fig. 6.4).  Anti-HA 
immunoprecipitation, followed by immunoblotting for HA, revealed DGAT2-HA isolation was 
successful.  An identical blot was probed with anti-FLAG antibody, detecting MGAT2 and 
MGAT3.  Lipin1 was not detected.  Re-probing with an anti-calnexin antibody found calnexin 
only in samples transfected with DGAT2-HA.  Therefore, immunoprecipitation of DGAT2 also 
isolated MGAT2, MGAT3 and calnexin.   Conversely, anti-FLAG immunoprecipitation 
followed by anti-FLAG immunoblotting showed that MGAT2, MGAT3 and Lipin1 were 
successfully isolated.  Calnexin was detectable only in MGAT2 transfected samples.  Anti-
FLAG immunoprecipitates probed with an anti-HA antibody revealed DGAT2-HA was present 
in MGAT2, MGAT3 and Lipin1 isolates.  Our lab has previously identified interaction of 
DGAT2 with Lipin1 (Jin et al., 2014).  Why DGAT2 was present in Lipin1 immunoprecipitates 
but Lipin1 was not detected in DGAT2 immunoprecipitates is unclear.  Immunoblotting with an 
anti-Hsp70 antibody returned no signal, demonstrating co-immunoprecipitation specificity.  To 
summarize, reciprocal interaction between DGAT2 and MGAT2/MGAT3 were demonstrated.  
Immunoprecipitation of DGAT2 did not isolate Lipin1 while DGAT2 did co-
immunoprecipitate with Lipin1.  Calnexin was detected in all DGAT2-HA derived co-
immunoprecipitations.  							
 
	 97	
 
 
 
 
 
 
Figure 6.3.  DGAT2, MGAT2 and MGAT3 exhibit high sequence similarity – Multiple 
sequence alignment comparing human DGAT2, MGAT2 and MGAT3.  ‘*’ denotes identical 
residues.  ‘:’ refers to conservation between groups of strongly similar properties. ‘.’ refers to 
conservation between groups of weakly similar properties.  
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Figure 6.4.  DGAT2 co-immunoprecipitated with MGAT2 and MGAT3 – HEK-293T cells 
were transfected with DGAT2-HA, MGAT2-Myc-FL, MGAT3-Myc-FL, Lipin1 or LacZ. 
Reciprocal anti-HA and anti-FLAG co-immunoprecipitation were conducted on total cell 
extracts.  Samples were analyzed by SDS-PAGE and immunoblotting with anti-HA, anti-
FLAG, anti-calnexin and anti-Hsp70 specific antibodies.  IP represents immunoprecipitation.  
HC and LC represent antibody heavy and light chains respectively.   
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6.2.3. DGAT2 interacts with MGAT2 and MGAT3 in situ 
 To confirm in vitro evidence of DGAT2 interaction with MGAT2 and MGAT3, we 
used a proximity ligation assay to examine the interactions in situ.  FL-DGAT2 and Myc-
DGAT2 were transfected into COS-7 cells individually or in tandem.  PLA analysis was 
conducted as previously described.  Samples were probed with anti-FLAG and anti-Myc 
specific antibodies.  No interaction signal was detected when either protein was transfected 
individually. When co-transfected, a strong interaction signal was observed, indicating DGAT2 
interaction with MGAT2 (Fig. 6.5).  An analogous experiment was conducted to confirm 
DGAT2 in situ interaction with MGAT3.  COS-7 cells were co-transfected with Myc-DGAT2 
and FL-MGAT3 or with DGAT2-HA and FL-MGAT3.  Samples were probed with anti-Myc 
and anti-FLAG specific antibodies (Fig. 6.6).  No signal was detected in the DGAT2-HA/FL-
MGAT3 samples, as the Myc-tag is absent.  An interaction signal was visible in the Myc-
DGAT2/FL-MGAT3 co-transfection, thus DGAT2 does interact with MGAT3 in situ. 
 
 
Figure 6.5. Interaction of DGAT2 and MGAT2 was detected in situ by proximity ligation 
assay - COS-7 cells expressing either FL-DGAT2, MGAT2-Myc, or both together were stained 
with anti-FLAG and anti-Myc antibodies. Interaction signals were detected using a Duolink® 
detection kit. Nuclei were stained with DAPI and lipid droplets were stained with BODIPY 
493/503. Scale bar, 10 µm.  
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Figure 6.6.  Interaction of DGAT2 and MGAT3 was detected in situ by proximity ligation 
assay - COS-7 cells expressing either myc-DGAT2 and FL-MGAT3 or DGAT2-HA and FL-
MGAT3 were  incubated with anti-FLAG and anti-Myc antibodies. Interaction signals were 
detected using a Duolink® detection kit. Nuclei were stained with DAPI. Scale bar, 10 µm.   
 
6.2.4. Calnexin co-immunoprecipitated with DGAT2 and MGAT2  
 Like DGAT2, calnexin is an integral membrane protein of the ER.  It has also been 
identified as a member of the lipid droplet proteome through mass spectrometry studies 
(Hodges and Wu , 2010; Bouchoux et al., 2011).  Calnexin was one of the proteins identified to 
interact with DGAT2 by mass spectrometry and was also isolated with DGAT2 when analyzing 
DGAT2 interaction with MGAT2/3 (Fig. 6.2, 6.4).  We chose to examine whether MGAT2 and 
MGAT3 also interact with calnexin and if these interactions were glycosylation dependent.  
HEK-293T cells were transfected with FL-DGAT2, FL-MGAT2, FL-MGAT3 or Myc-DGAT2.    
Cells were treated in the presence or absence of tunicamycin, an inhibitor of N-glycosylation.  
Tunicamycin inhibits the transfer of N-acetylglycosamine 1-phosphate to dolichol 
monophosphate (Heifetz et al., 1979).  Samples were subjected to anti-FLAG 
immunoprecipitation prior to SDS-PAGE and immunoblotting.  Anti-FLAG immunoblotting 
revealed that FL-DGAT2, FL-MGAT2 and FL-MGAT3 were successfully expressed and 
immunoprecipitated (Fig. 6.7A, B).  Anti-Myc immunoblotting showed Myc-DGAT2 was only 
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detected in total cell extracts.  Blotting with an anti-calnexin antibody revealed that it was 
present in anti-FLAG isolates from DGAT2 and MGAT2, but not MGAT3, transfected cells 
(Fig. 6.7B).  The calnexin band is slightly obscured by a non-specific band located marginally 
above it in the anti-FLAG immunoprecipitates, but is still visible.  Re-blotting with an antibody 
specific to lamin isoforms A and C yielded a signal in total cell extracts but not 
immunoprecipitates, demonstrating interaction specificity.  Tunicamycin did not have any 
apparent effect on calnexin interaction with DGAT2 and MGAT2, suggesting that the 
interaction is not glycosylation dependent.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 102	
A. 
 
B. 
 
Figure 6.7.  Calnexin co-immunoprecipitated with DGAT2 and MGAT2 via a 
glycosylation independent mechanism – (A) HEK293T cells were transfected with FL-
DGAT2, FL-MGAT2, FL-MGAT3 or Myc-DGAT2 and treated with 5 µg/mL of glycosylation 
inhibitor, tunicamycin, or an equal volume of DMSO, for 21 h.  Total cell extracts were isolated 
and analyzed by SDS-PAGE and immunoblotting with anti-FLAG, anti-Myc, anti-calnexin and 
anti-lamin specific antibodies. (B) Total cell extracts were subjected to anti-FLAG 
immunoprecipitation.  Immunoprecipitates were analyzed by SDS-PAGE and immunoblotting 
with anti-FLAG, anti-Myc, anti-calnexin and anti-lamin specific antibodies.  Control 
immunoprecipitations were performed on Myc-DGAT2 transfected cells and with buffer alone. 
HC and LC represent antibody heavy and light chains respectively. 
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6.2.5.  Calnexin interacts with DGAT2 in situ 
 Having identified that calnexin interacts with DGAT2 in vitro, we chose to examine this 
relationship in situ.  COS-7 cells were transfected with FL-DGAT2 or Myc-DGAT2.   
Interaction with endogenous calnexin was tested by PLA using anti-FLAG and anti-calnexin 
antibodies.  A clear interaction signal was observed in FL-DGAT2 transfected samples but not 
in those transfected with Myc-DGAT2 (Fig. 6.8).  This demonstrates that DGAT2 interacts 
with calnexin in situ.   
 
 
Figure 6.8.  Calnexin interaction with DGAT2 was detected in situ by proximity ligation 
assay - COS-7 cells expressing either FL-DGAT2 or Myc-DGAT2 were  incubated with anti-
FLAG and anti-calnexin antibodies.  Interaction signals were detected using a Duolink® 
detection kit.  Nuclei were stained with DAPI.  Scale bar, 10 µm.   
 
6.2.6. Calnexin is present in the lipid droplet fraction in MGAT2 and DGAT2 
transfected cells  
We have identified that calnexin interacts with DGAT2 and MGAT2 in vitro and 
confirmed DGAT2 interaction in situ.   We next decided to determine if calnexin is present on 
lipid droplets in MGAT2 and DGAT2 transfected cells.  HEK-293T cells were transfected with 
FL-DGAT2, MGAT2-Myc or both in tandem.  Crude mitochondria and lipid droplet fractions 
were isolated through differential- and sucrose gradient–centrifugation.  Samples were 
subsequently analyzed by SDS-PAGE and immunoblotting (Fig. 6.9).  Fraction identity was 
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evaluated with marker protein specific antibodies for Hsp70 (mitochondria) and perilipin-2 
(lipid droplet).  FL-DGAT2 and FL-DGAT2/MGAT2-Myc co-transfection increased lipid 
droplet production, as signified by the accumulation of perilipin-2.  Anti-calnexin 
immunoblotting showed that calnexin was in crude mitochondria and fat fractions for each 
transfection group.  Like DGAT2, calnexin is enriched in MAM present in the crude 
mitochondria fraction (Cuie et al. 1993; Rusinol et al. 1994; Stone et al. 2009; Stone and Vance 
2000; Lynes et al., 2013).  
 
Figure 6.9.  Calnexin is localized to lipid droplets in MGAT2 and DGAT2 transfected cells 
- HEK-293T cells were transfected with MGAT2-Myc or FL-DGAT2, individually or in 
tandem.  Crude mitochondria (CM) and lipid droplet (LD) fractions were isolated from total 
cell extracts (TCE) through differential- and sucrose gradient–centrifugation.  Samples were 
subsequently analyzed by SDS-PAGE and immunoblotting.  Fraction identity was evaluated 
with marker protein specific antibodies for Hsp70 (mitochondria) and perilipin-2 (lipid droplet).  
DGAT2 and MGAT2 were detected with anti-FLAG and anti-Myc antibodies respectively. 
 
6.2.7. Calnexin knockout mouse embryonic fibroblasts exhibited reduced lipid droplet 
size 
To gain insight into the role of calnexin in lipid droplet metabolism, we chose to 
examine lipid droplet production in calnexin knockout versus wild-type mouse embryonic 
fibroblasts.  Wild-type and calnexin knockout cell lines were a gift from Dr. Marek Michalak at 
the University of Alberta.  To first confirm that calnexin is efficiently knocked-out, cells were 
harvested and total cell extracts analyzed by SDS-PAGE and immunoblotting (Fig. 6.10A).  
Calnexin was abundant in wild-type mouse embryonic fibroblasts and in the HEK-293T 
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control, but absent in the knockout cell line.  Immunoblotting with an anti-Hsp70 specific 
antibody demonstrated equal protein levels in all samples.  To compare lipid droplet production 
in each cell line, cells were treated with oleic acid for 18 h to stimulate lipogenesis prior to 
preparation for immunofluorescence microscopy.  Lipid droplets were visualized by BODIPY 
493/503 staining; representative images of total cell populations were obtained by 
immunofluorescence microscopy (Fig. 6.10B).  Lipid droplet production was clearly hindered 
in calnexin knockout mouse embryonic fibroblasts.  The wild-type cells typically produced 
lipid droplets of larger average size when compared to the calnexin knockout cell line. 
A. 
 
B. 
 
Figure 6.10.  Calnexin knockout mouse embryonic fibroblasts produced smaller lipid 
droplets than wild-type - (A) Wild-type and calnexin knockout mouse embryonic fibroblasts 
total cell extracts were analyzed by SDS-PAGE and immunoblotting with calnexin and Hsp70 
specific antibodies.  (B) Mouse embryonic fibroblasts were treated for 18 h with oleic acid prior 
to immunofluorescence microscopy.  Lipid droplets were visualized with BODIPY 493/503 and 
cell nuclei with DAPI containing mounting medium.  These images are representative of the 
total cell populations.  Scale bar, 10 µm. 
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6.3. Discussion 
 Relatively little is known about proteins that interact with DGAT2.  We chose to take a 
mass spectrometry approach in order to identify proteins that bind and potentially influence 
post-translational regulation of DGAT2.   As detection of endogenous DGAT2 is not possible 
with current tools, we overexpressed an epitope tagged construct in human kidney cells.  While 
DGAT2 was successfully detected by mass spectrometry, the sequence coverage was lower 
than we would have hoped.  The exact reason for this is unclear but the large number of 
potential trypsin cleavage sites within DGAT2 could yield relatively short peptides, reducing 
the probability of identification.  Nevertheless, many interesting proteins were found to 
precipitate with DGAT2.  In addition to subunits of the proteasome, several other proteins 
involved in the ubiquitin-proteasome and associated ERAD pathways were revealed.  For 
example, B-cell receptor–associated protein 31 is a chaperone that plays a role in targeting 
proteins to the ERAD pathway, while COP9 signalosome complex (CSN) subunit 1 is essential 
in CSN mediated regulation of SCF E3 ligases  (Wang et a., 2008; Wang et al., 2015).  Also, 
the E3 ubiquitin ligase, TRIM13, was recognized.  To this point, the only E3 ligase implicated 
in DGAT2 regulation was AMFR (Choi et al., 2014).  The TRIM family of proteins, of which 
there are greater than 70, are RING-type E3 ligases (Ozato et al., 2008).  TRIM13 is ER 
anchored and has been implicated in degradation of ERAD substrates through the proteasome 
and autophagy pathways (Lerner et al., 2007; Tomar et al., 2012).   
Several proteins involved in lipid metabolism were also found to interact with DGAT2.  
Sterol-4-alpha-carboxylate 3-dehydrogenase is involved in cholesterol biosynthesis, while 
tafazzin and stomatin-like protein 2 both play roles in cardiolipin metabolism (Caldas and 
Herman, 2003;Vaz et al., 2003; Christie et al., 2011).  Finally, very-long-chain enoyl-CoA 
reductase catalyzes the final four reactions of the long-chain fatty acid elongation cycle (Moon 
and Horton, 2003).  Unfortunately, MGAT proteins were not detected.  In human kidney, 
MGAT2 is higly expressed, however, protein levels may be low, as MGAT activity appears to 
be modest (Yen and Farese, 2003).   
Intriguingly, several proteins involved in nuclear trafficking were detected, including: 
importin subunit beta-1, importin-4, exportin-7 and nuclear pore complex protein Nup98-
Nup96 (Jaekel and Goerlich, 1998, Jaekel et al., 2002; Mingot et al. 2004; Krull et al., 2004).  
The existence of lipid droplets in the nucleus has been reported, however, until recently it has 
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been unclear whether these lipid droplets are in the nucleoplasm or are situated on the 
cytoplasmic face of invaginations in the nuclear envelope (Hillman and Hillman, 1975; 
Layerenza et al., 2013; Uzbekov and Roingeard, 2013).  Recent evidence suggests that lipid 
droplets do exist in the nucleoplasm in cell lines such as Huh7, HepG2 and Mc-RH7777 
(Ohsaki et al., 2016).  It appears that triacylglycerols can be synthesized in the nucleus, as 
newly produced lipid esters were directly incorporated into nuclear lipid droplets; DGAT2 was 
able to localize to these same lipid droplets.  The physiological role of nuclear lipid droplets 
and the mechanism of DGAT2 relocalization are currently unknown. 
Calnexin was one of the proteins discovered to interact with DGAT2 by mass 
spectrometry.  We chose to confirm this finding and examine whether other DGAT2 family 
members shared this interaction.  We found that calnexin co-immunoprecipitated with DGAT2 
and MGAT2 but not MGAT3.  DGAT2 interaction with calnexin was also demonstrated in situ.  
DGAT2, MGAT2, and likely MGAT3, containing only a short luminal loop with no aspartate 
residues, are unlikely targets for N-glycosylation (Stone et al., 2006; McFie et al., 2014; McFie 
et al., unpublished; Anderson et al., 1996).  Yet, there is evidence that calnexin can bind non-
glycosylated proteins via a region in close proximity to the glycan-binding site within the 
globular domain (Danciczyk et al., 2001; Wijeyesakere et al., 2013).  Additionally, it has been 
reported that calnexin is able to monitor the assembly of transmembrane domains within the ER 
membrane, binding to misfolded regions in a glycan-independent manner (Swanton et al., 
2003).  To address whether DGAT2 and MGAT2 interaction with calnexin was glycosylation 
dependent, cells were treated with the glycosylation inhibitor, tunicamycin, prior to co-
immunoprecipitation.  We found that calnexin was still isolated with DGAT2 and MGAT2 in 
the presence of tunicamycin.  These results need to be confirmed in the presence of a positive 
control whose interaction with calnexin is disrupted upon inhibition of glycosylation. 
 Like DGAT2, calnexin is enriched in MAM of the ER (Cuie et al. 1993; Rusinol et al. 
1994; Stone et al. 2009; Stone and Vance, 2000; Lynes et al., 2013).  Under normal conditions, 
calnexin is preferentially relegated to MAM; ER stress causes calnexin to become 
palmitoylated and transition to the rough ER where it aids in protein quality control (Lynes et 
al., 2013).  Calnexin has previously been detected in the lipid droplet proteome but its function 
remains unknown (Brasaemle et al., 2004; Turró et al., 2006; Bartz et al., 2007b; Cho et al., 
2007; Bouchoux et al., 2011).  As MGAT2 does not traffic to lipid droplets unless co-expressed 
	 108	
with DGAT2, it suggests that the interaction detected through co-immunoprecipitation was 
between ER localized MGAT2 and calnexin (Jin et al., 2014).  Because DGAT2 is highly 
similar to MGAT2, interaction with calnexin at the ER can likely be extrapolated.  Whether 
DGAT2 or MGAT2 can interact with calnexin on the surface of lipid droplets has yet to have 
been explored.  
We demonstrated that calnexin knockout mouse embryonic fibroblasts were unable to 
produce large lipid droplets when treated with oleate.  This provides evidence that calnexin may 
play a role in lipid droplet biogenesis.  Nevertheless, it is still possible that perturbed lipid 
droplet formation could be a result of loss of calnexin chaperone function, leading to 
insufficient quantities of proteins involved in pathways of triacylglycerol synthesis and lipid 
droplet formation.  Quantification of lipid droplets in calnexin knockout and wild-type cells 
would be beneficial.  Treating wild-type cells with tunicamycin to inhibit glycosylation could 
help to illuminate whether this effect if dependent on calnexin lectin function.  Alternatively, if 
expression of mutant calnexin, deficient in carbohydrate binding, restored droplet formation in 
knockout cells, it would demonstrate that calnexin plays a more direct role in lipid droplet 
production. 
The functional significance of DGAT2 family member interactions has not been 
extensively studied.  We identified that DGAT2 co-immunoprecipitated with MGAT2 and 
MGAT3; this interaction was confirmed in situ.  Interestingly, further characterization of the 
MGAT3 construct used in the DGAT2 co-immunoprecipitation study (Fig. 6.4) revealed that it 
contained an inactivating C265Y mutation that was initially undetected.  Co-
immunoprecipitation of DGAT2 and MGAT3 was repeated using a wild-type MGAT3 
construct.  It was verified that C265Y did not alter MGAT3 interaction with DGAT2 (data not 
shown).  Unfortunately, the manufacturer of the mutant MGAT3 cDNA would not disclose the 
origin of the cDNA.  All additional experiments utilizing MGAT3 were performed with the 
wild-type construct. 
As DGAT2 has been shown to form homodimers, it is possible that the high degree of 
sequence conservation allows for heterodimer formation between DGAT2, MGAT2 and 
MGAT3 (Jin et al., 2014).  Co-expression of DGAT2 and MGAT2 has been shown to increase 
triacylglycerol synthesis (Jin et al., 2014).  Increased efficiency in substrate channeling, 
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through DGAT2/MGAT2 interaction, is one mechanism by which this could occur.  The 
metabolic effects of DGAT2 and MGAT3 interaction have not been studied. 
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CHAPTER 7: DGAT2 family protein interactions and regulation by ERAD 
7.1. Introduction 
ERAD is responsible for clearing polypeptides that fail to achieve the proper folded 
confirmation, an indispensible process in maintaining ER homeostasis in eukaryotes (Hartl and 
Hayer-Hartl, 2009).  Dysfunction can lead to the accumulation of misfolded proteins in the 
lumen and membrane of the ER, causing proteotoxicity that has been linked to several diseases  
(Walter et al., 2011; Guerriero and Brodsky, 2012).  In addition to its role in the degradation of 
improperly folded proteins, ERAD is involved in the targeted degradation of several native 
proteins of the ER membrane and lumen.  The ERAD pathway is required for the destruction of 
these proteins as they must transition across the ER membrane to the cytosol prior to being 
delivered to the proteasome (Wiertz et al. 1996; Ye et al. 2001; Lilley and Ploegh, 2004; Kalies 
et al., 2005; Kreft et al., 2006; Scott and Shekman, 2008; Horn et al., 2009; Carvalho et al., 
2010; Mehnert et al., 2014).   Many of the native proteins regulated by ERAD are involved in 
lipid metabolism (Shimakata et al., 1972; Mitchell et al., 1998; Lee et al., 2006; Choi et al., 
2014).  A functional relationship between ERAD and lipid droplets has been proposed on the 
evidence that several ERAD substrates and factors have been identified in the lipid droplet 
proteome following proteasome inhibition (Hartman et al. 2010; Ohsaki et al. 2006).   
DGAT2 has been found to be part of a triacylglycerol synthesis complex with several 
proteins, one of which is MGAT2 (Man et al., 2006; Jin et al., 2014; Xu et al., 2012; Gidda et 
al., 2011).  DGAT2 and MGAT2 possess a high degree of sequence identity and have been 
observed to cooperate in the synthesis of triacylglycerols (Jin et al., 2014).  MGAT3 exhibits 
greater sequence identity with DGAT2 than with other MGATs.  Also, it possesses both MGAT 
and DGAT activity, suggesting it may have arisen from a gene duplication event (Hall et al., 
2012; Cheng et al., 2003; Cao et al., 2007).  DGAT2, MGAT2 and MGAT3 are all believed to 
be transmembrane proteins of the ER, with similar membrane topographies (Stone et al. 2006; 
McFie et al., 2014; McFie et al., 2016).  We believe than MGAT2 and MGAT3, like DGAT2, 
are regulated by the ubiquitin proteasome system and that the ERAD pathway plays a role in 
their destruction (Choi et al., 2014) 
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7.2. Results 
7.2.1. MGAT2 is ubiquitinated  
 We chose to examine MGAT2 ubiquitination, believing that the considerable sequence 
similarity with DGAT2, coupled with its ability to interact with DGAT2, made MGAT2 a 
likely candidate for ubiquitin conjugation.  HEK-293T cells were transfected with MGAT2-
Myc-FL or MGAT2-Myc and treated in the presence or absence MG132.  MGAT2-Myc-FL 
was isolated by anti-FLAG immunoprecipitation prior to analysis by immunoblotting (Fig. 7.1).  
MGAT2-Myc-FL was detected in total cell extracts and immunoprecipitates.  Probing for 
ubiquitin revealed the typical polyubiquitin smear both in the presence and absence of MG132, 
signifying MGAT2 is polyubiquitinated.  No ubiquitin signal was observed in anti-FLAG 
immunoprecipitates from MG132 treated MGAT2-Myc expressing cells.  Notably, a strong 
increase in ubiquitin signal was not seen in MG132 treated MGAT2 samples, however the 
increase in ubiquitination of the corresponding total cell extracts was also modest.  
 
Figure 7.1.  MGAT2 is ubiquitinated - HEK-293T cells were transfected with MGAT2-Myc-
FL or MGAT2-Myc constructs.  Cells were incubated with 10 µM MG132 or an equal volume 
of DMSO for a period of 2 h prior to isolation of total cell extracts.  FLAG-tagged proteins 
were precipitated with anti-FLAG agarose.  Samples were separated by SDS-PAGE and 
immunoblotted with anti-FLAG, anti-ubiquitin and anti-Hsp70. 
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Proximity ligation assay was utilized to confirm MGAT2 ubiquitination.  COS-7 cells 
were co-transfected with MGAT2-Myc-FL and HA-ubiquitin in the presence or absence of 
oleic acid.  Transfection with Myc-DGAT2 and HA-ubiquitin was included as a negative 
control.  Anti-FLAG and anti-HA antibodies were used to detect interaction.  Ubiquitinated 
MGAT2 was detected in the presence and absence of oleic acid; no signal was observed in the 
negative control (Fig. 7.2).  Co-staining to detect MGAT2, lipid droplets and DGAT2 was also 
included.  These results confirm that MGAT2 is ubiquitinated in situ. 
 
 
 
Figure 7.2.  MGAT2 is ubiquitinated in situ - COS-7 cells were co-transfected with MGAT2-
Myc-FL and HA-ubiquitin or with control Myc-DGAT2 and HA-ubiquitin prior to incubation 
in the presence or absence of 0.5 mM oleic acid for ~18 hr.  Samples were probed with anti-
FLAG and anti-ubiquitin antibodies and analyzed by proximity ligation assay.  Cells were co-
stained with anti-Myc and anti-DGAT2 to show MGAT2 and DGAT2 respectively.  Lipid 
droplets were stained with BODIPY 493/503 and cell nuclei with DAPI.  Scale bar, 10 µm. 
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7.2.2.  DGAT2 and MGAT2 are regulated by ERAD 
 As DGAT2 and MGAT2 are both ubiquitinated membrane proteins of the ER, they are 
likely regulated by the ERAD pathway.  To examine this, HEK-293T cells were co-transfected 
with FL-DGAT2 and HA-ubiquitin or control Myc-DGAT2 and HA-ubiquitin prior to 
treatment with eeyarestatin I (EerI).  EerI directly inhibits VCP/p97 and the associated 
deubiquitinase, ataxin-3 (Wang et al., 2008, 2010).  Ultimately, this inhibits ERAD by blocking 
retrotranslocation out of the ER and into the cytosol (Cross et al., 2009; Aletrari et al., 2011).  
Samples were analyzed by SDS-PAGE and immunoblotting.  Probing with anti-FLAG and anti-
Myc antibodies demonstrated that FL-DGAT2 was successfully isolated, while Myc-DGAT2, 
as expected, was not present following ant-FLAG IP (Fig. 7.3).  Interestingly, a band the 
approximate size of a DGAT2 dimer (~85 kDa) was detectable in total cell extracts in EerI 
treated cells.  It was not present in the IP sample but may have been visible with a longer 
exposure.  Detection of ubiquitin conjugates with anti-HA clearly revealed a shift toward higher 
molecular weight ubiquitin chains following EerI treatment.  Inhibiting substrate 
deubiquitination by ataxin-3 should lead to the accumulation of longer and/or more 
polyubiquitin chains.  Ubiquitin was not detected in the negative control.  Taken together, these 
data provide strong evidence that DGAT2 is regulated by ERAD.   
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Figure 7.3.  DGAT2 is regulated by ERAD - HEK-293T cells were co-transfected with either 
FL-DGAT2 or Myc-DGAT2 and HA-ubiquitin. Cells were treated with 8 µM of ERAD 
inhibitor, EerI, or an equal volume of DMSO for 3 h.  FL-DGAT2 was immunoprecipitated (IP) 
with anti-FLAG agarose from detergent solubilized material. Immunoprecipitates were 
separated by SDS-PAGE and were then immunoblotted (IB) with anti-FLAG, anti-Myc and 
anti-HA antibodies.  HC represents antibody heavy chains. 
 
 An analogous experiment was conducted to analyze MGAT2 regulation by ERAD.  
HEK-293T cells were transfected with MGAT2-Myc-FL or positive control, FL-DGAT2.  Cells 
were subjected to treatment with DMSO, MG132 or EerI prior to anti-FLAG-
immunoprecipitation and immunoblotting (Fig. 7.4).  We found that DGAT and MGAT2 were 
successfully isolated in all treatment groups.  As we previously identified, MG132 does not 
appear to increase MGAT2 ubiquitination, however it is highly ubiquitinated under both DMSO 
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and MG132 treatments.  Similar to DGAT2, treatment with EerI caused a distinct shift towards 
higher molecular weight polyubiquitin conjugates in MGAT2 transfected samples.  Also of 
note, EerI treatment appeared to reduce the signal of a band at ~45 kDa, roughly 8-10 kDa 
above the primary MGAT2 band, possibly representing mono-ubiquitinated MGAT2.  This 
reduction is accompanied by an increased signal at ~75-80 kDa - the approximate size of an 
MGAT2 dimer.  The identity of these bands has not been confirmed. 
 
 
 
 
Figure 7.4.  MGAT2 is regulated by ERAD - HEK-293T cells expressing either FL-DGAT2 
or MGAT2-myc-FL were treated with 8 µM EerI, 10 µM MG132 or an equal volume of DMSO 
for 3 h. Samples were then anti-FLAG immunoprecipitated prior to SDS-PAGE and 
immunoblotting with anti-FLAG and anti-ubiquitin antibodies. HC represents antibody heavy 
chain. 
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7.2.3.  MGAT3 is ubiquitinated and regulated by ERAD 
Having identified that MGAT2 is ubiquitinated and regulated by ERAD, we were 
interested to look at MGAT3 as it contains even greater sequence identity with DGAT2 than 
MGAT2.  HEK-293T cells were transfected with FL-MGAT3 or LacZ control prior to 
treatment with MG132, EerI or an equal volume of DMSO. MGAT3 was isolated by anti-
FLAG immunoprecipitation before SDS-PAGE and immunoblotting with anti-FLAG and anti-
ubiquitin specific antibodies.  MGAT3 was detected in total cell extracts and in 
immunoprecipitates (Fig. 7.5A, B).  MG132 treatment yielded a sharp increase in 
polyubiquitination relative to DMSO treated sample, revealing that MGAT3 is likely degraded 
by the ubiquitin-proteasome system.  Treatment with EerI caused a shift towards high 
molecular weight polyubiquitination that was detected by both anti-FLAG and anti-ubiquitin 
antibodies.  EerI caused a distinct accumulation at ~70 kDa when probing with anti-FLAG, 
possibly representing a dimer.  This trend was also observed when MGAT2 was isolated 
following treatment with EerI (Fig. 7.4).   
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A. 
 
B. 
 
Figure 7.5.  MGAT3 is ubiquitinated and is a substrate for ERAD - (A) HEK-293T cells 
expressing either FL-MGAT3 or LacZ were incubated with 10 µM MG132, 8 µM EerI or an 
equal volume of DMSO for 3 h. Cell lysates were then prepared and analyzed by 
immunoblotting with anti-FLAG and anti-lamin antibodies. (B) FL-MGAT3 was 
immunoprecipitated with anti-FLAG agarose.  Immunoprecipitates were separated by SDS-
PAGE and probed with anti-FLAG and anti-ubiquitin antibodies. Control immunoprecipitations 
were performed on LacZ transfected cells and with buffer alone. HC represents antibody heavy 
chains. 
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7.2.4. VCP/p97 co-localizes with DGAT2 and MGAT2 
To gain additional evidence of DGAT2 and MGAT2 regulation by ERAD we looked at 
co-localization with the ERAD ATPase, VCP/p97.  COS-7 cells were transfected with FL-
DGAT2, MGAT2-Myc-FL or FL-DGAT1 prior to oleate treatment for ~18 h.  DGAT1, 
DGAT2 and MGAT2 were detected with anti-FLAG antibody.  Endogenous VCP/p97 
localization was detected with an anti-VCP/p97 antibody (Fig. 7.6).  For both FL-DGAT2 and 
MGAT2-Myc-FLAG transfected samples there was a clear correlation between 
DGAT2/MGAT2 signal intensity and VCP/p97 localization, particularly in the rough-ER 
directly surrounding the nucleus.  In contrast, VCP/p97 staining in FL-DGAT1 transfected 
samples was more diffuse and co-localization much less pronounced.  This was to be expected 
as even if DGAT1 was regulated by ERAD, it is stable with a half-life of ~18 h when 
overexpressed in adipocytes.  Thus, we would anticipate minimal DGAT1 interaction with 
VCP/p97 (Yu et al., 2002).  Additionally, we noted VCP/p97 localization on lipid droplets in 
FL-DGAT2 transfected samples (Fig. 7.7).  Concentrated co-localization of MGAT2 with 
VCP/p97 in the ER and with DGAT2 in the ER and on lipid droplets, provides further evidence 
that both are ERAD substrates.  
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Figure 7.6.  DGAT2 and MGAT2, but not DGAT1, co-localize with VCP/p97 - COS-7 cells 
were transfected with FL-DGAT2, MGAT2-myc-FL or FL-DGAT1 and then treated with 0.5 
mM oleate for 18 h. Cells were then stained with anti-FLAG (green), anti-p97/VCP (red) and 
BODIPY 493/503 (white). The bottom panels only show merged images of each acyltransferase 
and p97/VCP. Yellow color shows regions of co-localization. Scale bars, 10 µm.  
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Figure 7.7.  VCP/p97 is present on lipid droplets in DGAT2 transfected cells - COS-7 cells 
were transfected with FL-DGAT2 and treated with 0.5 mM oleate for 18 h. Cells were then 
stained with anti-FLAG, anti-p97/VCP and BODIPY 493/503.  Scale bars, 10 µm. 
 
 
 
7.2.5. DGAT2 and MGAT2 interact with VCP/p97 in situ 
To demonstrate that DGAT2 and MGAT2 co-localization with VCP/p97 is indicative of 
direct protein-protein interaction, we conducted a proximity ligation assay.  COS-7 cells were 
transfected with FL-DGAT2 or Myc-DGAT2 (Figure 7.8A).  Alternatively cells were 
transfected with MGAT2-Myc-FL or MGAT2-Myc (Figure 7.8B). Interaction was detected 
with anti-FLAG and anti-VCP/p97 specific antibodies.  Following completion of the PLA 
protocol, cells were co-stained with anti-DGAT2 or anti-Myc in order to confirm DGAT2 and 
MGAT2 expression respectively.  An interaction signal was detected for both FL-DGAT2 and 
MGAT2-Myc-FL with VCP/p97, demonstrating physical interaction of both proteins with 
endogenous VCP/p97.  There was no interaction signal in cells expressing negative controls 
Myc-DGAT2 or MGAT2-Myc. 
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A. 
       
B. 
 
 
Figure 7.8.  VCP/p97 interacts with DGAT2 and MGAT2 in situ - Protein interactions were 
detected using a proximity ligation assay. COS-7 cells were transfected with (A) FL-DGAT2 or 
Myc-DGAT2.  In an analogous experiment, COS-7 cells were transfected with (B) MGAT2-
myc-FL or MGAT2-Myc.  Myc-DGAT2 and MGAT2-Myc expressing cells represent negative 
controls.  Samples were stained with rabbit anti-FLAG and mouse anti-p97/VCP antibodies.  
Interaction signals were detected using a Duolink® detection kit. Nuclei were stained with 
DAPI. After the interaction assay was performed, DGAT2 and MGAT2 were visualized by 
staining cells with rabbit anti-DGAT2 and rabbit anti-Myc antibodies. Scale bar, 10 µm. 
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7.2.6. MGAT2 is more stable than DGAT2, and when co-expressed, inhibited DGAT2 
turnover  
As MGAT2 shares a great deal of primary sequence similarity with DGAT2 and is 
ubiquitinated, we expected it to be rapidly degraded.  HEK-293T cells were transfected with 
FL-DGAT2 or MGAT2-Myc-FL individually or in tandem prior to CHX degradation assay.  
Samples were separated by SDS-PAGE and analyzed by anti-FLAG immunoblotting (Fig. 7.9).  
While DGAT2 was unstable, with very little protein detectable after 6 h, MGAT2 showed no 
apparent decline.  What was more interesting was that co-expression with MGAT2 dramatically 
reduced DGAT2 turnover; ~70% of DGAT2 remained at 6 h.  MGAT2 degradation appeared to 
be unaffected by co-transfection. 
 
 
 
 
 
 
 
Figure 7.9.  MGAT2 is more stable than DGAT2, and when co-expressed, inhibited 
DGAT2 turnover – HEK-293T cells were transfected with FL-DGAT2 or MGAT2-Myc-FL 
individually or in tandem. pcDNA3.1/LacZ was used in individual transfections to keep total 
transfection DNA constant.  Cells were treated with 100 µg/mL CHX and harvested at the time 
indicated.  Samples were analyzed by SDS-PAGE and immunoblotting.  Proteins were detected 
simultaneously with anti-FLAG primary antibody.  Re-probing for calnexin was used to 
establish equal loading. The total amount of plasmid DNA was kept constant for each 
transfection, using pcDNA3.1/LacZ when transfecting with only DGAT2 or MGAT2. 
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7.2.7.  MGAT2 does not stabilize DGAT2 by reducing its ubiquitination 
 A possible mechanism by which MGAT2 could stabilize DGAT2 is through reducing 
DGAT2 ubiquitination.  To examine this, HEK-293T cells were transfected with FL-DGAT2, 
MGAT2-Myc-FL, FL-DGAT2 and MGAT2-Myc in tandem, or Myc-DGAT2 alone.  Cells 
were treated with DMSO or MG132 to observe effects under proteasomal inhibition.  In order 
to examine the ubiquitination of DGAT2 in isolation, samples were harvested so as to minimize 
co-immunoprecipitation of MGAT2 and other proteins with DGAT2.  Analysis of total cell 
extracts by SDS-PAGE and immunoblotting, with anti-FLAG followed by anti-Myc specific 
antibodies, revealed that all constructs were expressed (Fig 7.10A).  Anti-FLAG 
immunoprecipitation was conducted on total cell extracts prior to analysis by SDS-PAGE and 
immunoblotting (Fig. 7.10B).  Probing for FLAG showed that FL-DGAT2 and MGAT2-Myc-
FL were successfully isolated in the appropriate samples.  Re-probing of the blot with a Myc-
specific antibody revealed that interaction of MGAT2-Myc with FL-DGAT2 was largely 
eliminated and only a very faint MGAT2-Myc band was visible for both DMSO and MG132 
treated samples.  Myc-DGAT2 control was not detected following anti-FLAG pull-down.  A 
separate blot was probed to detect endogenous ubiquitin.  As expected, no signal was detected 
in the Myc-DGAT2 transfected control.  Comparison of the FL-DGAT2 and FL-
DGAT2/MGAT2-Myc transfections revealed that in the presence or absence of MG132, 
MGAT2 did not appear to have any observable effect on the polyubiquitination of DGAT2.  
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Figure 7.10.  MGAT2 does not reduce DGAT2 ubiquitination when co-expressed - HEK-
293T cells were transfected with FL-DGAT2, MGAT2-Myc-FL, FL-DGAT2/MGAT2-Myc or 
Myc-DGAT2 control and treated with 10 µM MG132 or an equal volume of DMSO.  Samples 
were harvested in order to minimize DGAT2 and MGAT2 interaction.  (A) Total cell extracts 
were separated by SDS-PAGE and analyzed by immunoblotting with anti-FLAG followed by 
anti-Myc specific antibodies.  Blotting for calnexin was included to establish equal loading.  (B) 
Anti-FLAG immunoprecipitation was conducted on total cell extracts prior to analysis by SDS-
PAGE and immunoblotting.  A blot was probed sequentially with anti-FLAG and anti-Myc 
specific antibodies.  A separate blot was probed with anti-ubiquitin specific antibody. IP 
represents immunoprecipitation.  HC and LC represent antibody heavy and light chains 
respectively. 
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7.2.8. MGAT3 is more stable than DGAT2, and when co-expressed, inhibited DGAT2 
turnover  
 We were interested to examine the stability of MGAT3.  As MGAT3 sequence 
homology is greater with DGAT2 than MGAT2, we expected the turnover rate to be rapid.  
HEK-293T cells were transfected with FL-DGAT2, FL-MGAT2, or FL-MGAT3 and turnover 
rates evaluated by treatment with CHX.  Samples were analyzed by SDS-PAGE and anti-FLAG 
immunoblotting (Fig. 7.11A).  We identified that MGAT3 existed as a doublet; to our 
knowledge this had not been previously reported.  Past studies expressed MGAT3 in COS-7 or 
sf9 insect cells, providing a possible explanation for this difference (Hall et al., 2012; Cheng et 
al., 2003).   At 3 h ~70% of MGAT3 remained, this was reduced to ~50% at 6 h of CHX 
treatment.  Comparatively, very little DGAT2 remained at 3 h and was undetectable at 6 h.  
MGAT2 did not show any appreciable degradation after 6 h CHX treatment.  Thus, MGAT3 is 
more stable than DGAT2 but less stable than MGAT2.  Having found that MGAT2 is able to 
reduce DGAT2 turnover, we were curious to see whether MGAT3 could as well.  HEK-293T 
cells expressing FL-DGAT2 individually, or in conjunction with FL-MGAT3, were analyzed 
by CHX degradation assay.  Total cell extracts were analyzed by SDS-PAGE and anti-FLAG 
immunoblotting (Figure 7.11B).  Despite modest expression relative to DGAT2, MGAT3 had a 
strong stabilizing effect.  When expressed on its own, DGAT2 was not detectable after 6 h.  
Comparatively, 30% of DGAT2 remained at 6 h when co-expressed with MGAT3.  Thus, 
MGAT3 also reduced DGAT2 degradation. 
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Figure 7.11. MGAT3 is more stable than DGAT2, and when co-expressed, inhibited 
DGAT2 turnover - (A) HEK-293T cells were transfected with FL-DGAT2, FL-MGAT2 or 
FL-MGAT3 and treated with 100 µg/mL CHX prior to harvest at the indicated time points.  
Cells lysates were separated by SDS-PAGE and analyzed by anti-FLAG immunoblotting. 
Calnexin was used as a degradation control.  Two exposures of FL-MGAT2/FL-MGAT3 are 
shown.  (B) HEK-293T cells were transfected with FL-DGAT2 or FL-MGAT3 individually or 
in tandem and incubated with 100 µg/mL CHX prior to harvest at the indicated time point.  Cell 
lysates were separated by SDS-PAGE and analyzed by anti-FLAG immunoblotting.  FL-
DGAT2 and FL-MGAT3 were detected simultaneously.  Two separate exposures are shown.  
The total amount of plasmid DNA was kept constant for each transfection, using 
pcDNA3.1/LacZ when transfecting with only DGAT2 or MGAT3.  Samples were separated on 
the same SDS-PAGE gel but images were cropped for clarification.   
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7.3. Discussion 
 Due to the high sequence identity between DGAT2 and MGAT2, we were unsurprised 
to find that MGAT2 was also polyubiquitinated.  However, the substantial difference in 
degradation rate was unexpected.  Human MGAT2 used in this experiment contains 13 lysine 
residues compared to 25 present in murine DGAT2.  Of these lysines, only 6 are conserved 
between the two proteins, all of which we identified to induce degradation when restored in the 
Lys-less-DGAT2 construct.  It is possible that the stability of MGAT2 is a result of having 
fewer ubiquitin-acceptor lysines. Yet, MGAT2 is polyubiquitinated at similar levels in the 
presence and absence of MG132.  The lack of polyubiquitin accumulation upon proteasome 
inhibition is consistent with a reduced turnover rate, however, it seems that MGAT2 is highly 
ubiquitinated even under basal conditions.  How polyubiquitinated MGAT2 evades destruction 
is unknown.  One possible answer is that ubiquitination of MGAT2 may have additional 
functions.  Poly-ubiquitin antibodies specific to traditionally non-degradative chain linkages 
(ex. K6, K63) could be useful in confirming this.  Ubiquitination and turnover of MGAT3 was 
more similar to DGAT2 than MGAT2.  A sharp spike in ubiquitination was observed upon 
MG132 treatment and there was an appreciable reduction in protein following 6 h of CHX.  
Comparison of the human MGAT3 and mouse DGAT2 utilized in the study shows that 
MGAT3 contains 10 lysine residues, only four of which directly align with those in DGAT2.  
Finally, comparison of the mouse MGAT2 and human MGAT3 constructs that were used 
revealed that again, four lysine residues align.  The four lysines conserved between MGAT3 
and DGAT2, and MGAT3 and MGAT2 are the same, corresponding to lysines 146, 260, 305 
and 374 of mouse DGAT2. 
  The effect of EerI treatment on DGAT2, MGAT2 and MGAT3 provide additional 
evidence that all three proteins are regulated by the ubiquitin-proteasome system.  EerI inhibits 
ERAD deubiquitination that is necessary for substrate retrotranslocation from the ER into the 
cytosol prior to degradation by the proteasome (Wang et al. 2006; Ernst et al. 2009; Zhang et 
al. 2013).  The observed shift towards high MW polyubiquitin conjugates suggests that 
DGAT2, MGAT2 and MGAT3 experience deubiquitination by ERAD associated 
deubiquitinases.  EerI also caused an increase in what may be dimer formation of MGAT2 and 
MGAT3.  This was also observed in DGAT2 total cell extracts but could not be detected in 
immunoprecipitates - possibly because the amount of DGAT2 isolated in EerI treated samples 
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was relatively low.  MGAT2 also exhibited a reduction in a band ~8 kDa above the unmodified 
protein.  The identity of these bands is currently unknown.  DGAT2 has been shown to form 
dimers, the significance of which is unclear (Jin et al., 2014).  The considerable sequence 
identity with MGAT2 and MGAT3 makes it likely they may form dimers as well.  We are 
unsure as to why inhibition of ERAD associated deubiquitination would cause a transition to 
dimer formation.  However, there is evidence that disulfide bonds must be reduced prior to 
dislocation from the membrane (Riemer et al., 2011; Christianson et al., 2012)  
 For VCP/p97 to perform its role in ERAD, it must be recruited from the cytosol to the 
ER.  This is facilitated by cofactors such as fas-associated factor family member 2 and the E3 
ligase AMFR (Ye et al., 2001, 2003, 2005; Ballar et al., 2006, 2011; Madsen et al., 2011).  We 
identified that overexpression of DGAT2 or MGAT2 caused a clear reorganization of VCP/p97.  
VCP/p97 became localized to the ER and was particularly concentrated in areas that DGAT2 or 
MGAT2 were abundant.  Conversely, VCP/p97 staining remained very diffuse and cytosolic in 
those cells, which were unsuccessfully transfected.  This was also observed in cells transfected 
with the very stable DGAT1.  Lack of VCP/p97 relocalization in DGAT1 transfected cells 
suggests VCP/p97 relocalization following DGAT2 and MGAT2 transfection is specific and 
not an artifact of overexpression.  Detection of VCP/p97 on the surface of lipid droplets was not 
surprising. VCP/p97 trafficking to lipid droplets has been previously noted, its migration 
controlled by fas-associated factor family member 2 (Olzmann et al. 2013b). 
 Co-expression studies in HEK-293T and COS-7 cells have identified that DGAT2 and 
MGAT2 interact to promote triacylglycerol accumulation above levels observed when either 
protein is expressed individually (Jin et al., 2014).  We identified that MGAT2 is much more 
stable than DGAT2.  Furthermore, when co-expressed, MGAT2 reduced DGAT2 degradation.  
This, in conjunction with substrate channeling of diacylglycerol, potentially provides the 
mechanistic basis for elevated triacylglycerol accumulation upon co-expression.  MGAT2 
induced stabilization of DGAT2 did not appear to be mediated by curbing DGAT2 
ubiquitination.  As MGAT2 itself is highly ubiquitinated, it is possible that the less potent, or 
potentially non–degradative, ubiquitination of MGAT2 obfuscates recognition of ubiquitinated 
DGAT2.   DGAT2 mRNA levels in adipose tissue and liver are decreased during fasting and 
increased upon re-feeding (Meegalla et al., 2002).  Liberation of fatty acids from triacylglycerol 
stored in cytosolic lipid droplets during fasting could explain the necessity for DGAT2 to be 
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rapidly degraded.  In contrast, mRNA levels in the intestine, where MGAT2 is expressed most 
highly, are held relatively constant, as are protein and activity levels (Chon et al., 2007).  
MGAT2 stability could be physiologically important, as the need to absorb dietary fats in the 
intestine could be required any moment a meal is consumed.  
 MGAT3 function and regulation has not been extensively characterized.  In humans, 
MGAT3 expression appears to be confined to the gastrointestinal tract (Cheng et al., 2003).  As 
so little is known about the enzyme, it is difficult to predict the significance of its degradation 
rate and stabilizing effect on DGAT2. 
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CHAPTER 8: General discussion 
8.1 Conclusions 
Obesity has reached epidemic proportions in the developed world.  The consequences 
associated with excess weight have dramatic impacts at personal, societal and economic levels.   
Therapeutic intervention in pathways involved in the synthesis and storage of triacylglycerols 
has shown clinical benefits.  Additional research is necessary to increase the efficiency of these 
treatments, enhancing manipulation of existing targets, while also identifying novel targets and 
means of treatment.  Understanding the regulatory network of key proteins involved in 
synthesis and degradation of dietary lipids provides crucial insight to attain these goals. 
DGAT2, catalyzing the final and only committed step in this process, represents a logical point 
at which to direct therapeutic influence.  Previous DGAT2 inhibitors have suffered from weak 
activity, however, recent reports show some promise. 
We identified that DGAT2 is ubiquitinated and degraded by the ubiquitin proteasome 
system.  DGAT2 has a very short half-life.  Degradation is lysine dependent and controlled by 
numerous lysines C-terminal of the second transmembrane domain.  Confirmation of 
ubiquitinated lysine residues through mass spec analysis would be beneficial; our attempt was 
unsuccessful.  In vitro, a lysine-less mutant retained full cataytic activity.  However, in situ, this 
mutant exhibited a nuclear/perinuclear-staining pattern and disrupted typical lipid droplet 
formation.  Two lysine clusters were identified; when mutated, they could recapitulate the 
abnormal nuclear localization.  As both of these clusters contained lysines found to promote 
degradation, this phenotype could be caused by the accumulation of degradation resistant 
protein.   
 As lipid concentrations have been found to influence the degradation rate of several 
proteins involved in triacylglycerol metabolism, we chose to examine whether DGAT2 was 
similarly regulated.  Stimulation of lipogenesis did not reduce DGAT2 degradation, suggesting 
that DGAT2 turnover may be controlled primarily at the transcriptional level.  Moreover, 
following the discovery that DGAT2 on both lipid droplets and the ER is ubiquitinated, we 
found that inhibiting re-localization to the lipid droplet during lipogenesis had no effect on 
DGAT2 turnover rate.  Finally, analysis of DGAT2 ubiquitination in situ demonstrated no 
apparent changes in the quantity or localization of ubiquitinated DGAT2 under basal or 
lipogenic conditions. 
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 In order to gain insight into DGAT2 regulation, we took a non-targeted mass 
spectrometry approach to identify interacting proteins.  Notably, the ERAD E3 ligase, TRIM13, 
was detected.  Further experiments to confirm and characterize this interaction would be 
beneficial.  Calnexin was also detected by LC-MS/MS in DGAT2 isolates; this interaction was 
confirmed in vitro and in situ.  MGAT2 was also found to co-immunoprecipitate with calnexin.  
DGAT2 and MGAT2 interaction with calnexin did not appear to be dependent on 
glycosylation, implying that these interactions are not simply due to calnexin chaperone 
function.  The possible impacts of calnexin on triacylglycerol metabolism were examined in 
calnexin knockout mouse embryonic fibroblasts, which exhibited stunted lipid droplet size 
compared to wild-type cells.  Additional experiments are necessary to determine whether this is 
simply a result of loss of chaperone function or if calnexin has a secondary role in lipid droplet 
formation.  The presence of calnexin on lipid droplets provides some evidence for the latter.   
 DGAT2, MGAT2 and MGAT3 have many commonalities in sequence, localization and 
function.  We were interested to examine interactions between these family members and check 
for similarities in regulation.  We reported that DGAT2 was able to interact with MGAT2 and 
MGAT3 in vitro and in situ.  As expected, both MGAT2 and MGAT3 were also found to be 
ubiquitinated, pointing to regulation by the ubiquitin-proteasome system.  Differences in 
stability were observed, with MGAT2 being much more stable than DGAT2, and MGAT3 
exhibiting an intermediate rate of degradation.  The functional significance of these interactions 
were examined in co-expression studies.  We recognized that MGAT2 and MGAT3 stabilized 
DGAT2, dramatically reducing its rate of degradation.  These interactions could serve to 
increase triacylglycerol synthesis capacity during lipogenesis.  In investigating MGAT2 
induced stabilization of DGAT2, we found that MGAT2 co-expression did not reduce DGAT2 
ubiquitination.  The mechanism of stabilization requires further analysis. 
  Accumulation of high molecular weight polyubiquitinated DGAT2, MGAT2 and 
MGAT3 were observed upon ERAD inhibition.  This provides evidence that these proteins are 
degraded through the ERAD pathway.  Additionally, DGAT2 and MGAT2 were found to co-
localize and interact with the ERAD ATPase, VCP/p97.  
 This project has provided insight into the post-translational regulatory mechanisms of 
DGAT2 and DGAT2 family members.  Furthermore, results from mass spectrometry based 
identification of DGAT2 interacting proteins offer numerous avenues of potential research.  
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Finally, MGAT2 and MGAT3 mediated stabilization of DGAT2 has potential physiological 
implications.  It has been noted that MGAT2 and DGAT2 can cooperate to increase 
triacylglycerol production (Jin et al., 2014).  The prospect of increased triacylglycerol synthesis 
through the stabilization of DGAT2 bound to a triacylglycerol synthesis complex requires 
additional inquiry. 	 	
8.2 Future directions 
Further mapping of DGAT2 post-translational modifications by mass spectrometry 
would be very beneficial.  While our attempt was unsuccessful, we would like to confirm 
findings from our mutagenic studies that numerous lysines C-terminal of the TMDs are 
ubiquitinated and responsible for destabilizing DGAT2.  Identification of other modifications 
would also help to elucidate the regulatory mechanisms of DGAT2. 
The recent finding that DGAT2 is present in the nucleus suggests that a mechanism 
must be present to transport it there (Ohsaki et al., 2016).  This provides some explanation as to 
why the degradation resistant Lys-less-DGAT2 mutant is found in the nuclear region.  Why it 
accumulates in or around the nucleus rather than the ER or cytosol is unclear.  Finding the 
sequence(s) in DGAT2 that modulates this localization would be valuable.  
 We identified that mutation of lysine residues 251, 257, 260 and 264 significantly 
reduced the size of lipid droplets and appeared to block DGAT2 localization to the lipid droplet 
surface.  It would be interesting to further examine this mechanism and determine whether this 
region is post-translationally modified or involved in protein-protein interactions that serve to 
target DGAT2 to lipid droplets.  An alternate explanation is that these residues directly interact 
with the lipid droplet monolayer. 
 Convincing evidence linking genomic variance in DGAT2 to increased adiposity has yet 
to be found.  Differences among individuals in the activity of proteins responsible for regulating 
DGAT2 abundance could also play a role.  Currently, AMFR is the only E3 ligase 
experimentally verified to regulate DGAT2 turnover (Choi et al., 2014).  We identified 
TRIM13 E3 ligase in DGAT2 co-immunoprecipitates.  This interaction should be further 
examined.   An in vitro ubiquitination assay would be useful to show DGAT2 is a substrate for 
TRIM13.  Additionally, siRNA mediated knockdown of TRIM13 would be expected to 
stabilize DGAT2.    
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 We were very interested to find that DGAT2 and MGAT2 interact with calnexin in a 
glycosylation independent manner.  In characterizing this interaction, we would first like to 
pinpoint the interacting regions of each protein.  We also found that lipid droplet production 
appeared to be inhibited in a calnexin knockout cell line.  Introduction of a calnexin mutant in 
these cells, made deficient in chaperone function through inactivation of its carbohydrate-
binding domain, could illuminate the role of calnexin in lipid droplet formation.  If this 
construct restored lipid droplet production, it would imply that calnexin plays a role in 
triacylglycerol metabolism that is not attributable to its function as a folding chaperone. 
 Finally, the observation that MGAT2 and MGAT3 stabilize DGAT2 has possible 
physiological implications.  As tools to examine endogenous DGAT2 protein levels are not 
available, this needs to be examined indirectly.  We intend to transfect human liver cells with 
MGAT2/MGAT3 and subject them to CHX degradation assay.  Total cell extracts would then 
be isolated and analyzed by in vitro DGAT activity assay in the presence of a DGAT1 inhibitor.  
If MGAT2 and MGAT3 reduce DGAT2 turnover, we would expect to see a more gradual 
reduction in DGAT activity over the time course of CHX incubation.  Additionally, it would be 
interesting to examine the effects of combined inhibition of MGAT2/MGAT3 and DGAT2 in 
obese mice. 
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CHAPTER 9:  Supplementary material 
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Figure 9.1.  DGAT2 is highly conserved among species – Multiple sequence alignment of 
DGAT2 orthologs.  Species are as follows: Ajellomyces capsulatus, AcDGAT2; Aspergillus 
oryzae, AoDGAT2; Branchiostoma floridae, BfDGAT2; Coccidioides immitis, CiDGAT2; 
Dictyostelium discoideum, DdDGAT2; Laccaria bicolor, LbDGAT2; Neosartorya fischeri, 
NfDGAT2; Penicillium marneffei, PmDGAT2; Saccharomyces cerevisiae, ScDGAT2; 
Schizosaccharomyces pombe, SpDGAT2; Talaromyces stipitatus, TsDGAT2; Umbelopsis 
ramanniana, UrDGAT2a, UrDGAT2b; Ustilago maydis, UmDGAT2; Arabidopsis thaliana, 
AtDGAT2; Chlamydomonas reinhardtii, CrDGAT2; Medicago truncatula, MtDGAT2; Oryza 
sativa, OsDGAT2; Ostreococcus tauri, OtDGAT2; Physcomitrella patens, PpDGAT2; Populus 
trichocarpa, PtDGAT2; Ricinus communis, RcDGAT2; Vernicia fordii, VfDGAT2; Vitis 
vinifera, VvDGAT2; Zea mays, ZmDGAT2; Bos taurus, BtDGAT2; Caenorhabditis elegans, 
CeDGAT2a, CeDGAT2b;	Homo sapiens, HsDGAT2; Mus musculus, MmDGAT2.  ‘*’ denotes 
identical residues.  ‘:’ refers to conservation between groups of strongly similar properties. ‘.’ 
refers to conservation between groups of weakly similar properties.  Conserved domains are 
marked in red boxes.  The position of transmembrane domains in ScDGAT2 and MmDGAT2 
are marked in blue boxes (Liu et al., 2011; Stone et al., 2006; McFie et al., 2014).  The position 
of lysine residues are highlighted in yellow.  
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Table 9.1.  DGAT2 interacting proteins detected by mass spectrometry 
Protein Accession Number 
Unique 
Peptide 
Count 
Percent 
Coverage 
Frequency in 
Contaminant 
Repository 
Eukaryotic initiation factor 4A-
I  IF4A1_HUMAN 4 4.93% 0.381924 
DNA replication licensing 
factor MCM6  MCM6_HUMAN 4 1.95% 0.166181 
Glyceraldehyde-3-phosphate 
dehydrogenase G3P_HUMAN 3 7.16% 0.577259 
ATP synthase F(0) complex 
subunit B1, mitochondrial  
AT5F1_HUMAN 3 7.42% 0.084548 
Diacylglycerol O-
acyltransferase 2 DGAT2_HUMAN 3 5.15% N/A 
T-complex protein 1 subunit 
alpha  TCPA_HUMAN 3 3.96% 0.396501 
Importin subunit beta-1  IMB1_HUMAN 3 3.88% 0.314869 
Importin-4  IPO4_HUMAN 3 1.76% 0.055394 
Peptidyl-tRNA hydrolase 2, 
mitochondrial  PTH2_HUMAN 2 12.80% 0.020408 
Small nuclear 
ribonucleoprotein Sm D1  SMD1_HUMAN 2 10.90% 0.422741 
Sideroflexin-1 OS=Homo 
sapiens  SFXN1_HUMAN 2 8.39% 0.058309 
Eukaryotic translation initiation 
factor 3 subunit G  
EIF3G_HUMAN 2 7.81% 0.172012 
Sterol-4-alpha-carboxylate 3-
dehydrogenase, 
decarboxylating  
NSDHL_HUMAN 2 3.49% 0.023324 
26S proteasome non-ATPase 
regulatory subunit 11  
PSD11_HUMAN 2 3.08% 0.195335 
Calnexin  CALX_HUMAN 2 2.53% 0.239067 
Erythroid differentiation-
related factor 1  EDRF1_HUMAN 2 2.26% N/A 
Delta-1-pyrroline-5-
carboxylate synthase P5CS_HUMAN 2 2.26% 0.166181 
Coatomer subunit beta'  COPB2_HUMAN 2 2.10% 0.131195 
Coatomer subunit gamma-1  COPG1_HUMAN 2 1.95% 0.113703 
Heat shock cognate 71 kDa 
protein  HSP7C_HUMAN 2 1.70% 0.962099 
DNA mismatch repair protein 
Msh6  MSH6_HUMAN 2 1.32% 0.093294 
Eukaryotic translation initiation 
factor 3 subunit C  
EIF3C_HUMAN (+1) 2 1.20% 0.209913 
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60S ribosomal protein L11  RL11_HUMAN 1 7.87% 0.443149 
ADP/ATP translocase 3  ADT3_HUMAN 1 7.05% 0.451895 
Heat shock protein 75 kDa, 
mitochondrial TRAP1_HUMAN 1 1.99% 0.198251 
Cytochrome c oxidase subunit 
NDUFA4  NDUA4_HUMAN 1 14.80% 0.034985 
60S ribosomal protein L23  RL23_HUMAN 1 14.30% 0.571429 
40S ribosomal protein S20 RS20_HUMAN 1 10.10% 0.373178 
40S ribosomal protein S13 RS13_HUMAN 1 9.93% 0.405248 
ATP synthase subunit g, 
mitochondrial  ATP5L_HUMAN 1 8.74% 0.055394 
Tafazzin  TAZ_HUMAN 1 8.56% N/A 
Prostaglandin E synthase 3  TEBP_HUMAN 1 8.12% 0.084548 
Heat shock protein beta-1  HSPB1_HUMAN 1 7.80% 0.163265 
Ubiquitin-60S ribosomal 
protein L40  RL40_HUMAN (+3) 1 7.03% 0.61516 
Kallikrein-7  KLK7_HUMAN 1 6.72% 0.020408 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 48 
kDa subunit  
OST48_HUMAN 1 6.36% 0.081633 
Guanine nucleotide-binding 
protein subunit beta-2-like 1  
GBLP_HUMAN 1 6.31% 0.233236 
Signal recognition particle 
receptor subunit beta  SRPRB_HUMAN 1 5.90% 0.037901 
Methylosome subunit pICln  ICLN_HUMAN 1 5.49% 0.341108 
Ras-related protein Rab-13  RAB13_HUMAN 1 5.42% 0.06414 
CMT1A duplicated region 
transcript 15 protein  CDRTF_HUMAN 1 5.32% N/A 
Leucine-rich repeat-containing 
protein 59  LRC59_HUMAN 1 5.21% 0.148688 
Ras-related protein Rab-15 RAB15_HUMAN 1 5.19% N/A 
Replication factor C subunit 3  RFC3_HUMAN 1 5.06% 0.069971 
Uridine-cytidine kinase 2  UCK2_HUMAN 1 4.98% 0.008746 
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
3, mitochondrial 
NDUS3_HUMAN 1 4.92% 0.03207 
Pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial  
ODPB_HUMAN 1 4.46% 0.084548 
Putative uncharacterized 
protein FLJ37770 YK006_HUMAN 1 4.33% N/A 
Hydroxysteroid 
dehydrogenase-like protein 2  HSDL2_HUMAN 1 4.31% 0.011662 
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Dolichol-phosphate 
mannosyltransferase subunit 1  
DPM1_HUMAN 1 4.23% 0.055394 
Stomatin-like protein 2, 
mitochondrial  STML2_HUMAN 1 4.21% 0.090379 
26S proteasome non-ATPase 
regulatory subunit 14  
PSDE_HUMAN 1 4.19% 0.139942 
Transmembrane emp24 
domain-containing protein 10  
TMEDA_HUMAN 1 4.11% 0.043732 
Heterogeneous nuclear 
ribonucleoprotein F  HNRPF_HUMAN 1 4.10% 0.516035 
Alpha-centractin  ACTZ_HUMAN 1 3.99% 0.169096 
Cytochrome b-c1 complex 
subunit 2, mitochondrial  
QCR2_HUMAN 1 3.97% 0.06414 
Voltage-dependent anion-
selective channel protein 1  
VDAC1_HUMAN 1 3.89% 0.084548 
T-complex protein 1 subunit 
epsilon  TCPE_HUMAN 1 3.70% 0.376093 
B-cell receptor-associated 
protein 31  BAP31_HUMAN 1 3.66% 0.075802 
Very-long-chain enoyl-CoA 
reductase  TECR_HUMAN 1 3.57% 0.110787 
Pachytene checkpoint protein 2 
homolog  PCH2_HUMAN 1 3.47% N/A 
26S protease regulatory subunit 
7  PRS7_HUMAN 1 3.23% 0.212828 
Pyruvate kinase PKM KPYM_HUMAN 1 3.20% 0.556851 
Sulfotransferase 4A1 ST4A1_HUMAN 1 3.17% N/A 
Serpin H1  SERPH_HUMAN 1 3.11% 0.107872 
Mitochondrial import receptor 
subunit TOM40 homolog  
TOM40_HUMAN 1 3.05% 0.03207 
Tyrosine-protein kinase CSK CSK_HUMAN 1 2.89% 0.017493 
Acetyl-CoA acetyltransferase, 
mitochondrial  THIL_HUMAN 1 2.81% 0.116618 
Trace amine-associated 
receptor 1  TAAR1_HUMAN 1 2.65% N/A 
Minor histocompatibility 
antigen H13  HM13_HUMAN 1 2.65% 0.037901 
Phosphoglycerate kinase 1  PGK1_HUMAN 1 2.64% 0.177843 
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
2, mitochondrial  
NDUS2_HUMAN 1 2.59% 0.029155 
ATP-dependent RNA helicase 
DDX3X  DDX3X_HUMAN (+1) 1 2.57% 0.443149 
THO complex subunit 3  THOC3_HUMAN 1 2.56% 0.043732 
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E3 ubiquitin-protein ligase 
TRIM13  TRI13_HUMAN 1 2.46% N/A 
Basic leucine zipper and W2 
domain-containing protein 1  
BZW1_HUMAN 1 2.39% 0.03207 
Bicaudal D-related protein 2  BICR2_HUMAN 1 2.36% N/A 
Kelch-like protein 10  KLH10_HUMAN 1 2.30% N/A 
T-complex protein 1 subunit 
beta  TCPB_HUMAN 1 2.24% 0.381924 
Glutaminase kidney isoform, 
mitochondrial  GLSK_HUMAN 1 2.24% 0.029155 
Katanin p60 ATPase-
containing subunit A1 KTNA1_HUMAN 1 2.24% 0.023324 
Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2  
AT2A2_HUMAN 1 2.21% 0.157434 
Cytochrome P450 3A43  CP343_HUMAN 1 2.19% N/A 
COP9 signalosome complex 
subunit 1  CSN1_HUMAN 1 2.04% 0.046647 
Calcium-binding and coiled-
coil domain-containing protein 
2  
CACO2_HUMAN 1 2.02% 0.011662 
T-complex protein 1 subunit 
gamma  TCPG_HUMAN 1 2.02% 0.361516 
Asparagine synthetase 
[glutamine-hydrolyzing]  ASNS_HUMAN 1 1.96% 0.052478 
DNA replication licensing 
factor MCM5 MCM5_HUMAN 1 1.91% 0.201166 
ATP-dependent Clp protease 
ATP-binding subunit clpX-like, 
mitochondrial  
CLPX_HUMAN 1 1.90% 0.040816 
Tyrosine--tRNA ligase, 
cytoplasmic SYYC_HUMAN 1 1.89% 0.110787 
Complement C1r 
subcomponent-like protein  C1RL_HUMAN (+1) 1 1.85% N/A 
cAMP-dependent protein 
kinase type I-beta regulatory 
subunit  
KAP1_HUMAN 1 1.84% N/A 
Cytoskeleton-associated protein 
4  CKAP4_HUMAN 1 1.83% 0.122449 
Telomere repeats-binding 
bouquet formation protein 1  
TERB1_HUMAN 1 1.79% N/A 
Eukaryotic translation initiation 
factor 3 subunit L  
EIF3L_HUMAN 1 1.77% 0.247813 
Transmembrane protein 200C  T200C_HUMAN 1 1.77% N/A 
Coiled-coil domain-containing 
protein 181  CC181_HUMAN 1 1.77% N/A 
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Centromere/kinetochore protein 
zw10 homolog ZW10_HUMAN 1 1.67% 0.026239 
Early endosome antigen 1 EEA1_HUMAN 1 1.63% 0.014577 
WD repeat-containing protein 
44  WDR44_HUMAN 1 1.53% 0.011662 
Zinc finger protein 408 ZN408_HUMAN 1 1.53% N/A 
Zinc finger protein 671  ZN671_HUMAN 1 1.50% N/A 
NACHT, LRR and PYD 
domains-containing protein 6 
NALP6_HUMAN 1 1.46% N/A 
Extended synaptotagmin-1  ESYT1_HUMAN 1 1.45% 0.061224 
Exportin-7  XPO7_HUMAN 1 1.38% 0.046647 
Solute carrier family 12 
member 2 S12A2_HUMAN 1 1.32% 0.011662 
Putative ATP-dependent RNA 
helicase DDX11-like protein 8  
D11L8_HUMAN (+2) 1 1.32% N/A 
tRNA (cytosine(34)-C(5))-
methyltransferase  NSUN2_HUMAN 1 1.30% 0.142857 
Vacuolar protein sorting-
associated protein 35  VPS35_HUMAN 1 1.26% 0.078717 
116 kDa U5 small nuclear 
ribonucleoprotein component 
U5S1_HUMAN 1 1.23% 0.314869 
X-ray repair cross-
complementing protein 5  XRCC5_HUMAN 1 1.23% 0.390671 
Dynactin subunit 1  DCTN1_HUMAN 1 1.10% 0.116618 
Band 4.1-like protein 2  E41L2_HUMAN 1 1.09% 0.078717 
Desmocollin-1 DSC1_HUMAN 1 1.01% 0.110787 
Short transient receptor 
potential channel 1  TRPC1_HUMAN 1 1.01% N/A 
DNA mismatch repair protein 
Msh2  MSH2_HUMAN 1 0.96% 0.072886 
X-linked retinitis pigmentosa 
GTPase regulator-interacting 
protein 1 
RPGR1_HUMAN 1 0.93% N/A 
DNA-directed RNA 
polymerase II subunit RPB1  
RPB1_HUMAN 1 0.91% 0.104956 
Zinc finger protein basonuclin-
2  BNC2_HUMAN 1 0.91% 0.005831 
Nebulin-related-anchoring 
protein NRAP_HUMAN 1 0.81% N/A 
Hermansky-Pudlak syndrome 3 
protein  HPS3_HUMAN 1 0.80% N/A 
Zinc finger protein 197 ZN197_HUMAN 1 0.78% N/A 
ATP-binding cassette sub-
family A member 7  ABCA7_HUMAN 1 0.75% N/A 
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Slit homolog 3 protein  SLIT3_HUMAN 1 0.72% N/A 
Brefeldin A-inhibited guanine 
nucleotide-exchange protein 3  
BIG3_HUMAN 1 0.64% N/A 
Tetratricopeptide repeat protein 
37  TTC37_HUMAN 1 0.64% 0.037901 
ATPase family AAA domain-
containing protein 5  
ATAD5_HUMAN 1 0.49% N/A 
Golgi-specific brefeldin A-
resistance guanine nucleotide 
exchange factor 1  
GBF1_HUMAN 1 0.48% 0.017493 
Filaggrin-2  FILA2_HUMAN 1 0.46% 0.206997 
Nuclear pore complex protein 
Nup98-Nup96  NUP98_HUMAN 1 0.44% 0.040816 
Coiled-coil domain-containing 
protein 168  CC168_HUMAN 1 0.33% N/A 
Nucleosome-remodeling factor 
subunit BPTF  BPTF_HUMAN 1 0.30% 0.046647 
Centromere protein F  CENPF_HUMAN 1 0.28% 0.040816 
Nesprin-2 SYNE2_HUMAN 1 0.15% 0.058309 
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